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Abstract 
Over the last decade, there has been a burgeoning interest in clinical research 
that link psychiatric illnesses - particularly major depressive disorder - to 
inflammatory processes. Most of the evidence that link inflammation to major 
depressive disorder in humans come from three observations - a) findings from 
at least 3 meta-analytic studies suggest that major depressive disorder is 
associated with elevated circulating inflammatory biomarkers; b) inflammatory 
illnesses - both central (brain) and peripheral (e.g. arthritis) - are associated 
with greater rates of major depressive disorder than the general population and 
c) patients treated with cytokines - both experimentally as well as 
therapeutically (for cancer or hepatitis) are at greater risk of developing a major 
depressive illness. As a corollary, anecdotal and experimental evidence suggest 
that anti-inflammatory medications may have some antidepressant effects. In 
fact, a number of preclinical studies have provided clues towards potential 
mechanistic pathways through which inflammatory processes may directly have 
an effect on  the brain, causing changes that may contribute to the 
aetiopathogenesis of major depressive disorder.  
The aim of the project was to explore the relationship between circulating 
(peripheral blood) inflammatory markers and brain structure in humans using 
state of the art magnetic resonance imaging (MRI) and single photon emission 
tomography (SPECT). I explored this relationship in two datasets. Firstly, in a 
series of cross sectional observational analyses on the PSOBID study sample 
(http://www.gcph.co.uk/work_themes/additional_work/psobid), I examined the 
association between circulating inflammatory markers and cortical thickness 
(MRI - surface based morphometry) in a group of neurologically healthy adult 
males. I found that circulating inflammatory markers explained significant 
variance in cortical thickness. Greater inflammatory marker levels were 
associated with cortical thinning across the cortical mantle. Using mediation 
analysis, I found that greater circulating inflammatory markers mediated the 
association between neighbourhood-level deprivation (a high risk condition for 
major mental illnesses) and cortical thinning. I then used complex network 
analysis using graph theory to show that greater inflammation mediated the 
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association between neighbourhood-level deprivation and poorer network 
structural properties of cortical thickness covariance networks. I also showed 
that greater inflammatory markers mediated the association between 
neighbourhood deprivation and smaller volumes pertaining to the limbic stress 
network. Next, in an experimental study, I examined the association between 
circulating inflammatory markers and serotonin transporters in the midbrain of 
patients with psoriasis/psoriatic arthritis using SPECT. I found that greater 
inflammatory marker levels were associated with greater serotonin transporter 
levels in the midbrain. I also showed that administration of an anti-inflammatory 
medication (anti-TNF-α agent) was associated with a reduction in the serotonin 
transporter levels.  
These findings provide some evidence to suggest that circulating inflammatory 
markers account for significant differences in cortical thickness and subcortical 
volumes in the human brain. I have shown that circulating inflammatory markers 
may mediate the association between high risk conditions - like neighbourhood 
deprivation and inflammatory medical conditions - and brain changes that may 
underlie the pathophysiology of major depressive disorder. Future work will 
focus on cementing the precise role of inflammation in depressive illness, 
through sophisticated animal models and clinical neuroscience. This may result 
in potential biomarkers that may facilitate diagnosis,  help predict prognosis and 
aid the development of beneficial treatments for what remains a significantly 
disabling psychiatric illness.
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1 Chapter 1 – Review of Literature 
 
1.1 Introduction 
Mental, neurological and substance use disorders account for a significant 
proportion of the global burden of disease, surpassing that of 
cardiovascular disease and cancer. Major depressive disorder (MDD) is the 
third leading cause of global disease burden (Collins et al., 2011).Research 
over the last few decades have increased our insight into the 
pathophysiology of MDD.  A number of biological findings have been 
replicated and have proven fruitful in terms of research outcomes. 
However, our understanding of what is essentially a highly heterogeneous 
disorder remains incomplete. Despite major research funding over the last 
twenty years, bringing the above research findings together and translating 
those into effective treatments have been largely ineffective (Krishnan and 
Nestler, 2010).  
Major depressive disorder is a heterogenous condition and is characterised 
by a number of emotional, cognitive and physical symptoms. The core 
symptoms of major depression are “depressed mood” and “anhedonia”. 
The associated symptoms include changes in sleep, appetite, weight loss, 
psychomotor retardation/agitation and cognitive symptoms. The DSM IV 
and ICD 10 criteria for a depressive episode are shown in Table 
1-1(Gruenberg et al., 2005). 
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Table 1-1: DSM IV and ICD 10 criteria for Major depressive disorder 
 DSM IV ICD 10 
Clinical 
Significance 
Symptoms cause  
clinically significant  
stress or impairment  
in social, occupational  
or other important  
areas of functioning. 
Some difficulty in continuing with 
ordinary work and social activities, but 
will probably not cease to function 
completely in mild depressive episode; 
considerable difficulty in continuing 
with social, work or domestic activities 
in moderate depressive episode; 
considerable distress or agitation, and 
unlikely to continue with social, work, 
or domestic activities, except to a very 
limited extent in severe  
depressive episode. 
Duration of 
symptoms 
Most of day, nearly  
every day for at least  
2 weeks. 
A duration of at least 2 weeks is usually 
required for diagnosis for depressive 
episodes of all three grades of severity. 
Severity Five or more of  
following symptoms;  
at least one symptom is 
either depressed mood or 
loss of interest or pleasure:  
(1) Depressed mood  
(2) Loss of interest  
(3) significant weight loss or 
gain or decrease or increase 
in appetite  
(4) Insomnia or hypersomnia  
(5) Psychomotor agitation or 
retardation  
(6) Fatigue or loss of energy  
(7) Feelings of worthlessness 
or excessive or 
inappropriate guilt  
(8) Diminished ability to 
think or concentrate, or 
indecisiveness  
(9) Recurrent thoughts of 
death, recurrent suicidal 
ideation without a specific 
plan, or suicide attempt or 
a specific plan 
Depressed mood, loss of interest and 
enjoyment, and reduced energy leading 
to increased fatigability and diminished 
activity in typical depressive episodes; 
other common symptoms are:  
(1) Reduced concentration and attention  
(2) Reduced self-esteem and self-
confidence  
(3) ideas of guilt and unworthiness (even 
in mild  
type of episode)  
(4) Bleak and pessimistic views of the 
future  
(5) Ideas or acts of self-harm or suicide  
(6) Disturbed sleep  
(7) Diminished appetite  
Typical examples of “somatic” 
symptoms are: loss of interest or 
pleasure in activities that are normally 
enjoyable; lack of emotional reactivity 
to normally pleasurable surroundings 
and events; waking in the morning 2 h 
or more before the usual time; 
depression worse in the morning; 
objective evidence of definite 
psychomotor retardation or agitation; 
marked loss of appetite; weight loss; 
marked loss of libido.  
Reused with permission from GRUENBERG, A., GOLDSTEIN, R. & PINCUS, H. A. 2005. 
Classification of Depression: Research and Diagnostic Criteria: DSM-IV and ICD-10. 
In: LICINIO, J. & WONG, M.-L. (eds.) Biology of depression : from novel insights to 
therapeutic strategies. Weinheim ; [Great Britain] : Wiley-VCH, 2005 
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Over the last two decades, there has been a burgeoning interest in 
preclinical and clinical research linking psychiatric illnesses to 
inflammatory processes (and vice versa). Most of this has arisen from an 
attempt to link these illnesses – particularly MDD - with “stress” biology, 
and have raised the possibility of an “initial common pathway” whereby 
immune/inflammatory and stress biomarkers combine to cause changes in 
brain structure and function (Raison et al., 2006).  Most of the evidence 
that links inflammation and major depressive disorder come from 3 
observations(Capuron and Miller, 2011). 
1. MDD (even in the absence of medical illness) is associated with raised 
inflammatory markers.  
2. Inflammatory medical illnesses – both CNS and peripheral – are 
associated with greater rates of major depression.  
3. Patients treated with cytokines for various illnesses are at increased risk 
of developing major depressive illness  
In this chapter, I intend to discuss each of the above observations. I then 
go on to discuss the possible mechanisms involved in the aetio-
pathogenesis of MDD, in the context of inflammation. Most of what is 
presented in this chapter is published in Krishnadas R, Cavanagh J. 
Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry. 2012 
May;83(5):495-502. (Reused with permission) 
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1.2 MDD is associated with increased inflammatory 
marker 
Inflammation has been linked to MDD in a number of ways (Capuron and 
Miller, 2011, Raison et al., 2006, Raison and Miller, 2011). More robust 
findings including:  
1) Mean value for inflammatory mediators/ markers is higher in MDD than 
normal, non-depressed subjects.  
2) Approximately one-third of people with MDD have higher levels of 
inflammatory markers, compared to the normal, non-depressed population.  
3) These increases are more modest than in autoimmune or infectious 
disease, e.g. 2-3 times higher than healthy controls. However, as Raison 
and Miller point out, small physiological differences can have profound 
consequences over time, especially if they change in a consistent 
direction(Raison and Miller, 2011). Similar findings have been found in 
cardiovascular disease, stroke and diabetes. 
 Alterations in serum and CSF concentrations of a number of inflammatory 
markers, including cytokines, chemokines and acute phase reactant 
proteins, have been found in patients with MDD, and exist in the absence 
of co-morbid medical illness. The most replicated findings pertain to raised 
CRP and proinflammatory cytokines - TNF-α and IL6, confirmed by at least 
3 recent meta-analyses of cross sectional studies(Dowlati et al., 2010, Liu 
et al., 2012a, Howren et al., 2009). All three meta-analyses found 
significant heterogeneity among the included studies; however, there was 
no evidence of publication bias.  
More recent of the three meta-analyses, by Liu et al found that TNF-α and 
IL6 are higher in patients with MDD compared to controls (Liu et al., 
2012a). In addition, IL1B also was found to significantly different in 
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European patients. The standardized mean differences from the study are 
shown in  
Table 1-2.   The results suggest the difference in cytokine level between 
MDD and healthy controls was of a moderate to large effect size.  
Interestingly, there is some evidence to say that the increase in 
inflammatory markers is corrected to an extent in response to 
antidepressant treatment. A meta-analysis of 22 antidepressant treatment 
studies found that, IL1β and IL 6 levels (but not TNF-α) decreased in 
response to therapy, along with a reduction in depressive symptoms 
(Hannestad et al., 2011). This response was found to be specific for 
selective serotonin reuptake inhibitors (SSRIs), the most common first line 
pharmacological treatments for MDD. These findings propose the possibility 
that inflammatory cytokines contribute to depressive symptoms, and that 
antidepressants may block the effect of inflammatory cytokines in the 
brain.   
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Table 1-2: Results of sensitivity analyses based on quality of studies for TNFα, IL6 and IL1β.  
  
TNF- α 
    
IL-6 
    
IL-1β 
   
  
SMD 
 
I2 
 
n 
 
p 
 
SMD 
 
I2 
 
n 
 
p 
 
SMD 
 
I2 
 
n 
 
p 
 
All studies 
 
 
0.56 
 
89.7 
 
15 
 
0.01 
 
0.68 
 
63.89 
 
18 
 
< 0.001 
 
-0.52 
 
95.13 
 
10 
 
0.22 
High quality 
studies 
 
0.99 
 
92.17 
 
8 
 
0.01 
 
0.791 
 
72.31 
 
9 
 
< 0.001 
 
-1.30 
 
142.08 
 
4 
 
0.34 
I
2
 denote heterogeneity. SMD - standardised mean difference. n - number of studies. High quality studies were based on an arbitrary cut off score 
of >7 on the Newcastle Ottawa Scale (a scale to tease out high quality studies). Reused with permission from Liu Y, Ho RC, Mak A. Interleukin (IL)-
6, and tumour necrosis factor alpha (TNF-α) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. Journal 
of Affective  Disorder. 2012 Aug;139(3):230-9
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The results of the above three meta-analyses show only a correlation between 
inflammatory markers and depression, and does not necessarily show a direction 
of relationship (or causation) between the two . More recently, longitudinal 
studies have shown an association between circulatory inflammatory markers 
and development of depression. Valkanova et al undertook a systematic review 
of longitudinal studies to investigate whether raised circulating inflammatory 
was suggestive of the development of subsequent depressive symptoms 
(Valkanova et al., 2013). They examined the relationship between CRP and IL6 
on the subsequent development of depressive symptoms. They found a 
significant association between CRP and depressive symptoms at follow up 
(adjusted r=0.05). The relationship at best was thought to be modest (yet 
significant). 
Despite these findings it is still hard to justify describing MDD as a primary 
“inflammatory” illness, because inflammation is neither necessary nor sufficient 
to be the sole cause of MDD. This is complicated by the fact that immune/ 
inflammatory disruption have been found in a number of other psychiatric 
conditions including schizophrenia and PTSD(Miller et al., 2011, Spitzer et al., 
2010). It is therefore more likely that inflammation and its mediators may play a 
more subtle role, as part of a generalised physiological response, or may act as a 
trigger to a cascade of events that ultimately lead to the depressive phenotype. 
Raison and Miller in this context have described a “super-network”, with 
immune response element amplification (IREA)(Raison and Miller, 2011). This 
includes multiple mechanisms through which inflammation may act, in 
precipitating the depression phenotype. These include -  
 Insensitivity to glucocorticoid inhibitory feedback  
Proinflammatory cytokines including TNF-α, induce glucocorticoid 
resistance. Cytokines induce functional inhibition by preventing the 
cortisol-glucocorticoid receptor complex entry into the nucleus and also 
preventing its binding to the DNA (Pace et al., 2007, Pace and Miller, 
2009).  This in turn leads to altered expression of glucocorticoid receptors 
in the cells. This phenomenon has been documented in major depressive 
disorder in the form of an impaired dexamethasone suppression test(Evans 
and Nemeroff, 1987). 
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 Impaired parasympathetic signalling  
Preclinical studies in rodents suggest that inducing a peripheral 
inflammatory state often produce a sickness behaviour that is dependent 
on vagal afferents(Ek et al., 1998). Visceral terminals of the vagal 
afferent nerves express cytokine binding sites(Goehler et al., 1997). 
Binding of pro-inflammatory cytokines to these sites, result in activation 
of brain structures implicated in interoception and homeostasis, and 
results in sickness behaviour(Wan et al., 1994). In addition, damage to the 
vagal afferents, result in an attenuation of this sickness behaviour(Bret-
Dibat et al., 1995).  
 Increased subgenual anterior cingulate cortex (SgACC) activity  
The ACC ventral to the genu of the corpus callosum has been implicated 
in neuroimaging studies of major depressive disorder(Drevets et al., 
2008). Mayberg demonstrated that provoking transient sadness in healthy 
volunteers increased subgenual cingulate blood flow(Mayberg, 1997, 
Mayberg et al., 1999). In depressed patients, this increase in blood flow 
was normalised on treatment with antidepressants. Grecius et al, using 
resting state fMRI found that during resting state, depressed patients, the 
SgACC showed greater connectivity with the default mode 
network(Greicius et al., 2007). Post mortem studies in suicidal patients 
with severe depression have shown an increase in microglial quinolinic 
acid in the SgACC, as an evidence for immune modulated glutamatergic 
neurotransmission(see below)(Steiner et al., 2011).  Studies that induce 
inflammation in humans have shown an increased activation of SgACC that 
directly correlated with negative mood symptoms(Harrison et al., 2009a). 
Magnetic resonance spectroscopy studies have shown an increase in 
glutamate metabolites in the SgACC in those  receiving interferon 
treatment(Haroon et al., 2013). 
 Reduced hippocampal volume.  
In health, proinflammatory cytokines like TNF-α are known to regulate 
synaptic plasticity by influencing the expression of AMPA glutamatergic 
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receptors (see below)(McAfoose and Baune, 2009). However, at higher 
concentrations, proinflammatory cytokines induce glutamate mediated 
excitotoxicity. In addition, inflammation also plays a role in adult 
hippocampal neurogenesis. Firstly, Ekdahl et al showed that 
intrahippocampal administration of LPS reduced neurogenesis in the adult 
hippocampus (Ekdahl et al., 2003). Monje et al, showed that this effect 
was prevented by indomethacin, a non-steroidal anti-inflammatory 
drug(Monje et al., 2003). In addition, Belarbi et al, showed that 
treatment with LPS also prevents the integration of new neurons into 
behaviourally relevant network(Belarbi et al., 2012). In humans, Marsland 
et al have shown that circulating interleukin-6, covaries inversely with 
hippocampal grey matter volume in middle aged adults even after 
controlling for a number of confounding factors(Marsland et al., 2008). 
The concept of IREA also resonates with the concept of “allostatic load” 
described by McEwen(McEwen, 1998). Allostasis has been described as the 
process of adaptation to acute stress, involving the activation of both the 
Sympathetic Adreno-medullary (SAM) and Hypothalamic – Pituitary – adrenal 
(HPA) axes in order to restore homeostasis when faced with a challenge. 
“Allostatic load” refers to the price the body pays for being forced to adapt to 
adverse situations – i.e. the wear and tear that the body experiences as a result 
of activation of the above systems. This wear and tear, represents either the 
‘excess’ or the ‘inefficient’ operation of the above systems and can occur due to 
one of four mechanisms – repeated stress leading to repeated activations of 
these systems over time, failure of the systems to adapt to multiple stimuli, 
failure to shut down after being activated once, or the other extreme, where 
the systems do not get activated at all (e.g. in autoimmune diseases). It is not 
surprising that, in this context, inflammation plays a key role in the process of 
allostasis. A number of studies have shown a significant association between 
allostatic load (measured using a composite score of inflammatory and metabolic 
markers) and medical health (for e.g. cardiovascular disease) and mental ill 
health (like major depression) (Juster et al., 2010). If indeed, inflammatory 
processes are important in the aetio-pathogenesis of MDD, a number of 
important questions still remain un-answered.  
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• Are the suggested biomarkers important in the aetio-pathogenesis of MDD or 
are they merely an epiphenomenon associated with MDD? 
• Do peripheral markers of inflammation in humans correlate with brain 
markers in what is essentially an illness of the central nervous system?  
• Is there CNS inflammation in MDD? 
• Does correcting peripheral inflammation also correct central inflammation? 
• If inflammatory markers are involved in the pathogenesis of major 
depression, does a dose response relationship exist between these markers 
and brain function?  
• How stable are these markers and what is the normal variability associated 
with the measures? Further studies are required to elucidate these processes. 
1.3  High risk of MDD is associated with greater 
inflammation  
In this section, I will explore the literature pertaining to the relationship 
between inflammation and mental health/brain in the context of socioeconomic 
status (SES) and medical illness. While the primary aim of this dissertation is not 
to explore the relationship between SES / medical illness and inflammation, in 
this section, I would like to present evidence that suggest SES and medical 
illnesses are risk factor for both raised inflammatory markers and mental illness. 
While the relationship between medical illnesses, particularly those that involve 
autoimmune processes and inflammation are clearly obvious, the relationship 
between SES and inflammation are less clear. I will review data from both cross 
sectional and longitudinal studies that illustrate associations and potential 
causal links between SES/medical illnesses, inflammation and mental health. My 
review will concentrate primarily on major depressive disorder, as this is the 
most prevalent mental illness that has been associated with SES and greater 
inflammation. However, I will occasionally dip into evidence from other 
psychiatric conditions.  
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1.4 SES and mental illness 
1.4.1 What is SES 
Socio-economic status (SES) refers to a multidimensional construct that is usually 
measured using a number of economic (e.g. income) and noneconomic (e.g. 
education) indicators (Hackman et al., 2010). SES can be measured at an 
individual/household or at a neighbourhood level. At an individual level, it may 
be measured using a number of markers that take into account a person’s SES as 
a child or as an adult. However, individual level explanations for poor health do 
not capture important disease determinants (Diez Roux and Mair, 2010). 
Neighbourhood level deprivation has been associated with poor health outcomes 
due to segregation based on ethnicity and individual level SES. This can lead to 
inequalities in resource distribution, which can further worsen the segregation. 
These segregated neighbourhoods have physical (e.g. access to food, quality of 
housing) and social (e.g. violence, cohesion) attributes that are contributors of 
health outcomes.  However, Individual level characteristics may modify the 
relationship between neighbourhood and health outcomes (Stafford and Marmot, 
2003).  
1.4.2 Lower Socioeconomic status is associated with greater risk 
of mental illnesses. 
A number of studies have shown an association between socioeconomic 
disadvantage and mental illness. While most of the studies have shown an 
association between lower SES and greater prevalence of mental illnesses, some 
studies have also shown an association between SES and incident mental 
illnesses. While greater prevalence of mental illness does not necessarily show a 
causal relationship, greater incidence of mental illness suggests that there may 
be a causal link between the two.  
In a cross sectional analysis of the National Comorbidity Survey, Kessler et al 
found that rates of all disorders increased with lower SES as measured using 
education status or income (Kessler et al., 1994). They found that the 
significantly greater risk involved with low SES were consistently larger in 
predicting 12-month than lifetime prevalence (Kessler et al., 2005). They 
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suggest that this meant that socioeconomic status was associated not only with 
onset but also with course of disorder. The cross sectional nature of the data 
prevented them from commenting on whether this was due to causal influence 
or to drift.  
Pulkki-Raback et al in a large cross sectional study of nationally representative 
sample of 4561 men and women aged 30–65 years in Finland – a high income 
country - found that low income (but not education or occupation status) was 
associated with an increased risk of depressive disorders [OR = 1.73] and anxiety 
disorders [OR=1.56] (Pulkki-Raback et al., 2012).  
In a longitudinal analysis of two waves of data collected in the New Haven 
epidemiologic catchment area study, Bruce et al found that poverty status at 
the first wave of the study, predicted an increased risk of development of any 
psychiatric disorders (OR = 1.92) – including major depressive disorder 
(OR=2.5)(Bruce et al., 1991). de Graaf  et al using data  from the Netherlands 
Mental Health Survey and Incidence Study, a prospective epidemiologic study of 
7,076 adults age 18–64 years who were interviewed with the Composite 
International Diagnostic Interview, found that lower educational level was 
associated with an increased risk of anxiety disorders (OR = 2.32) (de Graaf et 
al., 2002). In addition, lower educational level (OR =2.69), and unemployment 
(OR = 1.73) were associated with comorbid anxiety and mood disorders but not 
with pure mood disorders.  
Lorant et al conducted a meta-analysis of 51 prevalence studies, five incidence 
studies and four persistence studies to examine the relationship between SES 
and psychiatric morbidity (Lorant et al., 2003). They found that those from the 
lowest SES, had a higher odds of being depressed (OR-1.81) compared to those 
from the highest SES. They were also at greater risk of developing a new episode 
of depression (OR = 1.24) and also persisting depression (OR=2.06).  
1.4.3 Social causation vs Social selection theories 
Whether socioeconomic status is a cause or consequence of mental illness has 
long been a topic of debate. In this context, there are two main theories that 
have dominated the research that have explored the relationship between SES 
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and mental illnesses. The social causation theory suggests that conditions of life 
associated with low socioeconomic status markedly increase the risk of mental 
disorders. In other words, a person with a low SES is likely to develop a mental 
illness due to various adverse situations that he/she goes through.  On the other 
hand, the social selection hypothesis suggests that SES per se do not increase the 
risk of developing mental illnesses. However, once a person develops a mental 
illnesses, it impairs his/her attainment of social and occupational status that 
may in turn, drive the person down the social ladder (social drift).  
Classic studies by Kessler etc, have suggested the former explanation for the 
relationship between SES and mental health (Kessler et al., 2005, Kessler et al., 
1994). In fact, recent longitudinal studies do suggest that these mechanisms are 
particularly relevant for some conditions, but may not be for other conditions. 
For example, the Dunedin study found no support for either causation or 
selection processes suggesting that SES and depression have little influence on 
each other before the age of 21(Miech et al., 1999). In that study, depression at 
age 15 was not overrepresented among lower SES families, it did not influence 
subsequent educational attainment, and increases in depression between ages 
15 and 21 were not significantly overrepresented among study members with low 
educational attainment. However, the study population examined there 
consisted of adolescents and was not followed up to adulthood. Some of the life 
stressors that have been consistently linked to major depression – like divorce, 
or loss of jobs - may not have occurred at this age group, and hence the negative 
findings.  
More recently, Skapinakis et al in a longitudinal study of 2406 individuals in the 
general population found that financial difficulties at the baseline were 
independently associated with depression at 18 months follow up (Skapinakis et 
al., 2006). Another longitudinal study, using the Canadian national population 
health survey cohort, followed up 9589 patients over 6 years. They found that 
low education level and financial strain were associated with greater risk of MDE 
in those who worked (Wang et al., 2010).  
A seminal study published in 2005 by Christopher Hudson, who used structural 
equation modeling to show that SES does indeed exhibit a causal role in this 
relationship, presents the best evidence for social causation (Hudson, 2005). 
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Hudson used a statewide epidemiological data to show an association between 
lower SES and presence of mental illness. In addition, he showed that greater 
economic stress (but not family disintegration) played a mediating role in this 
relationship. Hudson found no evidence for either a geographic drift or individual 
socioeconomic drift in this population.  
1.4.4 Stressful life events may account for the link between SES, 
greater inflammation and mental health. 
Hatch et al (2007) conducted a systematic review of articles published between 
1967 and 2005 to examine the predictors of stressful and traumatic life events 
(Hatch and Dohrenwend, 2007).  They searched the following databases: Health 
and Psychological Instruments, MEDLINE, Psychinfo, Pubmed, and Socio- logical 
abstracts using the following search terms  “life events, stressful life events, life 
change, life stress, traumatic events, and/or stress”. They found that both 
traumatic and other stressful evens are reported at higher rates in the lower 
socioeconomic status groups. They suggest that this higher rates could be 
attributed to the limited opportunities and resources in lower SES that may 
expose the groups to greater negative events. However, they also conclude that 
the lower SES also may be associated with recall biases related to higher levels 
of distress in those living in low SES environments.  
In addition, neighbourhood level deprivation has been associated with greater 
stressful life events. Steptoe et al, in a study of 419 residents from 18 high SES 
neighbourhoods and 235 from 19 low SES neighbourhoods, found that 
neighbourhood problems were more common in those who lived in the low SES 
neighbourhoods and was  associated with poor self rated physical and mental 
health (Steptoe and Feldman, 2001). They suggest that residential 
neighbourhood problems can constitute a source of chronic stress that may 
increase the risk of poor health. However, it is likely that individual level SES 
may moderate the effects of neighbourhood deprivation. There is now evidence 
that although both individual level and neighbourhood deprivation increase the 
risk of poor mental health, the effect of neighbourhood deprivation was more 
marked in poorer individuals(Stafford and Marmot, 2003).  
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More recently, prospective studies have shown an association between SES and 
mental health. In particular, some reports have shown that life stressors 
determine the association between SES and mental health. Businelle et al 
conducted a mediation analysis on data from two waves of the National 
Epidemiologic survey on alcohol and related conditions study (Businelle et al., 
2013). Controlling for mental health during wave 1, they examined the 
relationship between socioeconomic variables during wave 1 and mental health 3 
years later – during wave 2. They also measured stressor exposure during wave 1.  
They found that SES during wave 1 predicted changes in mental health ratings in 
wave 2. More interestingly they found that the number of life stressors mediated 
the relationship between socioeconomic status and mental health.  
Prospective studies in children have also shown that cumulative life risks across 
childhood, mediate the relationship between poverty and chronic physiological 
stress. For example, Evans and Kim showed that the relationship between the 
time spent in poverty between birth and age 9 was linked to elevated allostatic 
load – a marker of chronic physiological stress (measured as a composite 
measure of resting diastolic and systolic blood pressure; overnight epinephrine, 
norepinephrine, and cortisol; and BMI)- at age 17 (Evans and Kim, 2012). More 
importantly they showed that a cumulative risk exposure measured at age 13 
(measured as exposure to physical risk factors and psychosocial risk factors) 
mediated the relationship between the exposure to poverty and elevated 
physiological risk. Evans and Schamberg also showed in the above population 
that the cumulative physiological stress (allostatic load) mediated the 
relationship between exposure to poverty in childhood and working memory in 
adulthood (Evans and Schamberg, 2009). 
Similar to greater life stressors, a number of cross sectional and longitudinal 
studies have shown an association between lower SES and greater circulatory 
inflammatory markers. Petersen et al found that both individual level and 
neighbourhood level SES was associated with greater inflammatory markers – 
CRP and Il6 in adults aged 30 to 54 years (Petersen et al., 2008). Koster et al 
examined the association between SES and inflammatory markers in adults aged 
between 70 and 79 (Koster et al., 2006). They examined SES using education, 
income, and ownership of financial assets. They found that low SES was 
associated with greater serum levels of interleukin-6, C-reactive protein, and 
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tumour necrosis factor-alpha, which was partly explained by greater smoking, 
drinking and obesity in the low SES group. 
More recently, prospective cohort studies have shown an association between 
life course socioeconomic status and raised inflammation. Stringhini et al 
examining the a prospective occupational cohort of adults from the British 
Whitehall II study found that cumulative exposure to low SES from childhood to 
middle age was associated with greater inflammatory markers – CRP and IL6 
levels after adjustment for sex, age and ethnicity (Stringhini et al., 2013). They 
also found cumulative low SES to be associated with greater risk of type 2 
diabetes.  
Caroll et al examined the association between SES across distinct periods of 
childhood (averaged across 2 year periods between age 1 and 18) and levels of IL 
6 in adulthood (Carroll et al., 2011). They found that lower SES during early 
childhood (years 1 and 2) was associated with greater levels of IL 6 in adulthood. 
They suggest that early environment may program immune phenotypes that 
contribute to disease risk. SES differences in gene regulation of response to 
stress can be reflective of environmental/dietary exposures occurring over the 
life course or be a direct consequence of developmental programming in early 
life. 
Stringhini et al proposed that elevated inflammation that result from altered 
gene expression and unhealthy lifestyle might mediate the association between 
SES and type-2 diabetes (Stringhini et al., 2013). Taking a similar approach, it 
could be argued that as autonomic nervous system (ANS) and the HPA axis are 
thought to play an important role in regulating circulating inflammatory 
markers, SES could impact on peripheral immune/ inflammatory markers through 
these stress-mediated pathways (HPA/ANS). The inflammatory and stress related 
pathways together have an impact on the brain (through signaling pathways 
mentioned earlier), thereby making it vulnerable to mental ill health (Figure 1-
1). 
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Figure 1-1: A simplified pathway through which socioeconomic status may affect mental 
health.  
 
 
 
Socioeconomic deprivation has been shown to be associated with greater risk of mental ill 
health. This relationship may be mediated through elevated inflammation that results from 
altered gene expression, unhealthy lifestyles, dysregulation of HPA and ANS axis as a result 
of adverse life events/ stressors. (This diagram is modified from Stringhini S, Batty GD, 
Bovet P, Shipley MJ, Marmot MG, et al. (2013) Association of Life-course Socioeconomic 
Status with Chronic Inflammation and Type 2 Diabetes Risk: The Whitehall II Prospective 
Cohort Study. PLoS Med 10(7): e1001479.)   
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1.5 Depression in the context of inflammatory medical 
conditions 
One possible way of improving our understanding of the relationship between 
inflammation and MDD is the study of MDD co-morbid with physical (medical) 
illness. This allows us to explore how a known inflammatory patho-physiological 
process might impact on the brain. MDD occurs at a 5-10 times higher rate in 
those with medical illness, and worsens prognosis and disability. This is 
particularly true when the medical illness is associated with an autoimmune 
process. MDD is by far the most common psychiatric manifestation of Multiple 
Sclerosis, with a lifetime prevalence of around 50% and rates of suicide as high 
as 15% (Lo Fermo et al.). This association is also seen in peripheral (as opposed 
to only CNS) inflammation, in diseases such as Psoriasis, Rheumatoid Arthritis 
(RA) and inflammatory bowel diseases. Conservative estimates of rates of MDD 
are between 13% and 30% in these patients (Krishnadas et al., 2011, Dickens et 
al., 2002, Graff et al., 2009). This is also true in cases of medical illness with 
“low grade” inflammation, eg cancer, stroke, coronary artery disease and 
epilepsy that are not traditionally considered to have a primary inflammatory 
aetio-pathology. Acute brain ischemia is associated with an inflammatory 
response that contributes to ischemic damage (Pascoe et al., 2011). 
Conservative estimates suggest that around 30% of people who survive a stroke 
experience clinical MDD (Hackett and Anderson, 2005). Similarly, epilepsy is 
associated with significantly high rates of MDD. Pro-inflammatory cytokine 
mediated changes in glutamatergic neurotransmission are thought to be relevant 
in the etio-pathogenesis of seizure and epilepsy(Vezzani et al., 2008a, Vezzani 
et al., 2011). Similar rates of MDD are seen in cancer and cardiovascular illness 
(Celano and Huffman, 2011). In the context of medical illness, inflammation may 
trigger a major depressive episode in vulnerable individuals. Inflammation, in 
this context may act as a precipitating and perpetuating factor in predisposed 
individuals.  Karg et al in a recent meta-analysis found that those with a short 
allele (SS) functional polymorphisms (5-HTTLPR), of the promoter region of the 
serotonin transporter gene, (predisposition) were more likely to develop a MDD 
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episode in the presence of specific medical condition (stressor)(Karg et al., 
2011).  
1.5.1 Cytokine therapy induces depressive symptoms 
Cytokines such as IFN-α (interferon alpha) and IL-2 (interleukin 2) are used as 
immunotherapy for the treatment of chronic hepatitis C and cancer (Myint et 
al., 2009, Capuron et al., 2002). There is good evidence to suggest that those 
who undergo these treatments are more prone to develop MDD. Sockalingam et 
al recently reviewed 9 prospective studies that used clinician-rated measures to 
detect major depressive disorder in patients treated with interferon-α for 
hepatitis C (Sockalingam et al.). They found that the prevalence of IFNα-induced 
depression was in the range of 10% to 40% with more rigorous studies suggesting 
a prevalence approximating 20% to 30%.  How these cytokines induce depressive 
changes, is a matter of much debate. Interferon-α-induced depressive symptoms 
are associated with changes in cytokine levels in the serum. Capuron and Miller 
proposed the timeline for the development of depressive symptoms during 
treatment with IFN alpha (Capuron and Miller, 2011). They suggest that within 
the first 4 weeks of treatment, people develop neurovegetative factors (similar 
to sickness behaviour) . However, in people who are vulnerable, core mood/ 
cognitive symptoms start to appear within 8 to 12 weeks (Figure 1-2).  The 
temporal relationship between the onset of inflammation, the onset of physical 
and emotional symptoms may however depend on the type of inflammatory 
stimulus, the instruments used to measure the symptoms and the presence of 
other comorbidities. For example, Wright et al have shown that injection with 
Typhoid vaccine in human adults can induce negative mood within hours of 
injection(Wright et al., 2005). They measured used the profile of mood states 
(POMS) scale, an instrument that can detect subtle fluctuations in mood.  
 
.  
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Figure 1-2: Temporal evolution of the neuropsychiatric symptoms induced by chronic 
interferon-alpha therapy.  
 
Interferon (IFN)-alpha therapy induces two types of behavioural symptoms with differential 
time course and responsiveness to antidepressants. The neurovegetative symptoms (e.g., 
fatigue, anergia and psychomotor slowing) develop rapidly (as soon as week 1 [W1]) in 
almost every individuals exposed to cytokines and persist during the duration of IFN-alpha 
therapy. These symptoms are minimally responsive to antidepressant treatment. In 
contrast, the mood and cognitive symptoms (e.g., depressed mood, anxiety, irritability, 
memory and attentional disturbance) develop in vulnerable patients at later stages of IFN-
alpha therapy (between weeks 8 and 12) and are highly responsive to antidepressant 
medication. Reused with permission from Capuron and Miller 2011 Immune system to brain 
signaling: Neuropsychopharmacological implications Pharmacology and therapeutics. 
Volume 130, Issue 2, May 2011, Pages 226–238  
 
A number of studies have therefore examined if there are certain biomarkers 
associated with depressive changes, that may predict who will go on to develop 
depression when treated with these cytokines. IFN-α treatment may directly or 
indirectly affect neurotransmitter systems in the CNS. A reduction in peripheral 
serotonin level has also been demonstrated in hepatitis C patients during IFN-α 
treatment (Schafer et al., 2010). Several studies have demonstrated positive 
correlation between increased depression symptoms during IFN-α therapy and 
metabolites of Indolamine deoxygenase enzyme (see below) in blood and CSF of 
patients with hepatitis C (Raison et al., 2010).  Another area of much interest 
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has been, trying to predict who will develop MDD in response to these 
treatments. Interestingly the short allele of 5HTTLPR has been associated with 
increased risk of depressive symptoms during IFN-α therapy(Bull et al., 2009). 
However, the findings are not consistent. A more recent study of hepatitis C 
patients demonstrated that those with ‘high transcription’ serotonin genotype 
(LL) showed greater depressive symptoms during IFN-α therapy compared to 
those with the short allele (SS) (Pierucci-Lagha et al., 2010).  Other studies have 
implicated polymorphisms in other genes (e.g. IL6) that may confer greater risk 
or protection from developing MDD in response to cytokine treatments (Bull et 
al., 2009). 
Lotrich et al in a prospective study of 124 euthymic people undergoing IFN 
alpha, assessed if  serum BDNF and the Val66Met BDNF polymorphism and the 
SERT ss/ll promoter region polymorphism predicted the depressive symptoms 
during treatment (Lotrich et al., 2009). Lower pre treatment BDNF was 
associated with higher depressive symptoms during IFN alpha treatment. 
However the Met allele was only associated with increased MADRS scores but not 
BDI or HADS. Met allele was also associated with suicidal ideation and sadness 
and worthlessness (cognitive / mood symptoms) but not the neurovegetative 
symptoms. Interestingly,  the SERT ss polymorphism was associated with 
neurovegetative symptoms, but not cognitive symptoms. IFN therapy also 
reduced the BDNF levels in serum. However, this was not associated with the 
development of depression. They suggest that while decrease in BDNF was not 
associated with a worsening of depressive symptoms, the fact that those who 
developed depressive symptoms had lower pre treatment BDNF, suggest that 
greater BDNF levels prior to treatment may protect against developing mood 
symptoms 
1.6 How may pro-inflammatory cytokines cause MDD? 
Pro-inflammatory cytokines may provoke changes in brain structure and 
function, leading to the development of MDD. The mechanisms by which these 
peripheral inflammatory responses signal the brain is unclear. Cytokines can 
directly modulate pathways implicated in the aetiology and treatment of 
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depression. Suggested mechanisms include the effect of cytokines on the HPA 
axis, on neurotransmission; and direct action on hippocampal neurogenesis. 
1.6.1 Cytokines exist in the brain, and may therefore exert an 
effect on the brain 
Traditionally the brain was considered an “immune –privileged” organ. However, 
it is now known that the brain is indeed susceptible to immune-mediated insult. 
Cytokines are large proteins – proteins, peptides or glycopeptides – that form 
part of a large family of cell signalling molecules. They are formed and released 
as a “cascade”, where induction of one of the molecules can trigger the 
activation of a number of molecules. In the brain, cytokines are produced by 
neurons, microglia and astrocytes. Cytokines in the brain are “gliotransmitters” 
that act on a number of receptors, and are thought to be key in a number of 
brain functions. They may be activated in a number of ways as shown Capuron 
and Miller in Figure 1-3. Where the primary focus of immune activity is the brain 
(eg post-stroke depression, MS), it is thought that cytokines are produced in the 
brain itself. Additionally, we now know that peripheral cytokines can signal the 
brain through at-least 5 mechanisms(Capuron and Miller, 2011). 
a. Passage of cytokines through “leaky” regions in the blood brain barrier (BBB) – 
e.g. the circumventricular organ - Humoral pathway 
b. Active transport of cytokines across BBB  
c. Transmission of signals along the afferent vagal pathway - neural pathway 
d. Entry of activated monocytes from periphery into the brain – chemokines are 
increasingly seen as having a role here.  
e. Second messenger signals from endothelial lining of the BBB, which in turn, 
leads to an excess production of cytokines by glia. 
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Figure 1-3: Communication pathways from the periphery to the brain.  
 
Different pathways by which cytokine signals access the brain have been identified. A) 
Humoral pathway: Pro-inﬂammatory cytokines released by activated monocytes and 
macrophages access the brain through leaky regions of the blood-brain barrier such as the 
choroid plexus and circumventricular organs (CVOs). Within the brain parenchyma, the 
activation of endothelial cells is responsible for the subsequent release of second 
messengers (e.g., prostaglandins [PGE2] and nitric oxide [NO]) that act on specific brain 
targets. B) Neural pathway: Pro-inﬂammatory cytokines released by activated monocytes 
and macrophages stimulate primary afferent nerve fibres in the vagus nerve. Sensory 
afferents of the vagus nerve relay information to brain areas through activation of the 
nucleus of the tractus solitarius (NTS) and area postrema. C) Cellular pathway: A cellular 
pathway has been recently described by which pro-inﬂammatory cytokines, notably TNF-α  , 
are able to stimulate microglia to produce monocytes chemoattractant protein-1 (MCP- α), 
which in turn is responsible for the recruitment of monocytes into the brain. Reused with 
permission from Capuron and Miller 2011 Immune system to brain signalling: 
Neuropsychopharmacological implications Pharmacology and therapeutics. Volume 130, 
Issue 2, May 2011, Pages 226–238. 
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1.6.2 Action on neurotransmitters 
1.6.2.1 Monoamine neurotransmission 
Serotonin (5-hydroxytryptamine, 5-HT), a monoamine neurotransmitter, has 
been implicated in many normal behaviours, including sleep, appetite, sexual 
behaviour(Canli and Lesch, 2007). It has also been implicated in cognitive and 
emotional function. More importantly, it is implicated in the mono-amine theory 
of depression (Schildkraut, 1965). In short, this hypothesis suggests that 
depressive states are caused due to a decrease in monoamine neurotransmitters 
– particularly serotonin in the synaptic cleft. Serotonin that is released into the 
synaptic cleft is either metabolised or actively transported back into the neuron 
by a protein in the neuronal cell membrane(Maximino, 2012). This protein is 
called the Serotonin transporter / reuptake transporter (SERT). The gene that 
codes for this protien (SERT) is situated on chromosome 17. This gene 
transcription is regulated by a polymorphic promoter region – (5HTTLPR) (Canli 
and Lesch, 2007).  
Serotonin levels in the brain are controlled by a number of factors including rate 
of synthesis, rate of release into the synaptic cleft, rate of enzymatic 
breakdown, rate of diffusion through the extracellular space and active reuptake 
(Hornung, 2010, Maximino, 2012). In the brain, SERT seems to be the 
predominant mechanism controlling the strength and duration of serotonergic 
neurotransmission. Therefore it is likely that SERT availability is directly related 
to serotonergic neurotransmission. In humans, SERT has been clearly identified 
in a number of brain regions, including the brain stem, hypothalamus, occipital 
and frontal cortices (Hornung, 2010). In the neurons, SERT is located in the 
presynaptic terminus – i.e. the axonal nerve endings. SERT plays a key role in 
scavenging serotonin transporter from synaptic cleft back to the axonal nerve 
ending. Surprisingly SERT is found in neuronal cells and non-neuronal cells. In 
humans, SERT has been found in glia, platelets, the GIT, monocytes and the 
placental syncitioblast.  
A number of studies have shown that the immune system may have prominent 
effects on SERT in cell systems and in adult animals (Baganz and Blakely, 2013). 
For example, as early as 1995, Ramamoorthy et al showed that interleukin-1β 
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(IL-1β) stimulates the activity of SERT in human JAR choriocarcinoma 
cells(Ramamoorthy et al., 1995). The stimulation was associated with an 
increase in the steady state levels of transporter mRNA and transporter density. 
They also showed that this increase in SERT mRNA was blocked by actinomycin D 
– a transcription inhibitor, thus suggesting that the increase in mRNA may due to 
an increased transcription of the SERT DNA. They in addition showed that this 
regulation may be independent of the cAMP pathway. However, there also seems 
to be cell surface SERT trafficking independent mechanisms through which 
inflammation may affect serotonin neurotransmission. Zhu et al. (2006) showed,  
that both IL-1β and TNF-α cause rapid activation of SERT in raphe neuron 
derived RN46A cells (Zhu et al., 2006). They also found that this increase in 
activity was p38 MAPK dependent. Given p38MAPK has an important role in 
sustaining SERT expression at the plasma membrane immune factors that 
operate via this signalling mechanism could have marked effects on serotonergic 
neurotransmission.  
SSRI antidepressants have been reported to be effective in inducing and 
sustaining remission of inflammation in patients with rheumatoid arthritis 
(Krishnadas and Cavanagh, 2011). There seems to be a bidirectional relationship 
between serotonergic systems and inflammation. A key site of action of 
antidepressants is the serotonin transporter (SERT), which regulates serotonergic 
neurotransmission. There is increasing data in animal and humans to suggest that 
inflammation is associated with neuronal SERT activity. Cavanagh et al in a small 
pilot study of 6 subjects, have previously shown that treatment with TNF-α 
blockade agent adalimumab led to a decrease in serotonin transporter binding 
by up to 20%, using [123I] Beta CIT – SPECT (Cavanagh et al., 2010).  
There is evidence that proinflammatory cytokines including TNF-α induce glial 
indoleamine dioxygenase (IDO)(Maes et al., 2011). This activates the kynurenine 
pathway, thus channelling the available dietary tryptophan (the substrate for 
serotonin synthesis) to form Kynurenine (Kyn), 3 Hydroxy kynurenine (3HK) and 
Quinolinic acid (QUIN), rather than the serotonin (5HT). In addition to decreasing 
serotonin availability in the neuron, the accumulating 3HK and QUIN- both NMDA 
receptor agonists, contribute to excitotoxicity and calcium mediated cell death 
(Christmas et al., 2011).  
Chapter 1  45 
 
Conversely, serotonergic systems have been found to significantly impact on 
inflammatory pathways. Descending spinal serotonergic pathways have been 
implicated in the physiology of pain modulation. Zhao et al showed that 
knockout mice that lacked these descending serotonin pathways in the brain 
exhibited enhanced inflammatory pain (but normal visceral and thermal pain) 
compared with their littermate control mice. They showed that the analgesic 
effects of SSRI antidepressants were absent in this strain of mice, suggesting 
that serotonergic pathways play an important role in modulating inflammatory 
pain, compared with mechanistic pain (Zhao et al., 2007).  
Recent findings suggest that antidepressants have anti-inflammatory and 
analgesic properties. O’Brien et al showed that CRP levels dropped following 
treatment with antidepressant (O'Brien et al., 2006). Piletz et al found that 
raised proinflammatory biomarkers in patients with major depressive disorder 
showed a decrease in response to treatment with venlafaxine (a serotonin and 
nor-epinephrine reuptake inhibitor, exhibiting serotonin reuptake inhibition at 
lower doses, and norepinephrine reuptake inhibition at higher doses) at the 
serotonergic (lower) dose range rather than the norepinephrine (higher) dose 
range, suggesting that sertonergic pathways mediate anti-inflammatory response 
to antidepressants (Piletz et al., 2009).  
Recent experimental data show that peripheral activation of 5-HT2A receptors in 
primary aortic smooth muscle cells leads to an extremely potent inhibition of 
TNF-α mediated inflammation, another possible mechanism of action of SSRIs in 
mediating the anti-inflammatory action (Yu et al., 2008). SSRIs including 
escitalopram are thought to increase extracellular serotonin concentrations at 
these receptors. However, SSRIs are thought to down-regulate 5HT2A in the long 
run. Surprisingly, blockade of 5HT2A receptors also has the same effect, i.e. 
down-regulation. However, it is possible that down-regulation of these receptors 
decreased with age, suggests that SSRI antidepressants may have a potential role 
in treating inflammatory conditions, at least in the older population. In spite of 
the good evidence for the use of tricyclic antidepressants and venlafaxine in the 
treatment of neuropathic pain (NNT = 3), data regarding the use of SSRI in 
neuropathic pain is inconclusive (Saarto and Wiffen, 2007). Evidence for the use 
of antidepressants in inflammatory conditions is even less promising, largely due 
to the lack of good quality data. Richards et al reviewed the available evidence 
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for the efficacy of antidepressants in pain in patients with RA, and found no 
conclusive evidence (Richards et al., 2011).  They reviewed eight randomised 
controlled trials looking at tricyclic antidepressants and two trials evaluated a 
SSRI as a comparator. The quality of the studies included was poor, and there 
was insufficient data for a number needed to treat to be calculated for the 
primary outcome measure of pain. They conclude that there is currently 
insufficient evidence to support the routine prescription of antidepressants as 
analgesics in patients with RA and that the use of these agents may be 
associated with greater adverse events. Similarly, Micocka-Walus in a review of 
12 non randomised controlled studies of antidepressants in inflammatory bowel 
disease, found no conclusive evidence of efficacy of antidepressants on disease 
prognosis in IBD (Mikocka-Walus et al., 2006). They found that although there 
was some benefit in the use of antidepressants in IBD, the quality of data 
available to reach a conclusion was not good enough. The authors of the both 
the above reviews, propose that better conducted prospective studies are 
required to address this issue.  
More recently, Thorsland et al showed a relationship between SERT availability 
and disease severity, chronic stress and depression in patients psoriasis 
(Thorslund et al., 2013). They used biopsies from involved and non involved skin 
from the back of 20 patients with chronic plaque psoriasis. SERT levels in the 
skin were assessed using immunohistochemistry. They showed a positive 
correlation between number of SERT positive dendritic cells in patients with 
psoriasis and PASI scores. There was a negative correlation between the number 
of SERT positive cells and salivary cortisol levels. They suggest that the 
relationship between chronic stress (as measured using cortisol) and disease 
activity in psoriasis may be mediated by local SERT expression.  
Another monoamine that has been implicated in major depression is dopamine, 
particularly in symptoms associated with anhedonia and sickness behaviour. As 
with serotonin, proinflammatory cytokines influence the synthesis and reuptake 
of dopamine (Moron et al., 2003, Wu et al., 2007). 
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1.6.2.2 Glutamate neurotransmission 
Glutamate induced excitotoxicity - excess activation of neuronal glutamate 
receptors that ultimately leads to cell death - has been implicated in mediating 
neuronal death in many disorders, including stroke and neurodegenerative 
disorders. Glutamate induced excitotoxicity has also been implicated in 
psychiatric disorders like depression (Lee et al., 2002). Excessive accumulation 
of intracellular calcium is thought to be the major step that leads to neuronal 
cell death. The type of receptor that has been most implicated in glutamate 
excitotoxicity is the NMDA subtype. It is thought that overstimulation of these 
receptors would lead to an overload of calcium, and in turn, neuronal death. 
Other receptors, like the AMPA and Kaininate receptors, are also thought to play 
a role in excitotoxicity, as their ion channels are partially permeable to calcium 
(Mark et al., 2001). Inflammatory processes have been found to be associated 
with an increase in glutamate-induced neurotoxicity. Pro-inflammatory cytokines 
are thought to mediate this process (Vezzani et al., 2008b). Mechanisms by 
which these inflammatory mediators cause an increase in glutamate 
neurotransmission include  
a. Up-regulation and augmentation of glutamatergic pathway  
It has been recognized that hippocampal neurons exposed to IL1β and TNF-α 
intensify the excitotoxic neuronal damage induced through NMDA and AMPA 
receptors(Bernardino et al., 2005, Pickering et al., 2005). Action of IL1 β on 
the glutamatergic system is thought to be through its action on the IL1 R1 
receptors. These receptors co-localise with NMDA receptors on hippocampal 
neurons. NMDA receptors consist of two subunits NR1 and NR2. NR2 subunits 
have further isoforms (Mark et al., 2001). It is proposed that IL1 β induces 
phosphorylation of the NR2B isoform, which leads to an upregulation of NMDA 
receptor function. This leads to an increase in calcium influx into the neuron, 
and consequent cell death (Viviani et al., 2003). 
b. Increased release and reuptake inhibition of glutamate  
IL1 β has also been found to inhibit the reuptake of glutamate by the glial 
cells. This is thought to be mediated through the action of these 
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proinflammatory cytokines on the expression of glutamate transporter. This 
malfunction of the transporter leads to an increase in extracellular glutamate 
and further NMDA mediated excitotoxicity. In addition to this, IL1β has been 
found to activate NO synthase which leads to an increase in production of NO 
and hence an increase in glutamate release (Hu et al., 2000).  
c. Action on AMPA receptors  
TNF-α has been shown to influence the trafficking of AMPA glutamate 
receptors in inflammatory conditions. Normally AMPA receptors have 4 
subunits GluR 1-4. The presence of TNF-α leads to a production of AMPA 
receptors lacking the GluR2 subunit. This receptor conformation is said to 
facilitate calcium influx into the neuron. This predisposes the neuron to 
glutamate induced excitotoxicity (Stellwagen et al., 2005).  
d. Activation of kynurenine pathway  
The impact of the kynurenine pathway on excitotoxicity was described 
earlier. This activation of kynurenine pathway by pro inflammatory cytokines 
thus channels the available tryptophan to form Kynurenine (Kyn), 3 Hydroxy 
kynurenine (3HK) and Quinolinic acid (QUIN). 3HK and QUIN are NMDA 
receptor agonists. High concentrations of these compounds are thought to 
contribute to excitotoxicity and calcium mediated cell death (Maes, 2008).  
1.6.3 Action on Hypothalamus- Pituitary – Adrenal (HPA) axis - 
HPA axis over-activity and glucocorticoid resistance 
HPA axis abnormalities have been reported in MDD (Pariante, 2003).  Over-
activity of this system has been attributed to glucocorticoid receptor (GR) 
resistance, secondary to either reduced expression of GR or decreased 
functionality of GR. There is some evidence that proinflammatory cytokines 
including TNF-α, induce glucocorticoid resistance through the above 
mechanisms. Functional inhibition is induced by preventing the entry of the 
cortisol-GR receptor complex into the nucleus (by inducing Jun aminoterminal 
kinase – JNK), and also by preventing the binding of the complex to the DNA (by 
inducing nuclear factor kB – NFkB) (Pace et al., 2007, Pace and Miller, 2009).  
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This in turn leads to altered expression of GR in the cells. Change in expression 
and functionality of the system can be measured in vitro, pre and post 
treatment, with TNF-α blockers. Recent work by Anacker et al links 
glucocorticoid mechanisms to neurogenesis (a process thought to be key in 
mediating the action of antidepressants). They suggest that an activation of the 
GR is necessary for the antidepressant-induced modulation of neurogenesis in 
humans (Anacker et al., 2011).  
1.6.4 Cytokine mediated neurogenesis and neuronal loss 
Neurogenesis in the hippocampus of the adult brain is thought to contribute to 
memory and learning. While, a pathogenic role for reduced hippocampal 
neurogenesis in depression is unclear, there is now considerable experimental 
evidence that the generation of new neurons in the dentate gyrus of the 
hippocampus is enhanced by antidepressant treatment (Sahay and Hen, 2007). 
There is a body of evidence to suggest that inflammation induces a decrease in 
neurogenesis. As mentioned above, this decrease may in part be due to HPA axis 
abnormalities, which, when corrected, restores neurogenesis. Cytokine-
mediated regulation of hippocampal neurogenesis in experimental animals is 
indicated by several pieces of evidence:- 
• Monje et al reported that neuroinflammation inhibits neurogenesis and that 
inflammatory blockage with an NSAID restores neurogenesis (Monje et al., 2003).  
• in exploring a potential mechanism underlying depression induced by IFN a, 
treatment, Kaneko et al found that IFN a suppressed neurogenesis in the 
dentate, and that IL1 β played an essential role in that suppression (Kaneko et 
al., 2006).  
• stress-induced reduction in hippocampal neurogenesis is attenuated by 
blockade of the IL1-beta receptor (Koo and Duman, 2008).  
• Mice deficient in TNF-α receptor-1 (responsible for neuronal damage) exhibit 
enhanced hippocampal neurogenesis (Iosif et al., 2006).  
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There is some data to suggest that inflammatory cytokines may affect the 
expression of trophic and growth factors. However the results are inconsistent 
(Saha et al., 2006). In spite of the above studies, there is still a dearth of data 
on the involvement of inflammatory mediators in decreasing neurogenesis. There 
are very few studies that have looked at the effect of anti-inflammatory drugs 
on neurogenesis and depression. 
1.6.5 Cytokine-induced inflammation modulates sickness 
behaviour and neuronal activation 
Systemic inflammation is known to elicit symptoms in healthy mammals, 
collectively called “sickness behaviour”(Capuron and Miller, 2011). This consist 
of behavioural changes, including disturbance in sleep, appetite, psychomotor 
slowing, memory impairment and behaviour that are thought to be very similar 
to biological symptoms of depression in humans(Dantzer et al., 2008, Kelley et 
al., 2003, Konsman et al., 2002). Interferon therapy is associated with sickness-
like symptoms, including lack of sleep, loss of appetite, weight loss, fatigue, 
usually occurred during the first 2-4 weeks of the therapy and can be early 
indicators for depression, which usually develops 1-3 month after the treatment 
(Capuron et al., 2002, Capuron and Miller, 2011). Capuron et al found that in 
spite of considerable overlap in symptom between cytokine-induced depression 
and idiopathic depression in medically healthy subjects, psychomotor symptoms 
were much greater in the cytokine induced MDD group, while cognitive 
distortions were greater in those with idiopathic MDD (Capuron et al., 2009). A 
common clinical experience is people receiving flu or typhoid vaccination 
developing symptoms of fatigue, psychomotor slowing and depressed mood. 
Clinical studies have shown that these changes are significantly associated with 
increased IL-6 levels (Wright et al., 2006, Wright et al., 2005). On fMRI, these 
people have also been shown to activate brain regions thought important in 
modulating mood. Areas that have been shown to be activated include the 
insula, an area thought to be important in body representation and subjective 
emotional experience, and substantia nigra that correlated with measures of 
fatigue and psychomotor slowing – findings that are consistent with the clinical 
findings of Capuron et al described above (Brydon et al., 2008, Harrison et al., 
2009b).  
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1.6.6 Cytokine-mediated cognitive dysfunction 
Neurocognitive function reflects functional integrity of neuronal structures. 
Patients suffering from MDD show a number of cognitive deficits during periods 
of illness – particularly in the domains of attention, memory and executive 
function. In patients who have recurrent episodes of MDD, deficits on 
performance on tests of executive function have been shown to persist into 
periods of recovery, suggesting that these deficits may be trait markers of the 
illness (Smith et al., 2006).  Cognitive dysfunction has been shown to correlate 
positively with the presence of proinflammatory cytokines and other 
inflammatory mediators in various illnesses (Wilson et al., 2002). There is 
considerable evidence to show that proinflammatory cytokines play an important 
role in cellular mechanisms underlying cognition including synaptic plasticity 
(Albensi and Mattson, 2000). IL1B and TNF-α play an important role in long term 
potentiation and depression. It is postulated that while normal levels of 
cytokines are essential for the consolidation and integration of AMPAs on the 
neuron, in excess, they tend to have a detrimental effect. In addition, TNF-α 
seems to play an important role in synaptic scaling (homeostatic plasticity) in 
hippocampal neurons(McAfoose and Baune, 2009). Any imbalance in the normal 
milieu of TNF-α is said to affect long term synaptic plasticity and hence 
cognition. In this respect, measures of neuro-cognition before and after 
treatment with TNF-α antagonists may provide us with some clue to the effect of 
the treatment on neuronal (structural/functional) integrity in various circuits/ 
parts of the brain involved in these tasks (McAfoose and Baune, 2009).  Recent 
reports show that TNF-α antagonist etanercept administered intrathecally has 
been used in the treatment of patients with Alzheimer’s disease (Tobinick, 
2009). Currently, there is one randomised controlled study underway, looking at 
the effects of sub-cutaneous etanercept in the treatment of alzheimer’s disease. 
(Clinicaltrials.gov - NCT01068353)
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2 Chapter 2. Problem statement and motivation 
for the project 
In the first chapter, I have summarised some evidence that may link 
inflammatory processes with mental illnesses, particularly Major depressive 
disorder. I have explored this in the context of major depressive disorder ( a 
primary psychiatric condition), medical illnesses and socioeconomic deprivation – 
the latter two being conditions that are high risk factors for the development of 
MDD.  However the relationship between circulating inflammatory markers and 
the brain is far from clear, especially in humans. Considering the theoretical 
evidence behind the relationship between inflammation and the brain, it is 
reasonable and worthwhile to explore the relationship between peripheral 
circulating inflammatory markers and the brain. 
 In the following chapters, I intend to describe methods and findings of a series 
of experiments that were conducted to answer one question (among the number 
of unanswered questions) 
Is there a relationship between circulating inflammatory markers in peripheral 
blood and the brain structure?  
In order to address this, I have done a series of analyses on both observational 
and interventional (experimental) data.  Firstly, I present observational data 
from a cohort of neurologically healthy individuals who have high levels of 
peripheral inflammatory markers in the context of neighbourhood 
deprivation(Velupillai et al., 2008). This cohort was derived from the larger 
PSOBID study, the details of which are available online. 
http://www.gcph.co.uk/work_themes/additional_work/psobid  
Secondly, I present data from an experimental study, exploring the effect of 
TNF-α Blockade treatment with Etanercept on the serotonin transporters in  a 
cohort of patients with a peripheral (non-CNS) inflammatory pathology – 
Psoriasis/ Psoriatic arthritis.  
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In order to measure the brain substrates, I have used two modes of imaging 
techniques – structural MRI and SPECT (to measure serotonin transporter).   
2.1 Aims of the thesis  
To explore the relationship between circulating inflammatory markers and the 
brain 
2.2 Objectives 
To use observational and experimental neuroimaging data to explore the 
relationship between circulating inflammatory markers and the brain. 
2.3 Overview of the following chapters 
1. In Chapter 3, I present the findings of an observational study that explores 
the relationship between circulating inflammatory and metabolic risk factors and 
cortical thickness in a cohort of neurologically healthy adult males. In this 
chapter, I conduct a correlation analysis of circulating inflammatory and 
metabolic markers with cortical thickness across the whole cerebral cortex. Here 
I show that inflammatory markers and indeed other metabolic markers may 
contribute to significant variance in the thickness across the cortical mantle.  
These findings were recently published as Krishnadas R, et al. Cardio-
metabolic risk factors and cortical thickness in a neurologically healthy 
male population: Results from the psychological, social and biological 
determinants of ill health (pSoBid) study.  Neuroimage Clinical. 2013 Apr 
22;2:646-57 (Krishnadas et al., 2013b). The materials in the chapter are 
presented with permission from the publishers. 
2. In Chapter 4, I explore the above relationship further, by demonstrating 
that a composite index of circulating inflammatory markers mediate the 
relationship between neighbourhood deprivation and cortical thickness. Using 
surface based morphometry, I initially show that neighbourhood deprivation is 
associated with differences in cortical thickness and surface area in regions of 
interest that have been implicated in key cognitive functions in the past. I then 
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used mediation analysis to show  that the relationship between SES and cortical 
thickness pertaining to the language regions of the brain, are at least in part 
mediated by greater inflammatory markers.  These findings were recently 
published as Krishnadas R, et al. Socioeconomic deprivation and cortical 
morphology: psychological, social, and biological determinants of ill health 
study. Psychosomatic Med. 2013 Sep;75(7):616-23 (Krishnadas et al., 
2013c). The materials in the chapter are presented with permission from 
the publishers. 
3. In chapter 5, I use complex network analysis using graph theory to show 
that network structural properties covary with neighbourhood deprivation. 
Specifically neighbourhood deprivation is associated with differences in 
modularity and overlapping modularity - a novel marker called grey nodes. I also 
show that greater circulating inflammatory markers at least in part mediate the 
difference in structural properties. The findings were recently published as 
Krishnadas R, et al. The envirome and the connectome: exploring the 
structural noise in the human brain associated with socioeconomic 
deprivation. Frontiers in Human Neurosciences. 7:722. doi: 
10.3389/fnhum.2013.00722 (Krishnadas et al., 2013a). The materials in the 
chapter are presented with permission from the publishers. 
4. In chapter 6, I explore the relationship between neighbourhood level 
deprivation and  cortical and subcortical regions that constitute the stress 
circuits. These included the hippocampus, amygdala and other cortical 
structures like perigenual anterior cingulate cortex (pgACC) and orbitofrontal 
cortex (OFC). Once again, I demonstrate that inflammatory pathways mediate 
the relationship between neighbourhood deprivation and cortical and subcortical 
stress circuits.  
5. In chapter 7, I present the findings of an experimental study that explores 
the relationship between circulating inflammatory markers and SERT in a cohort 
of patients with Psoriasis and psoriatic arthritis. Here, I also explore if TNF-α 
blockade therapy using Etanercept would be associated with a reduction in 
inflammation, and if this reduction in inflammation is associated with changes in 
SERT binding using SPECT (Beta CIT). I have also explored if this is associated 
with behavioural changes.  
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6. Finally, in chapter 8, I have summarised the finding from the thesis. I 
have detailed the limitations of the studies presented above, and provided a 
brief update on human research relevant to this area.  
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3 Chapter 3 - Relationship between cardio-
metabolic and inflammatory risk factors and 
cortical thickness in a neurologically healthy male 
population 
In this chapter, I will explore the relationship between circulating cardio-
metabolic risk markers - including the classic risk factors like circulating lipid 
levels and novel "emerging" risk factors like circulating inflammatory markers 
and the brain. The aim of the chapter is to explore the variance in cortical 
thickness across the mantle, that is attributable to circulating inflammatory and 
metabolic risk markers. Here, I used T1-weighted MRI to create models of the 
cortex for calculation of regional cortical thickness in 40 adult males (average 
age = 50.96 years). I examined the relationship between the above mentioned 
risk markers and cortical thickness across the whole brain, using general linear 
models. I also explored the relationship with other covariates of interest.   The 
findings of this chapter have been published in Krishnadas R, et al. Cardio-
metabolic risk factors and cortical thickness in a neurologically healthy male 
population: Results from the psychological, social and biological determinants 
of ill health (pSoBid) study. Neuroimage Clinical 2013 Apr 22;2:646-57.  
3.1 Introduction 
3.1.1 Classic cardio-metabolic risk factors and the brain 
Epidemiological studies have demonstrated a link between increasing body mass 
index (BMI) – a commonly used index to define obesity, elevated total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL), and triglycerides 
(TG) and cerebrovascular and cardiovascular disease (Denke et al., 1994, Krauss 
et al., 1998). While the above mentioned risk factors are thought to drive the 
development and progression of atherosclerosis, greater high-density lipoprotein 
(HDL) is thought to be anti-atherogenic and therefore protective against these 
diseases(Toth, 2004). These “classic” cardiovascular risk factors have also been 
associated with poor physical, mental health and neuro-cognitive function (Elias 
et al., 2005a, Elias et al., 2005b). Most studies that have examined the 
relationship between these risk factors and the brain in healthy adults have 
generally found an inverse association between the risk factors and brain 
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volume.   Gunstad et al in a large sample of 201 healthy individuals using voxel 
based morphometry (VBM) analysis, found that obese (BMI > 30) individuals had 
significantly smaller whole brain and total grey matter (GM) volume compared to 
normal and overweight individuals (Gunstad et al., 2008). Raji et al using tensor-
based morphometry (TBM) in 94 elderly subjects found that obese subjects with 
a high BMI (BMI > 30) showed atrophy in the frontal lobes, anterior cingulate 
gyrus, hippocampus, and thalamus compared with individuals with a normal BMI 
(18.5-25)(Raji et al., 2010). Studies that have examined the relationship 
between cholesterol and grey matter are fewer and have shown inconsistent 
results. For example, Ward et al in a sample of 183 individuals using VBM 
analysis did not find any association between non-HDL cholesterol and grey 
matter volume (Ward et al., 2010). They however found a significant positive 
correlation between HDL cholesterol and regional GM volumes pertaining to 
bilateral temporal and occipital regions. More recent studies have suggested that 
the relationship between these risk factors and brain morphology may be more 
complex, particularly in relation to cortical thickness (CT) - a robust measure 
that has been validated against histological analysis (Fischl et al., 2008, Rosas et 
al., 2002).  
3.1.2 Emerging risk factors (inflammatory markers) and the brain  
In recent years, novel biomarkers associated with inflammation and endothelial 
dysfunctions have ‘emerged’ as potential independent cardiovascular disease 
risk factors(Umemura et al., 2011, Wersching et al., 2010). These include high-
sensitivity C-reactive protein (hsCRP), an acute phase reactant protein, 
Interleukin-6 (IL-6), a pro-inflammatory cytokine and circulating forms of 
adhesion molecules like intercellular adhesion molecule (ICAM)-1, that are 
induced by inflammation and play a role in promoting atherosclerosis (Luc et al., 
2003, Danesh et al., 2008). These inflammatory markers have been shown to be 
associated with poor cognitive functioning in the healthy population and in 
disease (Phillips et al., 2011, Wright et al., 2006). Prospective studies have 
shown such factors to predict cognitive decline in initially healthy elderly 
subjects over follow-ups of between one and ten years (Yaffe et al., 2003, 
Teunissen et al., 2003). Greater inflammatory markers have also been shown in 
several psychiatric illnesses like depression, and schizophrenia (Dowlati et al., 
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2010, Miller et al., 2011). Although the precise role of these factors in 
neurocognitive function is not clear, there is evidence to suggest that 
inflammation may play a role in the aetiopathogenesis of mental and cognitive 
disorders(Krishnadas and Cavanagh, 2012). Other markers of haemostasis and 
endothelial function have also been found to be independent predictors of 
coronary heart disease and ischemic stroke. These include von Willebrand factor 
(vWF) and Fibrinogen, which play an important role in platelet adhesion and 
aggregation, and tissue Plasminogen activator (tPA) – which plays an important 
role in endogenous fibrinolysis(Wannamethee et al., 2012, Smith et al., 2005). 
They have been found to be significant risk factors for vascular dementia and 
cognitive impairment in older adults (Quinn et al., 2011, Gallacher et al., 2010). 
3.1.3 The rationale and the aims of the study  
The potential aetiological links between cardio-metabolic risk factors and brain 
structure and function need further exploration as possible explanations for the 
relationship between the burden of physical and mental ill health. A key 
question here is, is there a relationship between vascular health and neural 
health? Are cardiovascular risk markers potential endophenotypes for neuronal 
and hence psychiatric illnesses?  However, whether variance in risk markers in 
the healthy adult population explains inter-individual differences in grey matter 
correlates of neurocognitive function is not fully clear.  
The aim of this study was to explore the relationship between various circulating 
blood markers of inflammation and cardio-metabolic risk and cortical thickness 
(CT).  
Here, I  specifically examined if “classic risk factors” -  including blood lipid 
fractions, carotid intima-media thickness (CIMT) and BMI, and “emerging” risk 
factors - including hs C-reactive protein (CRP); inerleukin-6, (IL6); fibrinogen;  
tissue plasminogen activator (tPA) antigen and markers of endothelial 
dysfunction  - Intercellular  Adhesion  Molecule  (ICAM) and von Willebrand 
Factor (vWF) - could potentially explain inter-individual variance in cortical 
thickness (Helfand et al., 2009).  
Chapter 3  59 
 
3.2 Materials and methods 
3.2.1 Participants 
Participants were recruited as part of a larger study (Psychological, social and 
biological determinants of ill health (PSoBiD) 
(http://www.gcph.co.uk/work_programmes/psobid)(Knox et al., 2012, 
McGuinness et al., 2012, Shiels et al., 2011, Packard et al., 2011). Details of the 
design of PSoBiD have been described elsewhere (Deans et al., 2009). Briefly, 
election of participants was based on the Scottish Index of Multiple Deprivation 
2004 (SIMD), which ranks small areas on the basis of multiple deprivation 
indicators across six domains, namely: income; employment; health; education, 
skills, and training; geographic access and telecommunications; and 
housing. Sampling was stratified to achieve an approximately equal distribution 
of the 666 participants across males and females and age groups (35–44, 45–54 
and 55–64 years) within the most (bottom 5% of SIMD score) and least deprived 
areas (top 20% of SIMD score). Participants could opt-in for the neuroimaging 
component of the study. From a total of 327 male participants, 140 volunteered, 
and 42 (21 from least deprived and 21 from most deprived areas) of these were 
randomly selected. Individuals were excluded if they had a history suggestive of 
neurological or serious psychiatric illness. Participants with a history of 
cerebrovascular disease were excluded from the study. They were also excluded 
if they had a history of head injury or any contraindication for MRI. In addition, a 
Consultant Neuroradiologist examined all the scans. None of the participants 
included in the present study showed significant pathology on the scans. This 
chapter presents the results from the 40 individuals who had the complete data 
on the biomarkers. All participants in the MRI study were white Scottish males, 
who spoke English. 
3.2.2 Blood biochemical analysis 
This has been previously described in Deans et al (Deans et al., 2009). The below 
is an excerpt taken from the document from Deans et al, that is relevant for the 
analysis presented in this chapter. It should be noted that the coefficient of 
variations are for the whole sample of 666 participants from the original PSOBID 
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cohort. Ten to twelve hour fasting morning blood samples were collected, 
separated and frozen at -80oC within 1 hour of venepuncture, except for samples 
for high sensitivity C-reactive protein (CRP), which were analysed on fresh 
plasma. High sensitivity C-reactive protein (CRP) was measured by an 
immunoturbidimetric assay (Roche Diagnostics Ltd., Burgess Hill, United 
Kingdom; sensitivity = 0.1 mg/L) and had a coefficient of variation (CV) of less 
than 3%. Interleukin-6 (IL-6) (sensitivity = 0.11 pg/mL) and Intercellular Adhesion 
Molecule-1 (ICAM) (sensitivity = 0.254 ng/mL) were measured by sandwich ELISA 
(R&D Systems Europe Ltd., Abingdon, United Kingdom). The between batch CV 
for IL-6 was 8.3% at a concentration of 2.84pg/mL and 10.0% at 5.38pg/ml. The 
between batch CV for sICAM-1 was 5.5% at an analyte concentration of 190ng/ml 
and 8.1% at 240ng/ml. Fibrinogen was measured on an automated coagulometer 
(MDA-180, Organon Teknika, Cambridge, United Kingdom) with a between batch 
CV of 3.7% at a fibrinogen concentration of 2.89g/l.  von-Willebrand factor 
(vWF) was measured using an in-house enzyme linked immunosorbent assay 
(ELISA), employing rabbit anti-human polyclonal antibodies (DAKO UK Ltd, Ely, 
UK) and had a between batch CV of 3.4% at 128IU/dl.  Tissue plasminogen 
activator antigen (tPA) was measured by ELISA (Hyphen, Neuville-sur-Oise, 
France; sensitivity = 0.5 ng/mL) with a CV 6.5% at an analyte concentration of 
4.42ng/ml. Total cholesterol, triglycerides, low-density lipoprotein (LDL), high-
density lipoprotein (HDL), apolipoproteins (Apo) A1 and B were analysed on fresh 
plasma. Their concentrations were determined by enzymatic colorimetric assays 
on a Roche Hitachi 917 analyser (Roche Diagnostics Ltd, Burgess Hill, UK). Lipid 
fractions were measured using ultracentrifugation and precipitation methods. All 
the lipid analysis had a between batch CV of less than 3%.The details of the 
biomarkers are shown in Table 3-1.Table 3-1: The demographic and biomarker 
details of the participants in the study. 
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Table 3-1: The demographic and biomarker details of the participants in the study.  
 
Reference  Mean 
Std. 
Deviation 
Age (years) - 50.96 8.28 
Alcohol units per week - 17.68 16.51 
Number prescribed Statins - 7  
Number of smokers  19  
CIMT (mm)  .70 .13 
BMI (Kg/m2)  27.93 4.5 
Total Cholesterol (mmol/L) <5.0 5.41 .94 
Triglycerides (mmol/L) 0.77 – 1.7 2.01 1.70 
VLDL (mmol/L) 0.9 -1.8 1.06 .65 
LDL (mmol/L) <3.0 3.10 .80 
HDL (mmol/L) >1.0 1.24 .29 
APO-A1 (g/L) 1.0 – 2.2  1.40 .25 
APO-B (g/L) 0.6 – 1.3 .99 .21 
hsCRP (mg/l) <1.0 2.14 2.5 
ICAM (ng/ml)  269.90 72.31 
IL6 (pg/ml) 0 - 14 2.58 4.03 
Fibrinogen (g/l)  3.06 .79 
tPA (ng/ml) 3.5 – 7.2 4.42 1.85 
VLDL - Very Low Density Lipoprotein; LDL – Low density lipoprotein; HDL – High density 
lipoprotein; APO – apoprotein; BMI – Body mass index; CIMT – Carotid intima-media 
thickness; ICAM – Intercellular adhesion molecules; IL6 - Interleukin 6; tPA – tissue 
Plasminogen activator; vWF – von Willebrand factor; hsCRP – C reactive protein;  
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3.2.3 Dimension reduction of lipid fractions 
In order to reduce the number of dependent variables and to derive factors 
representing broad domains within the markers that are statistically 
independent, I subjected the raw scores from 6 measures of lipid fraction 
including HDL, LDL, VLDL, Trigycerides,  Apo A1, Apo B, to Principal components 
analysis (PCA). The statistical independence of the factors meant that the 
relationship of each factor to cortical thickness was likely to estimate the 
specific association that each factor had on CT. Varimax rotation was used and 
the minimum eigenvalue for extraction was set to one. The analysis revealed a 
set of 3 orthogonal factors that explained a total of 95.7% of the variance (Table 
3-2). The first factor called “TAG” explained 38.4% of the variance with high 
loadings from triglycerides and VLDL. The second factor was called an “LDL” 
factor, which explained 29.79% of the variance, with high loadings from LDL and 
APO-B. The third factor was called an “HDL” factor and explained 27.5% of the 
variance with high loadings from HDL and Apo A1. Factor scores were extracted 
using the regression method.  These factors were used as independent variables 
in the GLM model described below. A similar approach was attempted with the 
“emerging” factors. However, the Bartlett’s test of sphericity suggested that the 
correlation matrix was an identity matrix, which implied that the factor model 
was inappropriate.  Therefore an exploratory analysis of individual risk factors 
was performed separately.  
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Table 3-2: The result of the PCA – the rotated factor matrix and factor loadings.  
 
 
 
 
 
 
 
 
 
 
3.2.4 Carotid intima-media thickness (CIMT) measurement 
Carotid ultrasound scans were performed on an ACUSON Sequoia 512 Ultrasound 
System with an L7 5-12 MHz linear array broadband transducer (Siemens Medical 
Solutions, Erlangen, Germany). The details of the scan acquisitions have been 
published in detail previously (Deans et al., 2009). Below is an excerpt taken 
from Deans et al  (Deans et al., 2009). Briefly, the same research nurse, who 
was trained in ultrasound techniques at the Department of Vascular Medicine, 
Academic Medical Centre, Amsterdam, The Netherlands, performed majority of 
the scans. As pre-specified in the study protocol, research nurses performing 
ultrasonography were required to complete a minimum of 10 paired replicate 
volunteer scans before scanning participants. The mean absolute difference for 
the mean common carotid artery IMT measurement between nurses was 
0.0542mm, which was well within the predefined performance requirement for 
sonographer certification, with the requirement having been determined by the 
Department of Vascular Medicine, Academic Medical Centre, Amsterdam, to be a 
mean absolute difference of <0.15mm, and was also within the 88 more 
 Component 
 TAG factor LDL factor HDL factor 
Triglycerides .975 .013 .012 
VLDL .955 .045 -.054 
LDL -.196 .963 .015 
APOB .293 .932 -.088 
HDL -.337 -.103 .920 
APOA1 .240 .025 .958 
Extraction Method: Principal Component Analysis. Rotation Method: Varimax with 
Kaiser Normalization. VLDL - Very Low Density Lipoprotein; LDL – Low density 
lipoprotein; HDL – High density lipoprotein; APO – apoprotein; BMI – Body mass 
index.  
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stringent requirements suggested by the American Society of Echocardiography, 
who suggest a certification requirement of a mean absolute difference of 
<0.055mm (Stein et al., 2008). Further paired replicate scans of volunteers were 
performed at intervals throughout the study to demonstrate continued fulfilment 
of the quality criteria. Both left and right common carotid arteries were 
assessed. Intima-media thickness was measured on the far wall of each arterial 
segment, averaged along a 1 cm length or as much as could be read. The 
average of left and right maximum common carotid IMT was computed (van der 
Meer et al., 2004). 
3.2.5 MRI acquisition 
All MRI examinations were performed using GE Medical systems, 3T Signa Excite 
HD system (Milwaukee, USA) with an eight-channel phased array (receive only) 
head coil. An axial 3D T1-weighted IR-FSPGR was acquired with the following 
imaging parameters: TR = 6.8ms; TE = 1.5ms, Inversion Preparation time = 
500ms; Flip angle=12º; FOV = 26cm; Phase FOV= 70%; matrix: 320 x 320; 
Bandwidth 31.25 kHz; number of slices = 160; Slab thickness = 1mm. The 
acquisition time for this scan was 8min 54s.  
3.2.6 Cortical thickness (CT) measurements and analysis    
I used the method similar to that of Leritz et al (2011), who examined the 
association between cerebrovascular risk factors to CT in a normative sample of 
community dwelling adults (Leritz et al., 2011). Surface extraction, cortical 
parcellation and thickness computation was performed with the FreeSurfer 
image analysis suite.  
The pre-processing was carried out according to documentation, which has been 
validated and the description is available at 
(http://surfer.nmr.mgh.harvard.edu/)(Fischl and Dale, 2000b, Fischl et al., 
1999a, Dale et al., 1999).  This is described below, as given in the website 
(http://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferMethodsCitation). 
Briefly, this includes motion correction and averaging (Reuter et al., 2010) of 
multiple volumetric T1 weighted images (when more than one is available), 
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removal of non-brain tissue using a hybrid watershed/surface deformation 
procedure (Segonne et al., 2004), automated Talairach transformation, 
segmentation of the subcortical white matter and deep gray matter volumetric 
structures (including hippocampus, amygdala, caudate, putamen, 
ventricles)(Fischl et al., 2002, Fischl et al., 2004a) intensity normalization (Sled 
et al., 1998), tessellation of the gray matter white matter boundary, automated 
topology correction (Fischl et al., 2001, Segonne et al., 2007), and surface 
deformation following intensity gradients to optimally place the gray/white and 
gray/cerebrospinal fluid borders at the location where the greatest shift in 
intensity defines the transition to the other tissue class.  
In more detail,(as given in 
https://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferAnalysisPipelineOverview)  
first, the volume is registered with the Talairach (Talairach J and P, 1988) atlas 
(this is an affine registration). This allows FreeSurfer to compute seed points in 
later stages. The B1 bias field is estimated by measuring the variation in the 
white matter intensity. The main body of the white matter is used to estimate 
the field across the entire volume. Likely white matter points are chosen based 
on their locations in Talairach space as well as on their intensity and the local 
neighbourhood intensities. The intensity at each voxel is then divided by the 
estimated bias field at that location in order to remove the effect of the bias 
field. The skull is stripped using a deformable template model. Voxels are then 
classified as white matter or something other than white matter based on 
intensity and neighbour constraints. Cutting planes are chosen to separate the 
hemispheres from each other as well as to remove the cerebellum and brain 
stem. The location of the cutting planes is based on the expected Talairach 
location of the corpus callosum and pons, as well as several rules-based 
algorithms that encode the expected shape of these structures. An initial surface 
is then generated for each hemisphere by tiling the outside of the white matter 
mass for that hemisphere. This initial surface is then refined to follow the 
intensity gradients between the white and gray matter (this is referred to as the 
white surface). The white matter surface is tessellated by assigning 2 triangles 
to the square face of each surface voxel. This process yields approximately 160 
000 vertices per hemisphere.  
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The white surface is then nudged to follow the intensity gradients between the 
gray matter and CSF (this is the pial surface). The distance between the white 
and the pial gives us the thickness at each location of cortex. Cross-subject 
registration of hemispheric cortical surfaces was performed by projecting them 
onto the spherical representations. The maps produced are not restricted to the 
voxel resolution of the original images and are thus capable of detecting sub-
millimetre differences between groups. Procedures for the measurement of CT 
have been validated against histological analysis and manual measurements. In 
addition, FreeSurfer morphometric procedures have demonstrated good test-
retest reliability across scanner manufacturers and across field strengths and 
across various sequence parameters.  
Once the cortical models are complete, a number of deformable procedures can 
be performed for in further data processing and analysis including surface 
inflation (Fischl et al., 1999a), registration to a spherical atlas which utilized 
individual cortical folding patterns to match cortical geometry across subjects 
(Fischl et al., 1999b), parcellation of the cerebral cortex into units based on 
gyral and sulcal structure (Desikan et al., 2006b, Destrieux et al., 2010, Fischl et 
al., 2004b), and creation of a variety of surface based data including maps of 
curvature and sulcal depth. This method uses both intensity and continuity 
information from the entire three dimensional MR volume in segmentation and 
deformation procedures to produce representations of cortical thickness, 
calculated as the closest distance from the gray/white boundary to the gray/CSF 
boundary at each vertex on the tessellated surface (Fischl and Dale, 2000a). The 
maps are created using spatial intensity gradients across tissue classes and are 
therefore not simply reliant on absolute signal intensity. The maps produced are 
not restricted to the voxel resolution of the original data thus are capable of 
detecting submillimeter differences between groups. Procedures for the 
measurement of cortical thickness have been validated against histological 
analysis (Rosas et al., 2002) and manual measurements (Kuperberg et al., 2003, 
Salat et al., 2004). Freesurfer morphometric procedures have been 
demonstrated to show good test-retest reliability across scanner manufacturers 
and across field strengths (Han et al., 2006, Reuter et al., 2012). 
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3.2.7 Statistical analysis 
The procedure previously described by Leritz et al was adopted (Leritz et al., 
2011). Statistical comparisons of global data and surface maps were generated 
by computing a general linear model (GLM) of the effects of each risk factor 
variable (independent variable) on thickness (dependent variable) at each vertex 
in the cortical mantle, using the Query, Design, Estimate, Contrast (QDEC) 
interface of FreeSurfer. QDEC is a single-binary application included in the 
FreeSurfer distribution that is used to perform group averaging and inference on 
the cortical morphometric data produced by the FreeSurfer processing stream. 
(http://surfer.nmr.mgh.harvard.edu/fswiki/Qdec)  
In case of the lipid fractions, the factors extracted from PCA were entered as 
independent variables of interest.  For BMI, CIMT and the ‘emerging’ factors, 
individual risk factors were entered as independent variables of interest. Maps 
were created using statistical thresholds of p=0.05 and were smoothed to a full 
width half maximum (FWHM) level of 20mm. Since this analysis involved 
performing a GLM analysis at 160000 vertices, these maps were corrected for 
multiple comparisons by means of a cluster-wise procedure using the Monte 
Carlo Null-Z simulation method adapted for cortical surface analysis and 
incorporated into the QDEC processing stream. For these analyses, a total of 
10,000 iterations of simulation were performed for each comparison, using a 
threshold of p=0.05. The simulation cluster analysis was run for thickness 
analyses with each independent variable separately (Hagler et al., 2006, Leritz 
et al., 2011). There is considerable debate on the distinction between 
exploratory and confirmatory analysis and whether exploratory analysis should 
be corrected for multiple testing. Considering the fact that previous results have 
shown inconsistent relationships and that some of the biomarkers I tested were 
novel, I considered the present analysis to be predominantly exploratory in 
nature. However, rather than use conservative family wise error tests at this 
level, in order to adjust for exploring the relationship between 11 different risk 
factors on CT, I took an approach of exploring the strength of the significance of 
the relationship. Therefore, in the previous step, if the clusters survived the 
Monte Carlo simulation at a threshold of 1.3 (p<0.05), I repeated the analysis at 
thresholds of 2.0 and 2.3 corresponding to p values of 0.01 and 0.005. I report 
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the clusters that survived all 3 levels (Bender and Lange, 2001). Similar 
technique was also employed by Leritz et al (Leritz et al., 2011). 
3.2.8 Covariates in the model 
In order to improve the variance explained by the predictor of interest, I added 
as nuisance covariates, those variables that showed significant relationship with 
mean whole brain CT (dependent variable).  
There was a significant negative correlation between age and mean whole brain 
CT (rho = -0.57; p<0.001). The association between age and CT was widespread 
bilaterally. I therefore used age as a nuisance covariate in the model for all 
analyses. Alcohol use was examined next. A unit of alcohol here is defined as 
equivalent to 10ml or 8g of pure alcohol. I found no association between number 
of alcohol units consumed per week and mean CT (rho=0.06; p=0.68). Alcohol 
use was therefore not included as a nuisance covariate in further analyses. 
Similarly socioeconomic status as measured using the SIMD did not explain any 
significant variance in mean CT (Mann-Whitney U = 182.0; p=0.3).   
Two other variables - education status and smoking status - were found to have 
a significant association with the mean whole brain CT. There was a significant 
positive correlation between number of years spent in full time education (FTE) 
and mean whole brain CT (rho=0.36; p=0.02). Regionally, greater FTE was 
associated with greater CT in the left perisylvian regions.  I also found significant 
association between smoking status and mean whole brain CT (t=4.17; p=0.001). 
The relationship between smoking status and CT was spread across the cortex 
bilaterally.  However, I also found that in the present sample, FTE showed a 
positive correlation with the predictor variables LDL factor (r= 0.24; p = 0.17) 
and a significant negative correlation with CRP (rho = -0.48; p=0.002) and ICAM 
(r=-0.45; p=0.004) levels. Smoking status was associated with greater ICAM levels 
(t=-1.9;p=0.06) and lower LDL factor (t=1.9; p=0.05). I therefore did not include 
FTE or smoking status in the initial analysis, but I conducted a post hoc 
exploratory analysis of the relationship between LDL factor, ICAM, CRP, smoking 
status, FTE and CT. All covariates were examined at p<0.05 (cluster-wise 
corrected). 
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3.3 Results 
3.3.1 Classic risk factors 
The cluster-wise cortical analysis showed a number of regions of significant 
association (Figure 3-1). Only those for LDL and the TAG factors remained 
significant after multiple comparison correction. The regions corresponding to 
those that survived multiple testing are labelled with an asterisk in figure 1 (c 
and d). Both LDL and TAG factors showed a significant positive association with 
CT (warm colours). The clusters that survived for the LDL factor were located in 
the inferior and middle frontal, precentral gyrus, inferior post central, supra- 
marginal and superior temporal cortex on the left hemisphere, and 
supramarginal, inferior post central and posterior superior temporal gyri on the 
right.  TAG was associated with medial frontal on the left and medial frontal, 
middle temporal and parahippocampal gyri on the right. Although a few clusters 
showed up on initial analysis with HDL factor, CIMT and BMI, none of them 
survived multiple testing corrections. Table 3-3 shows the details of the 
significant clusters that were associated with each risk factor across various 
thresholds. Figure 3.3 shows the scatter plots of individual predictors plotted 
against CT pertaining to the most significant voxel that survived multiple testing 
corrections.  
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Figure 3-1: The relationship between classic risk factors and cortical thickness. 
 
a) BMI – Body mass index; b) CIMT – Carotid intima-media thickness; c) HDL factor – HDL 
and Apo A1; d) LDL factor – LDL and Apo B; e) TAG factor – Triglycerides and VLDL – * 
Only the relationship between LDL factor and cortical thickness and TAG factor levels and 
cortical thickness survived multiple correction using the Monte Carlo Null-Z simulation 
technique. The regions that survived are labelled with * for p<0.05; ** if p<0.01 and *** if 
p<0.005. The cortical surface is inflated, and the dark grey areas represent sulci, and light 
grey represents gyri. 
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3.3.2 Emerging risk factors 
Table 3-1 shows the details of emerging risk factors explored in the study. The 
cluster-wise analysis showed a number of regions of significant association. Only 
those for CRP and ICAM remained significant after multiple comparison 
correction. The regions corresponding to those that survived multiple testing are 
labelled in Figure 3-2. CRP and ICAM showed a significant inverse association 
with CT (cool colours). Although a number of regions showed up on initial 
analysis with the other inflammatory and clotting markers, none of them 
survived multiple testing corrections. Some of the associations between the 
markers and CT were positive (warm colours). Table 3-3 shows the details of the 
significant clusters that were associated with each risk factor across various 
thresholds. Figure 3.3 shows the scatter plots of individual predictors plotted 
against CT pertaining to the most significant voxel that survived multiple testing 
corrections. 
 
  
Chapter 3  72 
 
 
 
 
 
Figure 3-2: The relationship between emerging risk factors and cortical thickness. 
 
a) hsCRP – C-reactive protein; b) ICAM – Intercellular adhesion molecule; c) Fibrinogen; d) 
IL6 – Interleukin 6; e) tPA – tissue plasminogen activator ; f) vWF – von Willebrand Factor –
Only the  relationship between ICAM and cortical thickness and IL-6 levels and cortical 
thickness in the lateral aspects of the brain survived multiple correction using the Monte 
Carlo Null-Z simulation technique. The regions that survived are labelled. The cortical 
surface is inflated, and the dark grey areas represent sulci, and light grey represents gyri. 
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Table 3-3: Details of the clusters that survived the Monte Carlo Z simulation at various 
thresholds. 
Risk 
factor 
Thresh
old p 
value 
Clus
ter 
No
  
 
Region Size of 
cluster 
(mm2) 
Tal X
  
Tal Y
  
Tal Z
  
Numbe
r of 
vertice
s  
LDL 
factor 
0.05 1 lh  Superior 
frontal 
16225.7
2    
-11.5    -7.7    47.3 34785   
0.01 1 lh Precentral 2997.09 -57.2 -0.1 10.7 6863 
0.005 1 lh Precentral 2290.76 -57.2 -0.1 10.7 5209 
0.05 1         rh banks sts 9061.66     45.9   -43.8    7.5 20217 
TAG 
factor 
0.05   1     lh superior 
frontal 
4291.85     -6.6    33.8    49.8 6781 
0.05 1     rh precentral 9071.69     27.7   -14.4    60.2 15680 
0.05 2     rh superior 
temporal 
5446.62     47.5     5.0   -27.2   9395 
0.01 1 rh Rostral 
middle frontal 
3269.26 27.7 57.8 -9.5 4964 
0.01 2 rh Superior 
temporal 
2343.63 47.5 5.0 -27.2 3610 
0.005 1 rh Superior 
Frontal 
2064.68 9.3 41.1 30.0 3149 
0.005 2 rh Superior 
temporal 
1701.21 47.5 5.0 -27.2 2572 
hsCRP 0.05 1         lh Precentral 6662.41    -57.2   -0.1    10.7 14860 
0.01 1 lh Post central 1543.87 -62.6 -15.0 19.0 3489 
ICAM 0.05   1    lh precentral 4890.49    - 57.2    - 0.1    10.7 11789 
0.01 1 lh Superior 
temporal 
2134.62 -52.1 -24.0 -4.0 5232 
0.005 1 lh 
Supramarginal 
1353.83 -48.6 -28.2 19.3 3334 
Threshold p value represents Tal – Talairach coordinates of the vertex corresponding to the 
strongest association; lh – left hemisphere; rh – right hemisphere; hsCRP – C-reactive 
protein; b) ICAM – Intercellular adhesion molecule; LDL factor -LDL and Apo B; TAG factor – 
VLDL and TAG 
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Figure 3-3: Scatter plots of relationship between cortical thickness and risk factors. 
 
Scatterplots pertaining to the vertex showing the strongest association are shown. Those 
prescribed statins are shown in blue. Details of the clusters and vertex location are shown 
in table 2. 
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3.3.3 Covariate analysis 
The results are shown in Table 3-4. The relationship between LDL factor, ICAM, 
CRP and CT remained even after including FTE as a covariate in the model. 
However, the size of the clusters was reduced. Similarly, the relationship 
between LDL factor, CRP and CT remained even after including smoking status as 
a covariate in the model. With LDL, the size of the clusters reduced, while with 
CRP, the size of the cluster increased.  However, the relationship between and 
ICAM and CT disappeared completely when smoking status was added as a 
covariate in the model.  
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Table 3-4: Details of the clusters that survived after including smoking status or education 
status as covariates 
Risk 
factor 
Region Maxima 
(negativ
e log of 
p value 
)*  
Size of 
cluster 
(mm2) 
Tal X
  
Tal Y
  
Tal Z  Number 
of 
vertices
  
Covariate : Smoking 
status 
      
LDL  
factor 
Lh precentral 4.00 9736 -57.2 -0.1 10.7 22012 
Rh rostral 
middle frontal 
3.39 4587.95 43.7 24.0 28.2 10309 
CRP Lh precentral -4.00 7715.55 -57.2 -0.1 10.7 17163 
ICAM -       
Covariate: Education 
status 
      
LDL 
factor 
Lh precentral 4.00 13069.2
2 
-57.2 -0.1 10.7 28224 
Rh 
supramarginal 
3.15 4438.65 55.1 -38.4 27.5 10719 
CRP Lh precentral -2.85 4531.2 4 -52.5 -6.6    38.5 10086 
ICAM Lh insula -2.01 3502.00 -32.4 -31.9 17.1 8525 
Tal – Talairach coordinates of the vertex corresponding to the strongest association; Lh – 
left hemisphere; Rh – right hemisphere; *survived p<0.05 Monte Carlo z simulation; hsCRP – 
C-reactive protein; b) ICAM – Intercellular adhesion molecule; LDL factor – LDL and Apo B 
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3.4 Discussion 
The aim of the analysis was to examine the relationship between cardio-
metabolic risk factors and CT. I have shown that in a sample of healthy middle-
aged male subjects, lipid fractions – particularly those pertaining to TAG, VLDL 
and LDL explained significant variance in CT across a number of regions in the 
brain.  I have also shown that inflammatory markers, particularly CRP and ICAM-
1 explained significant variance in CT across a number of regions in the brain.  
3.4.1 Classic risk factors 
While obesity has a strong effect on lipoprotein metabolism, recent studies have 
shown that the relationship between BMI and lipid fractions may not be 
consistent and therefore, these may indeed be independent risk factors for 
cerebrovascular and cardiovascular risk (Nicholls et al., 2006, Shamai et al., 
2011). Hence the effect of BMI and cholesterol were examined separately. The 
results of the data reduction using PCA enabled us to examine the effect of 
broad domains within the markers that are statistically independent. The factors 
extracted from PCA were found to be meaningful – HDL cholesterol and Apo A1 
formed a single factor (HDL) and LDL and Apo B formed a second factor (LDL).  
Apolipoprotein A1 and Apolipoprotein B are the major protein component of HDL 
and LDL respectively in plasma. VLDL and triglycerides, which contains most of 
the triglycerides, formed the third factor (TAG). The density of a lipoprotein 
that carries the cholesterol depends on the amount of triglyceride in the 
fraction. Therefore I found that the lipoprotein fractions with greater 
triglyceride fraction (TAG, LDL and VLDL) were associated with greater CT, while 
HDL, which contains the least triglycerides, showed the smallest association. 
While BMI, and HDL showed associations with CT in some regions, none of these 
clusters survived multiple testing corrections.  These relationships were contrary 
to my expectations. I expected the presence of greater risk factors (LDL and TAG 
factors) to be associated with cortical thinning in a number of regions. Our 
findings are in contrast to a number of previous studies that have found a 
negative association between greater risk factors and grey matter morphology.  
Both cross sectional and longitudinal studies have shown significant negative 
association between BMI and regional grey matter volume (Gunstad et al., 2008, 
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Raji et al., 2010, Walther et al., 2010, Yokum et al., 2012). Although Ward et al, 
in their study found no relationship between non HDL cholesterol and grey 
matter volume, they found that those with decreased levels of HDL cholesterol 
showed GM volume reductions pertaining to a number of cortical and subcortical 
structures (Ward et al., 2010).  All of the above studies used techniques (Voxel / 
tensor based morphometry) that do not decompose cortical volume into 
thickness and surface area.  Cortical volume is a construct that is derived from 
two distinct properties of the cortical sheet: CT and surface area and have 
distinct cellular and genetic bases (Panizzon et al., 2009, Rakic, 2009).  This 
highlights the importance of studying CT independently in morphometric studies. 
Further, CT appears to be highly susceptible to various environmental influences 
such as exposure to smoking, metabolic risk factors and cannabis, while surface 
area seems to be more stable (Leritz et al., 2011, Habets et al., 2011). 
More recent studies that have used similar image analysis techniques have found 
interesting results. In the first study, Isaac et al, found a negative association 
between visceral abdominal fat measured using MRI and CT pertaining to frontal, 
parietal and occipital cortices(Isaac et al., 2011). They however, did not 
measure lipid fractions in the blood. A second larger study, which examined the 
association between CT and circulating cholesterol levels in an older population 
(mean age 68.3 years), found a similar relation to the present study. They found 
that an increase in cholesterol factor with high loadings from total cholesterol 
and LDL was significantly associated with an increase in CT. However, a second 
factor which included HDL and BMI did not show such an association (Leritz et 
al., 2011). They suggest that the results in their study could be explained by 
other studies that have shown that neurodegeneration (and hence cortical 
thinning) is associated with lower serum cholesterol due to disruption in brain 
cholesterol production (Solomon et al., 2009). The fact that I found a similar 
relationship in a smaller sample suggests that the relationship is more than 
trivial (Friston, 2012). Our sample was also younger suggesting that the 
relationship between risk factors and cortical morphology may be evident earlier 
on in life. In another study, the same group have found higher HDL and LDL 
cholesterol in normo-lipidemic individuals to be associated with compromised 
regional white matter integrity. These findings suggest that the relationship 
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between cholesterol, white matter and grey matter are complex (Williams et 
al., 2012).  
Although it accounts for only 2% of total body weight, the human brain contains 
as much as 25% of total body cholesterol. Cholesterol in the brain is primarily 
synthesised by glia.  It is an essential component of cell membrane and myelin in 
the white matter. In this context, cholesterol abnormalities have been 
implicated in a number of neurodegenerative illnesses, where the primary 
pathogenesis seems to involve deregulated cholesterol trafficking (Liu et al., 
2010). Leritz et al therefore suggest that a bidirectional mechanism between 
cholesterol and the brain may exist, such that higher levels in the brain 
predispose an individual to have higher levels in circulating blood (Leritz et al., 
2011).  Therefore the positive relationship between cholesterol and CT is a 
reverse epiphenomenon. It is also not clear if the association between CT and 
circulating cholesterol level is related to pathological processes. Consistent with 
my findings, more recently, Hoogendam examined the relationship between 
cardiovascular risk factors and cerebral volume measured using FreeSurfer in a 
community dwelling non-demented elderly sample of 3962 people. They found 
that higher total cholesterol levels were related to a larger cerebral volume. 
They found no association between HDL cholesterol and cerebral volume 
(Hoogendam et al., 2012). 
CIMT measured using carotid ultrasound is an efficient and validated method for 
assessing the degree of atherosclerosis in an individual. While previous studies 
have found an association between CIMT and a risk of stroke, I did not find a 
relationship between CIMT and CT (Lorenz et al., 2007).  Recently, Cardenas et 
al (2012) examined this relationship in an older sample. Using similar technique 
to ours, they found no relationship between CIMT and most measures of brain 
volume or CT (Cardenas et al., 2012). They however found CIMT to be associated 
with regional thinning pertaining to the parietal cortex. In their analysis, they 
divided the whole cortex into lobes, considering each lobe separately as a region 
of interest. This may have increased the power to detect subtle changes in 
individual lobes. None of the clusters survived multiple corrections in the 
sample. This may however be due to the small sample size.  
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3.4.2 Emerging risk factors 
There is a growing body of evidence linking circulating inflammatory markers to 
brain structure and function. Molecular imaging studies have shown that 
circulating inflammation immune/metabolic markers are directly associated with 
greater inflammation markers in the brain. Drake et al used PET tracer PK 11195 
to examine the relationship between cerebrovascular risk factors (but no stroke) 
and brain inflammation. They found that people with greater risk factors showed 
greater microglial activation in the brain, compared to normal controls (Drake et 
al., 2011). Similarly, a few studies have shown that modulating circulating 
inflammation is associated with both functional and structural changes in the 
brain. Harrison et al showed that inducing a circulating inflammatory response 
using typhoid vaccine in normal adults is associated with change in BOLD signals 
in regions pertaining to modulation of mood in the brain(Harrison et al., 2009a).   
More recently, Hannestad et al found that systemic inflammation induced by 
endotoxin in humans was associated with higher normalised glucose metabolism 
in the insula. This change was associated with change in peak cytokine levels 
and also changes in social interest, suggesting that these may be linked to each 
other (Hannestad et al., 2012b).  Previous research has shown that modulating 
circulating inflammation in patients with Rheumatoid arthritis, using 
adalimumab (a TNF-α inhibitor) is associated with a reduction in serotonin 
transporter availability in the brain (Cavanagh et al., 2010). A few structural MRI 
studies have shown an association between inflammatory markers and cortical 
and subcortical grey matter volume.  Jefferson et al in the Framingham cohort 
showed that inflammatory markers including IL6 were inversely associated with 
total brain volume (Jefferson et al., 2007).  Marsland et al, showed an 
association between circulating IL-6 levels and smaller grey matter volume in 
the hippocampus in middle aged adults (Marsland et al., 2008). Although I found 
an association between IL6 levels and CT pertaining to the parahippocampal 
gyrus, these clusters did not survive multiple testing corrections.  
My findings reflect those of a more recent study that found an association 
between hsCRP and cortical grey matter volume pertaining to perisylvian regions 
in a large cohort of healthy aging subjects (Taki et al., 2012).  I have replicated 
the finding in a smaller and younger sample. However, the clusters were more 
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extensive than those described by the study. While most of the above studies 
have shown an inverse relationship between circulating markers and cortical 
morphology, a few recent studies have suggested that the relationship between 
circulating risk factors and cortical morphology may be more complex than 
earlier thought. For example, greater circulating blood levels of TGF Beta, an 
anti-apoptotic and anti-proliferative factor have been associated with greater 
CT (Piras et al., 2012). I found similar relationships in the case of fibrinogen, IL6 
and a few other clusters in other markers. None of them however survived 
multiple testing corrections, suggesting that the relationship between them and 
CT may not be as robust for these measures.  However, this could be due to type 
2 error due to the small sample size.  
To my knowledge, no previous study has shown an association between ICAM-1 
and CT. ICAM-1 is an adhesion molecule expressed by endothelial cells in 
response to inflammation – particularly pro-inflammatory cytokines like tumour 
necrosis factor (TNF-α) (which also is a potent stimulator of CRP) and 
physiological stress (Dietrich, 2002, Frank and Lisanti, 2008). Inflammatory 
activation of ICAM-1 has been shown to be associated with an increase in 
leukocyte migration and region specific (frontal and parietal) microglial 
activation in the brain (Huber et al., 2006, Dietrich, 2002).  While this has 
mostly been demonstrated in primary inflammatory conditions of the brain, 
there are few studies examining the role of ICAM-1 in situations where 
inflammatory pathology is less manifest like major depression  .A recent study 
has shown that selective serotonin reuptake inhibitors (SSRIs) , medications 
primarily used in the treatment of depression, may have cardio-protective 
properties by directly inhibiting TNF-α induced ICAM -1 expression (Lekakis et 
al., 2010). The clusters in the present study that correlated with CRP and ICAM-1 
were in the inferior frontal and parietal cortices similar to that shown by 
Dietrich et al (Dietrich, 2002). While I could postulate that these findings could 
represent a region specific relation between circulating inflammatory and cell 
adhesion markers and the brain, causal assumptions cannot be made due to the 
cross sectional nature of the data.  
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3.4.3 Exploring Covariates in the model 
I found a significant positive relationship between education status and CT. This 
is similar to previous studies(Liu et al., 2012b) . Since education status was also 
related to LDL, ICAM and CRP, I explored the relationship between the above 
predictors and CT with education status as a potential covariate. All the 
predictors remained significantly associated with CT however, the strength of 
some of the relationships reduced, denoted by a reduction in the cluster size, 
suggesting that at least part of the variance explained by education status and 
the risk factors were shared. With regards smoking we found a significantly 
strong negative association between smoking status and CT, similar to previous 
studies(Kuhn et al., 2010) . Just as education status, smoking status also showed 
significant association with LDL, ICAM and CRP. Surprisingly, the relationship 
between smoking status and LDL cholesterol was contrary to previous studies.  
Those who smoked had lower LDL cholesterol. The relationship between CRP and 
CT remained significant even with smoking status as covariate in the model. 
However, the relationship between ICAM and CT disappeared. This suggests that 
almost all of the variance explained by ICAM and CT was shared with smoking 
status. Theoretically I could argue that greater ICAM levels may be statistically 
mediating the relationship between smoking and CT. Smoking has indeed been 
shown to induce adhesion molecules in both pulmonary and circulating blood 
(Schaberg et al., 1996, Noguchi, 1999). While this is mechanistically plausible, 
causal mediation cannot be attributed to my findings due to the cross sectional 
nature of the study. 
Seven subjects in the present study were prescribed statins. It could be argued 
that those with greater cholesterol who were prescribed statins, which have 
anti-inflammatory properties and may have contributed to an increase in 
regional CT.  The sample was underpowered to examine the effect of statin 
intake. On examining the scatter plot, in general, the distribution of those on 
statins was similar to those not on statins. However, at least in certain cases 
(TAG and ICAM), there seems to be an interaction between statin intake status 
and the relationship between the variables and cortical thickness. My result 
differs from the previous study that used similar technique to ours showed no 
effect of medication on CT. They found that the association was purely due to 
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the cholesterol factor itself (Leritz et al., 2011). The relationship between 
medication status and CT should be further explored in studies with larger 
sample size. 
3.4.4 Relevance of measuring the association between metabolic 
and inflammatory risk markers and cortical morphology 
Quantifying the variance in cortical parameters that could be attributable to risk 
markers in health and illness is key to the understanding of the relationship 
between cardiovascular health and neural health.  As mentioned above, PET 
studies have shown that greater levels of cardiovascular risk markers in the 
circulation are associated with greater microglial activation in neurologically 
normal subjects (Drake et al., 2011). This suggests that pathophysiological 
processes are in play even in normal subjects who are at high risk of developing 
cardio/cerebrovascular diseases. Interestingly, psychiatric morbidity has often 
associated with greater cardiovascular risk and mortality. While this has 
traditionally been attributed to poor health choices and health care utilisation 
by this population, recent research suggests that such simplistic modelling of 
physical health co-morbidities or multi-morbidity may not be useful and may 
indeed be misleading(de Jonge and Roest, 2012). There is now a call to examine 
the role of cardiovascular and metabolic risk markers as common 
endophenotypes of both physical and psychiatric illnesses. In other words, there 
may be common genetic and environmental factors that may contribute to 
chronic metabolic illnesses like obesity and psychiatric illnesses like major 
depression (Bornstein et al., 2006). The link between circulating cardiovascular 
risk markers and cortical thickness in the present study may therefore be the 
independent phenotypic representation of common genes or environment. It is 
now known that brain is not an immune privileged organ, and proinflammatory 
cytokines like TNF- α, which are potent stimulators of CRP, are also produced by 
astrocytes and microglia within the central nervous system and are important in 
synapse formation and synaptic neurotransmission and in turn neurocognitive 
function (McAfoose and Baune, 2009). Indeed, there is increasing evidence that 
inflammatory markers contribute to the pathophysiology of psychiatric 
illnesses(Krishnadas and Cavanagh, 2012) .   
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More importantly, the lack of progress in developing effective treatments in 
psychiatry has led to the search for markers that may aid diagnosis or predict 
treatment response in what are highly heterogeneous conditions (Krishnadas and 
Cavanagh, 2012). Recently there has been an emphasis on combining imaging 
markers with circulating blood risk markers in order to identify what may 
provide a “biological signature” that may help predict treatment response 
(Linden, 2012, Schmidt et al., 2011).   
Exploring the relationship between cardio-metabolic risk factors and cortical 
morphology can also give us clues as to the pathophysiological link between high 
risk environmental situations like poor socioeconomic status (SES) and mental 
illnesses. For example, SES has been consistently associated with cognitive and 
mental health – which is thought to be the result of coordinated activity of 
large-scale networks across the whole cortex. SES has also been associated with 
greater cardio metabolic risk. Therefore an emerging question is whether the 
association between SES and cortical substrates of neurocognitive functions is 
mediated by the presence of greater cardio-metabolic risk in this population. 
Current evidence suggests that cumulative (both in time and across multiple 
physiological systems) physiological risk across the life span associated with 
socioeconomic deprivation may contribute to both mental and physical health 
over the life span (Gruenewald et al., 2012). McEwen et al describe a process of 
allostasis, where physiological systems operate within and outside a given range 
of parameters in order to maintain homeostasis (McEwen and Seeman, 1999). In 
this context, “Allostatic load” is thought to be the wear and tear that the body 
experiences as a result of activation of the above systems. This wear and tear 
represents either the ‘excess’ or the ‘inefficient’ operation of the above 
physiological systems. It is not surprising that, in this context, metabolic and 
inflammatory systems play a key role in the process of allostasis. A number of 
studies have shown a significant association between allostatic load (measured 
using a composite score of inflammatory and metabolic markers) and medical 
health (for e.g. cardiovascular disease) and neurocognitive function(Juster et 
al., 2010). These potential mechanisms may provide insight into how chronic 
adversity can affect physical and mental wellbeing(Kin et al., 2007).  It is 
therefore reasonable to quantify any association between cardiovascular health 
and neural health in terms of gross cortical morphology.  
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In order to explore the role of causal mediators in this complex relationship, the 
findings should be replicated in larger study with greater variation in circulating 
risk markers and a longitudinal design. Further work should also involve 
replication of the study in a larger population, including younger population, 
targeting critical periods of brain growth. Finally, future work to develop a 
clearer biological framework of a more comprehensive investigation of metabolic 
and inflammatory markers may be more informative. 
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4 Chapter 4 - A composite measure of circulating 
Inflammatory markers mediate the relationship 
between neighbourhood deprivation and cortical 
morphology 
 
In this chapter, I extend my findings from the previous chapter. Here, I see if the 
circulating cardio-metabolic and inflammatory risk factors would explain the 
difference in cortical morphology between people from the most deprived and 
and the least deprived neighbourhoods in Glasgow. Using a cross-sectional study 
design, I compared the cortical morphology of 42 neurologically healthy adult 
men from the least deprived and most deprived neighbourhoods of Glasgow. I 
performed surface based morphometry on 3T structural MRI images to extract 
the cortical morphology - volume, thickness (cortical thickness) and surface area 
(surface area) of regions commonly associated with language and executive 
control. I compared cortical morphology between the two groups.  I used 
mediation analysis to examine whether cardio-metabolic and inflammatory risk 
factors mediated the relationship between deprivation status and cortical 
morphology. The findings of this chapter have been published in Krishnadas R, et 
al. Socioeconomic deprivation and cortical morphology: psychological, social, 
and biological determinants of ill health study. Psychosomatic Medicine 2013 
Sep;75(7):616-23  
4.1 Introduction 
4.1.1 Socioeconomic deprivation and the brain 
Socio-economic status (SES) refers to a multidimensional construct that is usually 
measured using a number of economic (e.g. income) and noneconomic (e.g. 
education) indicators(Hackman et al., 2010). SES can be measured at an 
individual/household or at a neighbourhood level. Regardless of the level of 
measurement (individual/neighbourhood), SES has been associated with 
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significant health disparities (Diez Roux and Mair, 2010). For example, adults 
living in the most deprived part of Glasgow perform poorly on cognitive tests of 
attention and executive function and are 3 times more likely to be diagnosed 
with a severe mental disorder (Srireddy et al., 2012, Packard et al., 2011). 
Studies examining this relationship in children have also shown a positive 
association between SES indicators and language skills(Hackman and Farah, 
2009). 
Two questions are crucial to our understanding of the association between SES 
and cognitive/mental health disparity. Firstly, is there an association between 
SES and neural substrates of these cognitive functions? It is widely recognised 
that cognitive and mental functions are the result of a number of brain regions 
working together as large scale networks.(Bressler and Menon, 2010) Recent 
neuroimaging studies that have examined the relationship between SES and the 
brain have shown a relationship between SES indicators and cortical and sub-
cortical grey matter volumetric differences in hippocampal, amygdalar and 
anterior cingulate cortex in adults and in addition, language regions in children 
(Gianaros et al., 2007a, Hanson et al., 2011, Butterworth et al., 2011, Noble et 
al., 2012, Staff et al., 2012). However, the results are conflicting (Butterworth 
et al., 2011). One potential reason for this inconsistency is the fact that cortical 
grey matter volume is a function of two distinct measures – cortical surface area 
and cortical thickness.(Winkler et al., 2010) Regional and global measures of 
surface area and cortical thickness are independent of each other, and have a 
distinct genetic and ontogenic basis(Rakic, 2009, Panizzon et al., 2009, 
Raznahan et al., 2011). Automated surface based morphometric techniques 
enabled us to deconstruct surface area and cortical thickness from structural MRI 
data. It would therefore be informative to explore the relationships between SES 
indicators and these quite distinct cortical parameters. Secondly, what are the 
pathways that link SES to poor cognitive health?  
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4.1.2 Socioeconomic deprivation, inflammation (cardio-metabolic 
risk) and the brain 
Pathways linking deprivation and poor health outcomes are diverse and complex 
(McEwen and Gianaros, 2010). Epidemiological studies have revealed an 
association between neighbourhood-level socioeconomic deprivation (SED) and 
raised cardio-metabolic risk markers  (Nazmi et al., 2010, Deans et al., 2009). 
Cardio-metabolic risk markers have in turn been associated with inter-individual 
differences in cortical morphology in adults, as shown in the chapter 3 and in 
previous studies (Marsland et al., 2008, Taki et al., 2012, Raji et al., 2010). 
Therefore, exploring the relationship between deprivation, cardio-metabolic risk 
and cortical morphology may provide us with clues to the potential pathways 
that link SES with poor health outcomes. In keeping with this theme, Gianaros et 
al recently in a study of 155 healthy adults found that behavioural and 
physiological markers of cardiovascular risk mediated the relationship between 
SES indicators and white matter tract integrity. They concluded that 
“socioeconomic inequalities may relate to health disparities via inflammatory 
pathways impacting the structural integrity of brain networks”(Gianaros et al., 
2012). In a similar vein, I embarked on an analysis exploring the relationship 
between SES, cardio-metabolic risk and cortical morphology of brain regions 
most often associated with language and executive function in men from the 
most and the least deprived neighbourhoods in the Greater Glasgow conurbation 
area.  
4.1.3 The rationale and the aims of the study 
In this analysis, I aimed to answer two questions. Firstly, are there cortical 
morphological differences pertaining to brain regions associated with language 
and executive function between people from the most deprived (MD) and least 
deprived (LD) neighbourhoods of Glasgow? The primary assumption that formed 
the basis of this analysis was that examining the distinct cortical parameters of 
cortical thickness and surface area of regions corresponding to nodes of 
previously defined functional networks, would inform us about the grey matter 
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element of the regions in question. For our analysis, I used the gyrosulcal 
parcellations based on the Destrieux atlas to define our regions of interest (ROIs) 
(FIgure 4-1) (Destrieux et al., 2010). Language regions of interest were the 
Wernicke’s area and its right homologue which included the supramarginal gyrus, 
planum temporale of the superior temporal gyrus and the posterior ramus of the 
lateral sulcus; the Broca’s area and its right homologue which included the pars 
opercularis, pars triangularis and pars orbitalis; and the posterior fusiform gyrus. 
All the above regions have been associated with language function in recent 
functional and effective connectivity studies (Sonty et al., 2007, Mesulam, 1990, 
Tomasi and Volkow, 2012). While language is thought to be predominantly left 
lateralised, there is increasing evidence that homologous areas on the right 
hemisphere also contribute to language function. See Hartwigsen and Siebner for 
a detailed review of the functions attributed to the right language homologous 
areas (Hartwigsen and Siebner, 2012). The executive control regions of interest 
included fronto-parietal regions that show strong co-activation during resting 
state fMRI and tasks that particularly involve executive function (Seeley et al., 
2007, Margulies et al., 2007, Jurado and Rosselli, 2007, Nee et al., 2013). They 
included the Destrieux parcellations of middle frontal gyrus, posterior parietal 
cortex (intra-parietal sulcus and superior parietal lobule) and middle-anterior 
part of the cingulate gyrus and sulcus (corresponding to dorsal anterior cingulate 
cortex) on each side (Destrieux et al., 2010).  
Secondly, can the difference in cortical morphology be explained by differences 
in cardio-metabolic risk factors between groups? In other words, can the 
relationship between SED and cortical morphology be explained by raised cardio-
metabolic risk markers in the most deprived population? Here, our assumption 
was that exploring the relationship between SED, risk markers and the two 
ontogenically distinct cortical morphological parameters of cortical thickness 
and surface area of the aforementioned ROIs, would point us towards possible 
mechanistic pathways that link socioeconomic disparities to structural integrity 
of the brain.  
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4.2 Methods 
4.2.1 Participants 
Ethical approval for the study was obtained from Glasgow Royal Infirmary 
Research Ethics committee. All participants gave informed consent and were 
recruited as part of a larger study (Psychological, social and biological 
determinants of ill health (PSoBiD)) 
(http://www.gcph.co.uk/work_programmes/psobid). Each participant attended 
3 visits to complete the study over a period of 2.5 years between winter 2005 
and spring 2008. Details of the design of PSoBiD have been described elsewhere 
(Deans et al., 2009, Shiels et al., 2011). Selection of participants was based on 
the Scottish Index of Multiple Deprivation 2004 (SIMD), which ranks small areas 
on the basis of multiple deprivation indicators across six domains, namely: 
income; employment; health; education, skills, and training; geographic access 
and telecommunications; and housing (TheScottishGovernment, 2004). Sampling 
was stratified to achieve an approximately equal distribution of the 666 
participants across males and females and age groups (35–44, 45–54 and 55–64 
years) within the most (bottom 5% of SIMD score) and least deprived areas (top 
20% of SIMD score). Participants could opt-in for the neuro-imaging component 
of the study. From a total of 327 male participants, 140 volunteered, and 42 (21 
from LD and 21 from MD neighbourhoods) of these were selected. The present 
paper presents the results from the 42 neurologically healthy right handed men.  
4.2.2 Mediators and other variables of interest  
4.2.2.1 Cardio-metabolic risk factors 
For this analysis, I examined the role of 9 blood markers - C-reactive protein 
(CRP), Interleukin-6 (IL-6), Intercellular Adhesion Molecule-1 
(ICAM),Triglycerides, High density lipoprotein (HDL), Very low density lipoprotein 
(VLDL), Fibrinogen, D-dimer and Insulin – and an anthropometric measure- BMI. 
These were selected as we had complete data on these variables for all 42 
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individuals.  Details of measurement of CRP, IL-6, ICAM, HDL, VLDL and 
Fibrinogen are detailed in 3.2.2. In addition, insulin was measured by a sandwich 
Enzyme-Linked Immunosorbent Assay (ELISA) (Mercodia AB, Uppsala, Sweden; 
sensitivity = 1mU/L). Between batch analytical CV was 7.26% at 6.04mU/L and 
7.85% at 11.2mU/L. D-dimer was measured by ELISA (Hyphen, Neuville-sur-Oise, 
France; sensitivity=2ng/ml). The between batch CV for D-dimer was 5.3% at a 
concentration of 109ng/mL. 
4.2.2.2 Principal components analysis and dimension reduction of 
cardio-metabolic markers 
While greater levels of the most of the above markers have been associated with 
poor cardiovascular health, greater HDL levels have been associated with better 
health outcomes. In order to reduce the number of independent variables and to 
derive factors representing broad domains within the markers that are 
statistically independent, I subjected the Z scores (reversed for HDL) of the 
above markers to a Principal components analysis (PCA). The statistical 
independence of the factors meant that the relationship of each factor to 
deprivation and cortical morphology was likely to estimate the specific 
association that each factor had on these variables.  Varimax rotation was used 
and the minimum eigenvalue for extraction was set to one. The analysis revealed 
a set of 3 orthogonal factors which explained a total of 68.19% of the variance. 
The first factor called “Inflammation factor” explained 26.23% of the variance 
with high loadings from Fibrinogen, ICAM, IL6, CRP and D-dimer. The second 
factor was called a “TAG” (triacylglycerol) factor, which explained 24.05% of the 
variance, with high loadings from triglycerides and VLDL – the lipid fractions with 
the greatest amount of triglycerides. The third factor was called “BMI-HDL-
Insulin” factor and explained 17.91% of the variance with high loadings from 
HDL, BMI and Insulin. Factor scores were extracted using the regression method.  
I used these as continuous measures in our analysis. Greater scores on the above 
indices meant poorer health. The details of the factor loadings of the principal 
components analysis are shown in Table 4-1.  
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Table 4-1: Factor loadings on the principal components analysis of cardio-metabolic risk 
factors of interest 
Variables of 
interest 
Factor loading 
Inflammation  
factor 
TAG factor BMI-HDL-Insulin 
hsCRP .682 -.192 .151 
ICAM .603 .222 -.327 
Fibrinogen .496 -.326 .262 
D_Dimer .772 -.145 .042 
IL6 .717 .286 .146 
Triglycerides .095 925 .101 
VLDL -.032 .913 .095 
HDL -.183 .346 .790 
Insulin .098 .013 .836 
BMI .227 -.135 .752 
Extraction Method: Principal Component Analysis;  Rotation Method: Varimax with 
Kaiser Normalization; KMO test of sampling adequacy was 0.53, and Bartlett’s test 
of sphericity was significant (Chi square = 149.21; p<0.001). 
 
4.2.3 MRI acquisition 
All MRI scans were performed using GE Medical systems, 3T Signa Excite HD 
system (Milwaukee, USA) using an eight channel phased array (receive only) head 
coil. The parameters of acquisition has been described in section 3.2.5.  
4.2.4 FreeSurfer volume extraction and ROI (region of interest) 
analysis 
Surface extraction, cortical parcellations and thickness computation was 
performed with the FreeSurfer image analysis suite. The pre-processing was 
carried out according to documentation, which has been validated and the 
description is available at (http://surfer.nmr.mgh.harvard.edu/)(Fischl and 
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Dale, 2000b, Fischl et al., 1999a, Dale et al., 1999). This has been described in 
detail in section 3.2.6. The parcellations were obtained using the Destrieux 
sulcogyral-based atlas, which follows the anatomical conventions of Duvernoy 
(Figure 4-1) (Destrieux et al., 2010). The FreeSurfer image processing pipeline 
was visually inspected and corrected at critical points in order to avoid errors 
permeating through the subsequent analyses. Procedures for the measurement 
of cortical thickness have been validated against histological analysis and manual 
measurements.  
 
Figure 4-1:  Regions of interest pertaining to language and executive function. Parcellation 
of interest are shown in blue on the cortical surface 
 
  
Chapter 4  94 
 
4.3 Data analysis 
4.3.1 Most deprived vs. least deprived 
An initial Multivariate analysis of covariance (MANCOVA) was conducted with 
volumes of individual ROIs as dependent variables, group (deprivation status) as 
a fixed factor and age, intracranial volume (ICV) and self-reported measure of 
alcohol use in units as covariates. Since the differences in volume could reflect a 
change in cortical thickness or surface area, I repeated the MANCOVA with 
cortical thickness and surface area of ROIs as dependent variables, in order to 
test for between group differences. For all cortical thickness analyses, I included 
age, self-reported measure of alcohol use and mean whole brain cortical 
thickness, and for the cortical surface area analysis, I included age, alcohol use 
and ICV as nuisance covariates. All analyses were corrected for multiple testing 
using Benjamini- Hochberg False discovery rate (FDR) procedure (q=0.05) for 36 
analyses (6 ROIs, 2 hemispheres and 3 morphological parameters)(Benjamini and 
Hochberg, 1995). 
4.3.2 Mediation analysis 
To explore the relationship between deprivation, cardio-metabolic risk factors, 
and cortical morphology, I conducted a mediation analysis with deprivation 
status as independent variable, “inflammation factor” as mediator and cortical 
morphology as dependent variable. Here, I aimed to examine if the relationship 
between deprivation status and cortical morphology could be explained by the 
inflammation factor score.  In classic mediation analysis, causal models are 
tested using longitudinal data; such an assumption is not made here. While it 
could be argued that the difference in brain morphology between groups may be 
pathophysiologically linked to the raised risk factor score, due to the cross 
sectional nature of the data, such an inference is not possible with our data. 
This type of an approach has been taken previously to examine the contribution 
of MRI surface based measures to volume based measures measured using VBM 
(Palaniyappan and Liddle, 2012). 
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The analysis here, tests the hypothesis that the deprivation category accounts 
for variance in the mediator and in turn, this variance in the mediator accounts 
for a proportion of the variance in brain morphology. “The adjustable 
parameters of the model represent the unidirectional influence between pairs of 
variable in the model. The best fitting values of the parameters are estimated 
by using the General Linear Model to solve the linear equations that describe the 
relationships within the model. This analysis differs from multiple regression 
which estimates the proportion of variance in the dependent variable accounted 
for by each of several independent predictor variables while allowing for the 
variance accounted for by the other predictors in the model.” In other words, 
the mediation analysis partitions the variance explained by the predictor into a 
part that is independent of the mediating variable (direct), and a part that is 
accounted for via the mediating variable (indirect) (Figure 4-2)(Palaniyappan 
and Liddle, 2012).  
 
Figure 4-2: The figure depicts the relationship between the predictor, mediator and the 
outcome variables.  
 
 
 
 
 
 
 
 
 
The mediation analysis partitions the total variance (total effect) explained by the predictor 
into a part that is independent of the mediating variable (direct effect), and a part that is 
accounted for via the mediating variable (indirect effect). a represents the ‘a’ path and b 
represents the ‘b’ path. 
  
b a 
Inflammation 
factor 
(mediator) 
Brain 
morphology 
(outcome) 
Deprivation 
(predictor) 
Indirect effect  
Total effect  
Direct effect  
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I used the bootstrap method of Preacher and Hayes to estimate the indirect 
effect and bias-corrected 95% confidence interval (CI) for each individual 
mediator based on 20,000 bootstrap samples using an SPSS macro(Preacher and 
Hayes, 2008). I also obtained effect ratios for indirect effects (IE ratio), which 
express the proportion of the total effect that can be explained by the indirect 
(mediated) effects. In other words, an indirect effect ratio of 0.25 would mean 
that a quarter (25%) of the total effect of the deprivation status on the cortical 
morphology is explained by the mediator. This analysis requires no assumption 
regarding the underlying distributions since the statistical significance level is 
determined non-parametrically.  
4.4 Results 
Details of the demographic variables and cardio-metabolic risk markers are given 
in Table 4-2. 
4.4.1 Cortical volume  
The results of this analysis are shown in Table 4-3. On the multivariate analysis, 
deprivation status predicted cortical volumes [Wilk’s lambda= 0.51;F(12,26) 
=2.24;p=0.04 ηp
2=0.51]. The MD group had statistically significantly smaller 
volumes pertaining to the left posterior parietal cortex (Cohen’s d = 0.89) and 
right Broca’s homologue (Cohen’s d = 0.91) compared to the LD group. The left 
fusiform region volume was also smaller in the MD. However, this did not survive 
multiple testing corrections. 
4.4.2 Cortical surface area  
On multivariate analysis of cortical surface area, deprivation status predicted 
cortical surface area [Wilk’s lambda= 0.61;F(12,26) =4.32;p=0.004;ηp
2=0.61] 
(Table 4-3). The MD group had statistically significantly smaller surface area 
pertaining to left posterior parietal cortex (Cohen’s d = 0.89) and left fusiform 
cortex (Cohen’s d = 1.05).  
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4.4.3 Cortical thickness  
On multivariate analysis of cortical thickness, deprivation status predicted 
cortical thickness [Wilk’s lambda= 0.52;F(12,26) =2.33;p=0.03;ηp
2=0.52] (Table 
4-3). The MD group had statistically significantly thinner left Wernicke’s region 
(Cohen’s d = 0.93) and its right homologue (Cohen’s d = 1.12). The left fusiform 
and right posterior parietal cortices were thicker in the MD. However, these did 
not survive multiple testing corrections.   
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Table 4-2: Demographic and clinical characteristics of study participants 
 Least deprived 
n = 21 
mean (s.d.) 
Most Deprived 
n=21 
mean (s.d.) 
 
t 
 
p 
Age (years) 51.18 (8.7) 50.70 (8.75) 0.224 0.82 
Alcohol units per 
week 
15.81 (9.39) 18.61 (21.32) -0.55 0.58 
Intracranial volume 
(cc) 
1572.94 
(143.52) 
1542.66 (161.72) 0.642 0.52 
Mean cortical 
thickness(mm) 
2.45 (0.08) 2.43 (0.1) 0.78 0.44 
CRP (mg/L) 1.17 (1.34) 3.40 (2.94) -3.16 0.004 
IL6 (pg/ml) 2.62 (5.42) 2.53 (1.76) 0.07 0.94 
Fibrinogen (g/L) 2.94 (0.61) 3.17 (0.95) -0.89 0.37 
Intercellular 
Adhesion Molecule-
1 (ng/ml) 
234.48 (25.72) 309.67 (84.19) -3.82 0.001 
D-dimer 89.81 (47.35) 150.32 (104.27) -2.32 0.029 
Inflammation 
factor 
-0.52 (0.67) 0.52 (1.06) -4.02 <0.001 
HDL (mmol/l) 1.22 (0.20) 1.26 (0.36) -0.46 0.64 
BMI (kg/m2) 27.02 (2.69) 28.42 (5.86) -0.99 0.33 
Insulin (uIU/ml) 7.1820 (4.82) 9.857 (68.43) -1.23 0.22 
BMI-HDL-Insulin 
factor 
0.025(0.67) -0.025 (1.26) 0.16 0.86 
Triglycerides 
(mmol/l) 
1.71 (0.72) 2.29 (2.23) -1.14 0.26 
VLDL (mmol/L) 1.05 (0.50) 1.08 (0.78) -0.14 0.89 
TAG factor -0.11 (0.63) 0.11(1.27) -0.73 0.45 
t – unpaired t test ; BMI – body mass index; C-reactive protein (CRP), interleukin-6 (IL-6); 
ICAM  VLDL -  Very Low Density Lipoprotein ;HDL – High density lipoprotein; Alcohol unit 
defined as equivalent to 10ml or 8g of pure alcohol; TAG- triacylglycerol 
Chapter 4  99 
 
Table 4-3: Difference in brain region of interest between least deprived and most deprived population.  
Dependent 
Variable 
Mean 
Difference 
Surface area 
(95% CI) 
mm2 pa 
Cohen’s d 
(95% CI) 
Mean Difference 
Cortical 
thickness 
(95% CI) 
mm p a 
Cohen’s d 
(95% CI) 
Mean Difference 
Cortical volume 
(95% CI) 
mm3 p a 
Cohen’s d 
(95% CI) 
L Middle 
frontal gyrus 
63.0 
(-188.95 – 
314.95) 
0.89 
 
0.16 
(-0.44 – 
0.76) 
0.01 
(-0.05 – 0.06) 
0.81 
 
0.08 
(-0.51 – 0.69) 
424.02 
( -466.01 – 
1314.06) 
0.57 
 
0.3 
(-0.3 – 0.9) 
L Post Parietal 
cortex 
471.08 
(226.92 – 
715.24) 
0.003 
 
1.24 
(0.58 – 
1.90) 
-0.04 
(-0.09 – 0.011) 
0.29 
 
-0.52 
(-1.14 – 
0.089) 
1000.34 
(281.38 – 
1719.30) 
0.04 
 
0.89 
(0.26 – 1.5) 
L dACC 10.19 
(-79.9 – 100.3) 
0.79 0.07 
(-0.05 – 
0.67) 
0.02 
(-0.07 – 0.10) 
0.86 0.12 
(-0.47 – 0.73) 
52.8 
(-180.97 – 
286.59) 
0.86 0.14 
(-0.46 – 0.75) 
L Broca’s area 95.67 
(-47.25 – 
238.60) 
0.36 
 
0.43 
(-0.18 – 
1.04) 
0.007 
(-0.05 – 0.06) 
0.80 
 
0.08 
(-0.51 – 0.69) 
383.72 
(-149.35 – 916.8) 
0.32 
 
0.46 
(-0.14 – 1.07) 
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L Wernicke’s 
area 
81.34 
(-194.52 – 
357.22) 
0.84 0.18 
(-0.41 – 
0.79) 
0.07 
(0.02 – 0.12) 
0.05 
 
0.93 
(0.29 – 1.5) 
447.20 
(-302 – 1197.2) 
0.41 
 
0.38 
(-0.22 – 0.99) 
L Fusiform 
gyrus 
256.02 (99.5 – 
412.55) 
0.02 
 
1.05 
(0.41 – 
1.69) 
-0.12 
(-0.22 - -0.011) 
0.09 
 
-0.7 
(-1.3 – -0.08) 
743.90 
(103.78 – 
1384.01) 
0.09 
 
0.74 
(0.12 – 1.3) 
R Middle 
frontal gyrus 
-46.72 
(-317.83 – 
224.39) 
0.83 
 
-0.11 
(-0.71 – 
0.49) 
0.019 
(-0.034 – 0.072) 
0.76 0.22 
(-0.38 – 0.83) 
105.30 
(-872.15 – 
1082.76) 
0.79 
 
0.069 
(-0.53 – 0.67) 
R Post Parietal 
cortex 
51.31 
( -236.49 – 
339.13) 
0.85 
 
0.11 
(-0.49 – 
0.72) 
-0.05 
(-0.085 - -
0.007) 
0.08 
 
-0.73 
(-1.35 - -
0.11) 
-110.98 
(-861.99 – 
640.01) 
0.83 
 
-0.09 
(-0.7 – 0.51) 
R dACC 50.02 
(-32.3 – 
132.35) 
0.42 0.39 
(-0.21 – 
1.0) 
0.01 
(-0.08 – 0.10) 
0.77 0.06 
(-0.54 – 0.66) 
183.55 
(-53.01 – 420.13) 
0.29 0.49 
(-0.16 – 1.11) 
R Broca 
homologue 
180.70 
(28.13 – 
333.27) 
0.08 
 
0.76 
(0.13 – 
1.38) 
0.018 
(-0.05 – 0.09) 
0.86 
 
0.16 
(-0.44 – 0.76) 
711.17 
(209.95 – 
1212.40) 
0.05 
 
0.91 
(0.27 – 1.54) 
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R Wernicke 
homologue 
-30.15 
(-258.35 – 
198.03) 
0.81 
 
-0.08 
(-0.7 – 
0.52) 
0.09 
(0.039 – 0.14) 
0.01 
 
1.12 
(0.46 – 1.76) 
169.82 
(-585.72 – 
925.37) 
0.86 
 
0.114 
(-0.46 – 0.75) 
R Fusiform 
gyrus 
118.39 
(-4.43 – 
241.23) 
0.16 0.62 
(0.0007 – 
0.099) 
0.007 
(-0.09 – 0.11) 
0.78 0.05 
(-0.55 – 0.6) 
363.40 
(-81.66 – 808.47) 
0.26 0.52 
(-0.09 – 1.14) 
Positive values of mean difference suggest that the morphology is greater in the least deprived group. The analysis based on estimated 
marginal means with covariates appearing in the model evaluated at the following values: ICV (for surface area and volume) = 1557.80cc (for 
cortical thickness –Mean thickness = 2.44mm); Age in years = 50.94, Number of alcohol units per week = 17.21. a. All p values are adjusted for 
multiple comparisons using Benjamini- Hochberg FDR correction for 36 analysis (q=0.05). L – Left; R – Right ; dACC – dorsal anterior cingulate ; 
95% CI -  95% confidence intervals. 
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4.4.4 Correlation between inflammatory/metabolic composite 
factors and cortical thickness 
Figure 4-3 shows the relationship between the relationship between the 3 
factors derived from the principal components analysis and cortical thickness. In 
each of the analysis, the other factors and age were entered as covariates in the 
model. So, for example, when examining the relationship between inflammation 
factor and cortical thickness, I included TAG factor and BMI-HDL-Insulin factor as 
covariates. Similarly, with the other factors. These analyses characterise the b 
path in the mediation analysis shown below. As can be seen in the figure, the 
inflammation factor showed a significant negative correlation with cortical 
thickness along the left peri-sylvian and fronto-parietal regions. It should be 
noted that the 3 factors which were obtained using the PCA were orthogonal. In 
addition, since we added them as covariates, there is hardly any spatial overlap 
between the variance explained by these factors. As seen in the previous 
chapter, the TAG factor and the BMI factors showed significant positive 
correlation with cortical thickness in on both left and right side.  
4.4.5 Mediation analysis 
Only the inflammation factor, within the cardio-metabolic risk markers was 
found to be significantly different between groups (‘a’ path) (table 1). Therefore 
only the inflammatory factor was considered as a potential mediator. All the 
cortical morphological parameters that differed between the two populations 
(total effect) were examined. See Table 4-4 for the details of the ‘a’ path, ‘b’ 
path, the ‘total’ effect and the ‘indirect’ effect and the effect ratios of all 
mediations tested. Inflammation factor mediated the relationship between 
deprivation status and left Wernicke’s region cortical thickness (Beta=-0.32; SE = 
0.12; 95%CI = -0.65 to -0.14). The relationship with the right homologue cortical 
thickness failed to reach statistical significance. None of the other regions 
showed a significant b path and therefore, the relationships were not tested. 
The detailed results of the mediation analysis are given in Table 4-4. 
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Figure 4-3: The relationship between inflammation, TAG and BMI factor on cortical 
thickness.  
 
The regions of the brain that survived multiple correction using the Monte Carlo Null-Z 
simulation technique (p<0.05). The regions that survived are labelled. The cortical surface is 
inflated, and the dark grey areas represent sulci, and light grey represents gyri. 
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Table 4-4:  Results of the mediation analysis 
ROI Coefficient SE p Boot strap  
95% CI 
Effect 
ratio 
Right   Broca 
homologue 
volume 
 r2 = 0.46 ; F(5,36)=6.2; p<0.0003 
a path 1.06 0.26 0.0003   
b path 0.03 0.17 0.87   
Total effect -0.68 0.23 0.0067   
Direct effect -0.71 0.30 0.02   
Indirect effect 0.029 0.22  -0.44 to 0.49 4.26% 
Left Posterior 
parietal volume 
r2 = 0.53 ; F(5,36)=8.3; p<0.00001 
a path 1.06 0.26 0.0003   
b path 0.11 0.16 0.49   
Total effect -0.63 0.22 0.007   
Direct effect -0.74 0.28 0.01   
Indirect effect 0.11 0.16  -0.19 to 0.44 18.3% 
L Posterior 
parietal surface 
area 
r2 = 0.57 ; F(5,36)=9.7; p<0.0001 
a path 1.06 0.26 0.0003   
b path -0.009 0.15 0.95   
Total effect -0.83 0.21 0.0004   
Direct effect -0.82 0.27 0.004   
Indirect effect -0.009 0.14  -0.34 to 0.24 1.08% 
L Fusiform 
surface area 
r2 = 0.41 ; F(5,36)=4.9; p<0.0014 
a path 1.06 0.26 0.0003   
b path 0.017 0.18 0.92   
Total effect -0.83 0.25 0.002   
Direct effect -0.85 0.31 0.01   
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Indirect effect 0.018 0.24  -0.35 to 0.36 2.16% 
Left Wernicke 
cortical thickness 
r2 = 0.76 ; F(5,36)=23.6; p<0.00001 
a path 1.06 0.26 0.0003 - - 
b path -0.31 0.116 0.009 - - 
Total effect -0.49 0.17 0.007 - - 
Direct effect -0.18 0.199 0.37 - - 
Indirect effect -0.32 0.12  -0.65 to -
0.14 
65.3% 
Right Wernicke 
homologue 
cortical thickness 
 r2 = 0.72 ; F(5,36)=18.7; p<0.00001 
a path 1.06 0.26 0.0003 - - 
b path -0.18 0.12 0.14 - - 
Total effect -0.64 0.18 0.001 - - 
Direct effect -0.45 0.21 0.04 - - 
Indirect effect -0.19 0.17  -0.62 to 0.08 29.6% 
Bootstrap samples for bias corrected bootstrap confidence intervals: 20000. Covariates in 
the model for the dependent variable include age, mean cortical thickness  (ICV for volume 
and surface area) and number of alcohol units; the initial r
2
 statistic shows the fit of the 
model with all variables including the mediator. Mediating variable – Inflammation factor; 
details of the path are shown in Figure 2. Coefficients are interpreted as Betas. Indirect 
effect is the product of coefficients of ‘a’ and ‘b’ paths.  
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4.5 Discussion 
The aim of this analysis was to examine the relationship between neighbourhood 
level deprivation and cortical morphology of anatomical ROIs pertaining to 
language and executive functions. The rationale behind this was to examine the 
grey matter element most commonly associated with these cognitive functions. I 
have demonstrated that neurologically healthy middle-aged men from the most 
deprived (MD) and least deprived (LD) neighbourhoods of Glasgow show 
significant cortical morphological differences in the above ROIs. 
The findings from the analysis are unlikely to be due to global differences in 
cortical morphology for the following reasons. 1) Cortical morphology was not 
smaller in the MD in all the regions of interest. The LD had smaller morphology 
pertaining to a few ROIs, although they did not survive multiple testing 
corrections; 2) neither ICV nor mean cortical thickness differed between groups 
and 3) differences in all the above regions survived even after co-varying for the 
above global measures. Our findings are similar to that of previous studies that 
have found an association between SES and regional brain anatomy, rather than 
global changes (Noble et al., 2012).  
4.5.1 Comparison with previous studies 
A few previous studies have found an association between SES and inter-
individual variations in regional brain morphology in adults. Staff et al found an 
association between childhood SES and hippocampal volume in 235 elderly 
adults, even after adjusting for adult SES levels(Staff et al., 2012). They propose 
that their findings are consistent with a neuro-developmental trajectory where 
effects of childhood SES on structural brain development are detectable even 
after 50 years. However, not all studies have found a relationship between 
childhood SES and regional brain morphology. Butterworth et al found no 
association between childhood SES and hippocampal or amygdalar volume in 403 
middle-aged individuals. They found that financial hardship over the past year 
was associated with smaller hippocampal and amygdalar volumes (Butterworth 
et al., 2011). It should however be noted that automated measurements of sub-
cortical structures using FreeSurfer are less reliable than cortical surface based 
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measurements (Morey et al., 2009). In addition to conventional measures of SES, 
Gianaros et al suggest that complex psychological factors may moderate the 
relationship between SES and health outcomes throughout the life span 
(Gianaros et al., 2007a). They found that lower perceived parental social 
standing was associated with greater amygdalar activation in response to angry 
faces, even after co-varying for parental education (Gianaros et al., 2008). In a 
separate study, they found that self-reports of low subjective social status was 
associated with reduced grey matter volume in the perigenual anterior cingulate 
cortex (pACC), a region highly associated with affect related processes, even 
after co-varying for conventional SES indicators.  
Although it is possible that regions like the hippocampus, amygdala and ACC that 
are involved in stress related processes are more sensitive to lifelong 
experiences associated with poverty, it can only be speculated that these 
processes are directly responsible for the differences in cortical morphology 
(Gianaros et al., 2007a, Gianaros et al., 2012, McEwen and Gianaros, 2010). The 
differential associations between SES and specific brain regions may explain the 
poor neuro-cognitive health in these individuals. I did not find an association 
between neighbourhood deprivation and ACC morphology. However, our 
parcellation was more dorsal than Gianaros et al – a region associated with 
cognitive control showing high connectivity with fronto-parietal regions (Bush et 
al., 2000, Margulies et al., 2007). While the results of the aforementioned 
studies are not directly related to the ROIs that I tested, Gianaros et al using 
fMRI along with a positive and negative feedback task, found that higher 
parental education predicted greater activity in pars-triangularis and the angular 
gyrus, both in the vicinity of language regions explored in our study (Gianaros et 
al., 2010).   
A small number of studies have examined the associations in children. Noble et 
al examined the relationship between SES and volumes pertaining to language, 
episodic memory (hippocampus), ACC and amygdala in sixty 15 year old children. 
SES was found to predict differences in hippocampal and amygdalar volumes. 
They also observed an SES X age interaction in the left superior temporal gyrus, 
associated with phonological skills. Some of their negative findings may however 
be explained by the fact that they did not explore cortical thickness and surface 
area separately (Noble et al., 2012, Jednoróg et al., 2012). Previous studies have 
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found that regions that do not show volumetric differences, may show cortical 
thickness differences (Jednoróg et al., 2012). These findings emphasise the 
importance of selecting the appropriate phenotype to be measured when 
exploring inter-individual differences in cortical morphology associated with SES 
in both adults and children.  
4.5.2 Exploring cortical thickness and surface area separately 
Cortical volume is a function of surface area and cortical thickness. I found that 
that the MD group had smaller surface area pertaining to the left fusiform and 
left posterior parietal cortex. They also had smaller cortical thickness pertaining 
to Wernicke’s area and its right homologue. Interestingly, the cortical thickness 
difference between groups did not show up as a volumetric difference. This is 
because cortical grey matter volume is almost entirely driven by surface area 
rather than cortical thickness (Im et al., 2006). Our findings reflect those of 
Jednorog et al, who found that SES in a group of 10 year old children was 
associated with differential involvement of cortical volume, cortical thickness 
and surface area pertaining to different regions and highlight the importance of 
examining both cortical thickness and surface area separately. (Jednoróg et al., 
2012)  
There are several theoretical reasons why one should examine these distinct 
cortical parameters separately. Firstly, cortical volume is derived from two 
properties of the cortical sheet with a distinct cellular basis: cortical thickness 
and surface area.(Panizzon et al., 2009, Rakic, 2009)   Ontogenically cortical 
expansion (increase in surface area) is independent of cortical thickness. The 
radial unit hypothesis proposes that symmetrical cell division within the neural 
stem cell pool in the ventricular zone results in an exponential increase in the 
number of radial columns, contributing to an increase in surface area. This is 
independent of asymmetrical cell division in the neural progenitors that results 
in an  increase in the number of neurons within a radial column, contributing to 
an increase in cortical thickness. Cortical structural covariance networks derived 
from cortical thickness and surface area shows different structural properties, 
suggesting that they contribute to different properties within cortical networks 
(Sanabria-Diaz et al., 2010).  
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Secondly, recent large scale studies have shown that these two parameters – 
cortical thickness and surface area- have an independent genetic basis.  
Panizzon et al found that although total cortical thickness and surface area were 
both highly heritable, they were essentially unrelated genetically (genetic 
correlation = 0.08)(Panizzon et al., 2009).   
Life course trajectories of these cortical parameters seem to be different. While 
gyrification – a ratio of total surface area to pial surface area remains fairly 
stable post childhood through to early adulthood, cortical thickness changes 
dynamically throughout this period (Raznahan et al., 2011, Salinas et al., 2012). 
Cortical thickness in addition appears to be highly susceptible to various 
environmental influences over the life course such as smoking and alcohol 
dependence, while surface area appears to be influenced by various unique 
developmental factors (Kuhn et al., 2010, Momenan et al., 2012).  Furthermore, 
there is some evidence that surface area and cortical thickness may be 
differentially affected in relation to timing of environmental events that affect 
cortical morphology. For example, Park et al, found that a group of congenitally 
blind adults had significantly reduced cortical surface area in the primary visual 
areas, compared in contrast to those who developed blindness after two years of 
age, who had cortical thinning but no difference in the surface area (Park et al., 
2009).  
In our study, cortical thickness differences in the Wernicke’s region were 
mediated by the inflammation factor. It is tempting to speculate that the 
cortical thinning in the MD is a result of greater inflammation accumulated over 
the life course, while the surface area differences may have occurred in early 
life. While theoretically plausible, the cross sectional nature of our study 
precludes us from making such causal assumptions. It should also be noted that 
processes that affect cortical morphology may affect both parameters (cortical 
thickness and surface area) at different intensities, such that one may be 
affected more than the other. Therefore, pathological processes may affect both 
parameters, but may be apparent only in one. In addition, the apparent 
differential involvement may be due to inadequate power, rather than actual 
differential involvement. In fact, a number of strong relationships in our study 
did not attain statistical significance, suggesting that conclusions about the 
differential regional involvement, timing or pathological processes underlying 
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the associations are speculative at best. While such assumptions can only be 
made using longitudinal studies, examining just one parameter or a composite 
parameter like volume, which is primarily driven by cortical surface area, could 
lead to false negative findings. 
4.5.3 Role of neighbourhood deprivation and mediators  
Most of the studies previously mentioned have examined the association 
between individual level SES and brain morphology. A small number of studies 
have combined individual level SES indicators with neighbourhood level 
indicators. However, individual level explanations for poor health do not capture 
important social and structural determinants of ill health (Diez Roux and Mair, 
2010). It is well established that social circumstances have direct biological 
consequences, as well as impact on health behaviours. Neighbourhood level 
deprivation has been associated with poor health outcomes due to inequalities in 
resource distribution. These neighbourhoods have physical (e.g. access to food) 
and social (e.g. violence) attributes that are contributors to health outcomes.  
Previous epidemiological studies have found an association between SES and 
raised inflammatory markers (Nazmi et al., 2010). The results of the data 
reduction using PCA enabled us to examine the mediation effects of broad 
domains within the markers that were statistically independent and 
physiologically meaningful – inflammatory and metabolic markers. The variance 
explained by the inflammatory factor on cortical thickness, was significant even 
after including the TAG and BMI-HDL-Insulin factors as covariates. This is not 
surprising, as the initial PCA meant that the factors were statistically 
independent. Nevertheless, the results suggests that although previous results 
suggest that BMI, lipid markers and inflammatory markers covary significantly, 
they may explain significant independent variance in cortical thickness. 
The “inflammation factor” mediated the relationship between deprivation status 
and cortical thickness in the left Wernicke’s area. A similar relationship was 
demonstrated by Gianaros et al who found that circulating levels of CRP 
mediated the relationship between SES and measures of white matter integrity 
(Gianaros et al., 2012). McLean et al have previously shown that a composite 
cardio-metabolic risk index, mediated the relationship between neighbourhood 
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deprivation and N-acetyl-aspartate, a measure of neuronal integrity in the 
hippocampus (McLean et al., 2012). Taken together, these findings suggest that 
SES may be related to different systems in the brain through similar pathways. 
Recent studies have demonstrated an association between circulating 
inflammatory markers and brain structure and function.  Drake et al using the 
PET tracer PK11195 found that people with greater cerebrovascular risk factors 
(but no stroke) showed greater microglial activation in the brain, compared to 
normal controls (Drake et al., 2011). Marsland et al have previously shown an 
association between greater circulating IL-6 levels and smaller hippocampus, 
medial prefrontal cortex and cerebellar grey matter volume in middle aged 
adults (Marsland et al., 2008). These findings suggest that certain brain regions 
may be particularly associated with variations in circulating inflammatory 
markers. It remains unknown if a causal relationship exists between these 
variables or if the changes in circulating inflammatory markers and cortical 
morphology are a phenotypical presentation of common aetio-pathological 
factors. While Gianaros et al found a mediating effect of adiposity on white 
matter integrity, I found no such effect (Gianaros et al., 2012). While this could 
be due to differential relationship of these mediators on different structures, a 
type 2 error due to small sample size cannot be ruled out.  
In conclusions, neighbourhood level deprivation is associated with differences in 
cortical morphology pertaining to regions of the brain commonly associated with 
language and executive function. I also provide evidence about potential factors 
that may contribute to these associations. Future longitudinal studies should 
enable us to explore the complex relationship between SES and variations in 
various cortical morphological parameters.
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5 Chapter 5 - Inflammation mediates the 
difference in cortical thickness covariance network 
structure associated with neighbourhood 
deprivation 
Recently, complex network analysis has been used to characterize various 
structural properties of the large-scale network organization of the brain. For 
example, the human brain has been found to have a modular architecture i.e. 
regions within the network form communities (modules) with more connections 
between regions within the community compared to regions outside it. In this 
chapter, examine the modular and overlapping modular architecture of the brain 
networks from people from the least and most deprived neighbourhoods of 
Glasgow, using complex network analysis. For the first time, I have shown that 
neighbourhood deprivation is associated with changes in network structure. More 
interestingly, I show that this difference may be partly driven by differences in a 
circulatory inflammatory index between groups. Part of this chapter, has been 
published as Krishnadas, R., et al. The envirome and the connectome: exploring 
the structural noise in the human brain associated with socioeconomic 
deprivation. Front. Hum. Neurosci. 7:722. doi: 10.3389/fnhum.2013.00722 
5.1  Introduction 
Overlapping large-scale networks that are organised across the cortex form the 
anatomical and functional foundations of complex cognitive processes (Bressler 
and Menon, 2010). Complex network analysis based on graph theory has been 
recently used on neuroimaging data (MRI, MEG and EEG) to explore different 
properties of these large-scale cortical network organization (Sporns, 2011). 
These studies have shown that human brain networks are optimally functioning 
systems that demonstrate small world properties, and a modular architecture 
(Bassett et al., 2008, He et al., 2007, Bullmore and Sporns, 2012). Modularity is 
an index of community structure within a large-scale network (Newman, 2006). 
That is, these networks have a tendency to form modules or communities with 
more connections between nodes within the module than between modules than 
expected. Structurally, modules represent discrete entities whose functions are 
separable from those of other modules (Hartwell et al., 1999).  
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While modularity (segregation) is usually associated with robustness of the 
network in biological systems, complex cognitive processes (an index of 
performance of the network) are unlikely to occur optimally within isolated 
modules (Hintze and Adami, 2008). Rather, they are likely to be dependent on 
the coordinated activity between several modules within the large-scale network 
(integration). Indeed, most biological networks that survive in nature are those 
that achieve some balance between robustness and performance (segregation 
and integration). Intuitively, it would be beneficial if the human brain network 
demonstrated modularity – increasing its robustness - but also had an 
architecture that facilitates efficient information transfer between modules – 
thereby improving performance. Therefore, while maintaining the advantages of 
having a modular architecture, I propose that the human brain will also 
demonstrate an overlapping modular architecture, where certain nodes (I call 
grey nodes) are included in many modules at the same time (Figure 5-1) (Zhao et 
al., 2011). Within an information processing system, such an architecture, will 
improve information transfer between modules thereby increasing efficiency and 
performance of the network in terms of having lesser number of edges and 
shorter average path lengths. In short, while modularity represents the 
community architecture within a network, grey nodes represents an index of 
overlapping communities.  
Survival in adverse environments may be associated with changes in network 
structure that make them less robust and reduce their performance. 
Neighborhood level socioeconomic status (SES) is associated with adversity and 
the presence of risk factors for reduced physical and neurocognitive health (Diez 
Roux and Mair, 2010). If indeed, cognitive functions are dependent on optimal 
functioning (and hence structure and topology) of large-scale brain networks, it 
is possible that SES is associated with changes in large-scale network structure. A 
small number of neuroimaging studies have shown SES to be associated with 
variations in individual brain anatomy and functional connectivity in adults 
(Gianaros et al., 2007a, Gianaros et al., 2008). While network structure and 
topology have been found to be disrupted in a number of mental illnesses, no 
study has examined the relationship between neighborhood socioeconomic 
deprivation and brain network structure in humans. The aim of the present study 
was to apply complex network analysis to examine the structural characteristics 
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– modularity and grey nodes – of cortical networks derived from cortical 
morphology correlation (Figure 1). 
I also examined these structural characteristics in relation to socioeconomic 
deprivation. There is growing evidence that cortical morphology covariation is an 
indicator of connectivity between different regions of the brain (Worsley et al., 
2005, Lerch et al., 2006, He et al., 2007, Bassett et al., 2008, Alexander-Bloch 
et al., 2013). Graph-theoretical network analyses based on morphological 
correlations have been used to examine brain network structure in healthy and 
clinical samples (He et al., 2009, He et al., 2007, Bassett et al., 2008).  
Figure 5-1: Shows the modular architecture (top Figure) and grey nodes (bottom Figure), 
Grey nodes  
 
Consider two fully connected networks (bottom Figure), with four nodes each and are fully 
connected. The two networks can be connected in two different ways. If they are connected 
as the first left in the bottom, then one additional edge is used. On the other hand, if they 
share the two nodes depicted in grey, then the combined module saves resources, i.e. there 
are two nodes and two edges less than the first combination. In addition, the average path 
lengths are shortened than the one of non-sharing combination. 
 
Using complex network analysis of magnetic resonance imaging (MRI) surface-
based morphometry I investigated the topological features of whole cortical 
anatomical networks in 42 neurologically healthy men from the most deprived 
(MD) and least deprived (LD) neighborhoods of Glasgow . The connectivity 
matrices in the present study were derived from region-wise cortical thickness 
correlations between 68 anatomical parcellations and subjected to complex 
network analyses. I propose that the brain networks derived thus will show an 
overlapping modular architecture – by the presence of modules and grey nodes. I 
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also sought to determine if these structural properties differed significantly 
between neurologically healthy people living in the most deprived (with higher 
risk of reduced mental health cognitive functioning) and the least deprived 
regions of Glasgow. Throughout the paper, “structural” refers to the network 
structure (e.g. modularity or proportion of grey nodes). I have used the term 
“anatomical” to refer to brain anatomy.  
5.2 Materials and Methods  
5.2.1 Participants 
Participants were recruited as part of a larger study Psychological, social and 
biological determinants of ill health (pSoBid) and have been described in chapter 
4 section 4.2.1. 
5.2.2 Cardio-metabolic risk factors 
For this analysis, I once again, as in the previous chapter, examined the role of 9 
blood markers - C-reactive protein (CRP), Interleukin-6 (IL-6), Intercellular 
Adhesion Molecule-1 (ICAM),Triglycerides, High density lipoprotein (HDL), Very 
low density lipoprotein (VLDL), Fibrinogen, D-dimer and Insulin – and an 
anthropometric measure- BMI.  The details of this analysis are in chapter 3 
section 3.2.2 and chapter 4 section 4.2.2.1. 
5.2.2.1 Principal components analysis and dimension reduction of 
cardio-metabolic markers 
This step is same as the step in the previous chapter, and has been detailed in 
section 4.2.2.2. 
5.2.3 Image acquisition 
This has been detailed in chapter 3 section 3.2.5. 
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5.2.4 Cortical thickness measurements and parcellations  
Cortical reconstruction was performed with the FreeSurfer (FS) image analysis 
suite, which is documented and freely available for download online 
(http://surfer.nmr.mgh.harvard.edu/) (Fischl and Dale, 2000b, Fischl et al., 
1999a, Dale et al., 1999). This has been detailed in section  3.2.6. The 
parcellations were obtained using the Desikan sulcogyral-based atlas, which 
follows the anatomical conventions of Duvernoy. The FS image-processing 
pipeline was visually inspected and corrected at critical points in order to avoid 
errors permeating through the subsequent analyses. Procedures for the 
measurement of cortical thickness have been validated against histological 
analysis and manual measurements. The Desikan Killiany atlas produces 68 
parcellations based on gyri and sulci (Desikan et al., 2006a). In addition to the 
Desikan Killiany atlas parcellation scheme, I also used fine-grained parcellation 
schemes based on anatomical sulcogyral boundaries including the Destrieux 
atlas, (148 parcellations) and fine-grained parcellation schemes (200, and 1000 
parcellations) that did not follow anatomical conventions as described in 
Echtermeyer et al (Destrieux et al., 2010, Echtermeyer et al., 2011). The 
analysis pipeline is shown in Figure 5-2.  
 
 
 
 
 
 
 
 
Chapter 5  117 
 
 
 
 
Figure 5-2: Analysis pipeline, including the parcellation schemes.  
 
Desikan atlas and Destrieux atlas showing the sulcogyral parcellations and the Finegrain 
200 and 1000 atlas as in (Collins et al., 2011) 
 
5.2.5 Cortical thickness – between group comparison 
Statistical comparisons of global data and surface maps were generated by 
computing a general linear model (GLM) of the effect of neighbourhood 
deprivation (independent variable) on thickness (dependent variable) at each 
vertex in the cortical mantle, using the Query, Design, Estimate, Contrast 
(QDEC) interface of FreeSurfer. Age was used as nuisance covariate in the 
model. QDEC is a single-binary application included in the FreeSurfer distribution 
that is used to perform group averaging and inference on the cortical 
morphometric data produced by the FreeSurfer processing stream. 
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(http://surfer.nmr.mgh.harvard.edu/fswiki/Qdec). Maps were created using 
statistical thresholds of p=.05 and were smoothed to a full width half maximum 
(FWHM) level of 20mm. Since this analysis involved performing a GLM analysis at 
160000 vertices, these maps were corrected for multiple comparisons by means 
of a cluster-wise procedure using the Monte Carlo Null-Z simulation method 
adapted for cortical surface analysis and incorporated into the QDEC processing 
stream. For these analyses, a total of 10,000 iterations of simulation were 
performed for each comparison, using a threshold of p=.05. 
5.2.6 Network construction  
Network construction was based on parcellations of cortical thickness as 
described by He et al (He et al., 2007). I defined an anatomical connection 
(edge) as statistical associations in cortical thickness between cortical 
parcellations based on the Desikan Killiany atlas included in the FreeSurfer 
pipeline (nodes). The statistical similarity in cortical thickness between 2 regions 
was measured by computing the Pearson’s correlation coefficient across subjects 
to create an interregional correlation matrix (N × N, where N is the number of 
brain regions based on Desikan cortical parcellation atlas, here N = 68). In order 
to keep the analysis as close as possible to previous reports, prior to the 
correlation analysis, a linear regression was performed at every region to 
remove the effects of age, and mean overall cortical thickness; the residuals of 
this regression were then substituted for the raw cortical thickness values (Chen 
et al., 2008).  In order to be consistent with the cortical thickness group 
difference analysis presented above, the complex network analyses were 
repeated without mean overall cortical thickness in the model, but the results of 
this analysis did not differ significantly. A separate matrix was produced for the 
MD (21 subjects) and the LD (21 subjects). As a first step, all negative 
correlations were discarded.  As the correlation analysis was performed for all 
68 × 68/2 = 1431 pairs of regions, I performed a multiple comparisons correction 
to test the significance of these correlations.  
We applied the false discovery rate (FDR) procedure separately to each matrix in 
order to correct the multiple comparisons at a q value of 0.2 (this was chosen as 
at 0.05, both matrices were very sparse) (Genovese et al., 2002). Using this 
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threshold, I constructed a symmetric connection matrix (Figures 5 and 6), whose 
element was 1 if the cortical thickness correlation between 2 regions was 
statistically significant and 0 otherwise. This binarised connection matrix 
captures the underlying anatomical connection patterns of the human brain 
common to the population sample under study. I repeated all the analyses on 
matrices derived from the fine grained parcellation schemes described above, in 
order to validate my findings using multiple parcellation schemes.  
5.2.7 Modularity 
All the modularity metrics were calculated on the above two adjacency matrices 
separately and compared to corresponding random networks.  Modularity is an 
intuitional concept and there are variations in the mathematical definitions, 
where each has its own advantages and disadvantages. One common property 
among the various ways of defining modularity, however, is accounting for the 
agreed intuition about modularity, i.e. a module is a subset of nodes in a graph, 
whose connections among the elements within the subset are much denser than 
the ones to nodes outside the subset. Newman suggested the following 
modularity measure,Q : 
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where s  is a column vector and element of the set S , S  is the set of all column 
vectors whose dimension are equal to the number of nodes in the graph, n , and 
each component of the vector is either -1 or +1,  
T
  is the transpose. B  is equal 
to   mkkA
T 2/ , A  is the adjacency matrix, whose dimension is nn , and the i
-th column (or row) and j -th row (or column) element is 1 (or 0) if i -th and j -
th nodes are connected by an edge (or if there is no edge), k is a column vector 
whose element is the number of edges connected for each node, i.e. the degree 
of node, and m  is the total number of edges. Roughly speaking, B quantifies the 
difference between the number of edges found in a subset of the given network 
structure, i.e. A , and the expected average from the random graphs, whose 
nodes degree is the same as the one of the given graph, i.e.  mkk
T 2/ . Hence, 
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positive Q  values imply that there are more edges found than the expected and 
it is, therefore, a module. 
By obtaining  that maximizes the modularity, Q , the nodes are divided into 
two groups, i.e. modules, depending on the corresponding values in the 
maximizing vector, s . The maximization problem, however, is the integer 
quadratic programming problem, which is NP-hard. It is even computationally 
very difficult to obtain the true solution, which gives the global maximum value 
ofQ . Note that Q  is always less than or equal to 1. If the condition for s  is 
relaxed so that it can take any real numbers, then the problem becomes finding 
maximum eigenvalue and the corresponding eigenvector of the matrix, . This 
can be solved efficiently using the power-iteration, i.e. choosing an arbitrary 
initial vector, 0
s
, and recursively updating the vector using kk
Bss 1  until it 
converges. Then, s  maximizing Q  is calculated simply by taking the sign of 
converged k
s
. To increase the chance of finding the global solution, these 
procedures are repeated a number of times with a different random initial 
vector, 0
s
. If the calculated maximum value, Q , is positive (or negative), then 
the graph is divided (or declared indivisible). 
Once the graph is divided into two modules, then each module is inspected 
whether it can be further divided by solving the following the maximization 
problem: 
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where r  is an element of the set 
gs , 
gs  is the set of g
n
-dimension column 
vectors whose element is either +1 or -1, g
n
 is the number of nodes in the 
module, which is found in the previous step, 
gB is equal to  
gij kB diag , 
ijB  is a 
matrix constructed by a part of , where the rows and columns belong to the 
module, 
gk  is the degree of each nodes only concerning 
gB , and  diag  is the 
diagonal matrix, where the diagonal terms are given by the vector in the 
argument and the other elements are zero. Again, if 0Q (or 0Q ), then the 
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module is divided into two smaller modules (or declared indivisible). The above 
procedures are repeated on every module recursively until all modules are 
declared indivisible. By definition, the divisibility of a module is determined 
based on whether the modularity measure is positive or not. Very often, it is, 
hard to justify whether some subgroups of a graph are modules if the modularity 
contribution, i.e. Q  or Q , is very close to zero. As the mathematically possible 
maximum value is 1, the modular structure is much clearer if the modularity is 
closer to 1. Hence, the number of modules is calculated for various Q -
threshold, which decides when modules are declared as indivisible. 
5.2.8 Grey Nodes 
A network, in general, is not a simple collection of modules but a combination of 
complicated overlapped modular structures, i.e. it demonstrates a hierarchical 
modular architecture. The overlapped modular structures are hard to decipher 
into elementary modules that pertain to the whole network. There are several 
methods to unravel the overlapping modular structure. In order to use a 
consistent measure with the modular calculation, an extended modularity ( e
Q
) is 
defined as follows: 
e
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where e
s
 is an element of the set, e
S
, and the set e
S
 is the collection of vector, 
es , whose dimension is again, n , i.e. , the number of nodes, and its element is 
either -1, +1, or 0. Compare to the vector s  in S , e
s
 has one more degree of 
freedom in possible values (Zhao et al., 2011). The nodes corresponding to zero 
are called grey nodes, which are included in multiple modules at the same time 
or are not included in any module. e
Q
 is defined in the similar manner.  Grey 
node is a similar concept to that of connector hub and hierarchical or 
overlapping modular structure. While connector hubs are defined as nodes with 
greater than average degree of the network and distributed between both local 
and long range connections, grey nodes are defined as nodes that are shared by 
modules. It is an index of overlapping modular architecture of the network. 
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Previous literature has described such overlapping architecture based on a prior 
definition of modularity by Girvan and Newman (Girvan and Newman, 2002) . On 
the other hand, “grey nodes” are a unified way to define the structure in the 
more recent modularity definition by Newman (Newman, 2006). This provides an 
advantage that I measure modular architecture, and the overlapping 
architecture using a consistent measure without requiring significant changes in 
the algorithm (Newman, 2006).  
All calculations presented in this paper are based on Monte-Carlo simulations 
performed 1000 times. The distributions of all calculations are confirmed to be 
similar to Gaussian distributions (data not shown). Hence, there is no danger 
that the analyses based on the mean and the variance may give any false 
interpretations of the true distribution of the data. All graphs were compared to 
random graphs (with the same number of nodes and degree distribution as the 
corresponding brain networks). 
5.3 Inflammation and network structural difference 
In order to examine the role of inflammation in mediating the network structural 
difference between the two groups, I constructed a separate correlation matrix, 
to repeat the above analysis. This time, prior to the correlation analysis, I 
performed a linear regression at every region (based on the Desikan-Killiany 
atlas) to remove the effect of age, the mean overall cortical thickness and the 
“inflammation factor” derived from the principal component analysis in section 
5.2.2.1. Among the factors from the PCA, I covaried only for the inflammation 
factor, as only this was different between the two groups.  
5.4 Results 
Demographic details, differences in risk factors and performance on cognitive 
tests of the participants are shown in Table 1. In general, participants in the MD 
group had higher inflammatory and metabolic risk markers, poorer GHQ scores 
and performed poorly on a number of cognitive tests.  
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5.4.1 Cortical thickness differences between groups 
Initial analysis of cortical thickness across groups showed that those from the 
most deprived population had significant cortical thinning pertaining to bilateral 
perisylvian cortices (Figure 5-3).  
Figure 5-3: Shows the difference in cortical thickness between the most deprived and the 
least deprived groups.  
 
Red regions pertain to regions where the most deprived group showed cortical thinning. 
Covariates in the model – Age and alcohol use. 
5.4.2 Network analysis 
I conducted all analyses on binarised matrices derived from interregional 
correlations of cortical thickness. Initial examination of number of isolated 
modules showed that for a given correlation threshold, the least deprived group 
had greater number of isolated groups compared to the deprived group (Figure 
5-4).  
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Figure 5-4: The correlation values in the matrices are distributed between 0.1 to 0.9.  
 
By changing the correlation threshold from 0.2 to 0.85, the number of isolated 
groups are counted for the both groups. The least deprived has more isolated 
groups than the deprived over the almost all values of the correlation threshold. 
The raw networks and FDR filtered networks are shown in Figure 5-5 and Figure 
5-6.  
Figure 5-5: The raw correlation matrix for each group shows that two groups have almost 
equal number of non-zero components in the matrix.  
 
The correlation matrix for each group is  a 68x68 matrix, where each value in the matrix is 
calculated from the cortical thickness correlation measured in 21 individuals. 
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Figure 5-6: In the correlation matrix for each group, all values below the FDR threshold are 
set to zero. 
 
About three-times more edges survived the FDR procedure in the most deprived than the 
least deprived group 
The distribution of the groups’ correlation coefficients is shown in Figure 5-7. 
Figure 5-7: The distributions of correlation coefficients for both groups.  
 
The vertical lines are the FDR threshold values for each group. 
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A direct comparison of the networks derived from the above populations, was 
not possible, as for a given correlation threshold, the sparsity (density) of the 
two networks were significantly different (Figure 5-8).  
Figure 5-8: Correlation and sparsity (Number of zeros divided by Maximum possible number 
of edges) relations in cortical thickness network. 
 
The most deprived group had more edges (denser network) than the least deprived for a 
fixed correlation threshold. On the other hand the least deprived would have more false 
positive edges than the deprived and/or the deprived would have more false negative edges 
than the least deprived for a fixed sparsity.  
 
In addition, the FDR procedure thresholded the two networks significantly 
differently. This method of thresholding resulted in different number of edges - 
k - (sparsity) in the networks of the two groups because of differences in their 
inter-regional cortical thickness correlations. I therefore compared the network 
structure derived from the groups to their corresponding random networks. The 
results of this analysis are shown in Figure 5-9 and Figure 5-10. 
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Figure 5-9: Number of modules and the corresponding random graphs (indicated by “(R)”) 
with respect to various modularity ( ) threshold 
 
Error bars represent the -bound for each case. In the module calculation algorithm, if the 
module contribution,  or , is less than the threshold, it was declared indivisible. 
Higher thresholds imply strong modules. 
Figure 5-10: Proportion of grey nodes  with respect to the corresponding Modularity 
threshold 
 
Error bars represent the -bound for each case. In the module calculation algorithm, if the 
module contribution,  or , is less than the threshold, it was declared indivisible. 
Higher thresholds imply strong modules. Grey nodes have two implications in the network 
structure: i) efficient usage of resources and ii) shorter average distance between nodes. 
Recycle of existing nodes and edges to combine multiple modules saves limited resources 
to construct the network. It is believed that reducing wiring resources is one of the major 
selection pressure on the brain network evolution 
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5.4.2.1 Modularity and grey nodes  
Firstly, the networks derived from both groups showed a modular architecture, 
and the presence of grey nodes. Towards a modularity of 0.3 (strong 
modularity), the least deprived network had more modules, compared to its 
corresponding random network. However, the most deprived network, showed 
no difference from its random counterpart.  
With regards the grey nodes, for a given a modularity towards 0.3, the least 
deprived network showed significantly greater number of grey nodes compared 
to the corresponding random network. However, the most deprived network 
showed significantly smaller proportion of grey nodes compared to its random 
counterpart. While the differences between groups were maintained in the 
Destreaux atlas (148 parcels) that followed the sulcogyral boundaries, these 
differences were not seen with the finer grain parcellations of 200 and 1000 
parcels that did not follow the sulcogyral scheme (Figure 5-11).  
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Figure 5-11: The number of modules and proportion of grey nodes at a fine grain level  
 
a) parcellation following sulcogyral boundaries – Destrieux atlas (148 parcels) and b) a 
parcellation scheme that does not follow the sulcogyral boundaries (b. 200 parcels and c. 
1000 parcels). 
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5.4.3 Network structural difference and inflammation 
I repeated the above analysis using the correlation matrix constructed after co-
varying for inflammation factor. The results of this analysis are shown in Figure 
5-12.  
Figure 5-12: The difference in network structure derived from networks constructed from 
cortical thickness correction for inflammatory factor.  
 
 
a) the number of modules with respect to modularity; b) the proportion of grey nodes with 
respect to modularity. Note that at a modularity of 0.3, the two least deprived and the most 
deprived networks are similar in terms of both number of modules and proportion of grey 
nodes.  
As can be seen, towards the modularity of around 0.3, the number of modules in 
the affluent network is very similar to its corresponding random network and to 
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the deprived network. Similar is true regarding the proportion of grey nodes. 
These results suggest that at least part of the difference in network structure 
was driven by the difference in inflammatory index scores.  
 
5.5 Discussion 
I have shown here that brain networks derived from cortical morphological 
correlations show a modular organization, and indeed an overlapping modular 
architecture as demonstrated by the presence of grey nodes. I have also shown 
that neurologically healthy subjects from the MD regions of Glasgow differ 
significantly in their brain network structure from those from the LD regions in 
comparison to their corresponding random networks on relatively coarse 
parcellations schemes that followed the sulcogyral boundaries. Brain networks in 
the MD group showed same number of modules and smaller proportion of grey 
nodes compared to their corresponding random network. These differences 
however disappeared at fine-grained parcellation schemes that did not follow 
the sulcogyral schemes.  
A number of recent studies have shown that human brain network structure 
derived from anatomical covariance demonstrates a modular architecture (Chen 
et al., 2011, Chen et al., 2008). There are a number of advantages in having a 
modular architecture. Kaiser suggests that this feature allows for low wiring 
costs; are time scale separable; allows for the coexistence of integration and 
segregation within a network; transient chimera states of desynchronisation and 
synchronization; and also allows for rapid and robust assembly (Kaiser, 2007). In 
addition, a modular architecture is robust against random attacks on the 
network and helps to contain the effects of these attacks to the module, rather 
than spreading through the network. 
 I compared the brain network graphs with random graphs that had similar 
degree to the corresponding brain network. For both the LD and MD groups, at 
lower modularity thresholds, the brain network graphs had fewer modules 
compared to their corresponding random graphs. However, this phenomenon was 
reversed at higher thresholds. This is possibly because within the constraints of 
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fixed resources (nodes/edges), brain networks enhance a few specific modules 
by rewiring and sacrificing unwanted modules.  
In the current study, for a given number of modules, the brain networks in the 
LD group showed stronger modular organization than their corresponding random 
graphs. In other words, the networks derived from the MD group had more edges 
between modules, which weakened the modular architecture. Previous work by 
Chen et al using a similar technique showed that modules derived using 
correlations of cortical thickness, broadly gave out six functionally relevant 
modules (Chen et al., 2008). Using the same number (six modules) as Chen et al, 
the modules were functionally more relevant in the LD population (data not 
shown). For example, all anatomical regions pertaining to language function 
were integrated together within a given module. However, this was not the case 
with the MD. Anatomical regions pertaining to similar function were distributed 
across several modules, consistent poor functional modular organization at a 
given threshold. While these modularity differences may be due to anatomical 
differences between groups that we have shown, these may have functional 
implications, as anatomical networks have been found to overlap with functional 
networks (Alexander-Bloch et al., 2013). If we consider these networks as 
information processing systems, then such a difference in network structure 
could contribute to greater noise and less efficient information processing within 
the system. However, a direct interpolation of the results of the present study is 
not possible due to the static nature of my data.  
I describe a new metric – grey node – as a measure of overlapping modular 
organization. While modularity improves the robustness within a system, it is 
unlikely that our brain network achieves optimal performance by operating as a 
number of different isolated modules. As stated previously, cognitive processes 
are likely to be the result of a number of modules interacting with each other in 
a fast and efficient way. The overlapping modular architecture – represented 
here by the presence of grey nodes - is beneficial in that given a fixed number of 
resources it provides the best modular architecture, maximizing the 
communication between modules thereby achieving a balance between 
robustness and optimal performance. Grey nodes have two implications in the 
network structure: i) efficient usage of resources and ii) shorter average 
distance between nodes. Recycling existing nodes and edges to combine multiple 
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modules saves limited resources to construct an efficient network. It is believed 
that reducing wiring resources is one of the major selection pressures on the 
brain network evolution. The results suggest that the networks derived from the 
MD group show much lower efficiency compared to their corresponding random 
network (Bullmore and Sporns, 2009, Achard and Bullmore, 2007). While metrics 
describing overlapping modules have been outlined previously, grey nodes have 
the advantage that it was derived from Newman (2006) and integrates well with 
the given modularity metric (Newman, 2006). 
While the structural differences may be driven by the difference in cortical 
thickness between the two groups, the reason for the anatomical difference 
between the two groups is not clear. It should be noted that the groups differed 
on a number of variables that could potentially explain the observed difference. 
For example, those from the most deprived had poorer mental health and also 
had higher levels of inflammation. (See Table 1 in chapter 4) I have previously 
shown inflammatory markers to be associated with cortical thickness . The data 
was however underpowered to explore the role of potential mediators that could 
explain the difference between groups in structural properties. Previous studies 
have demonstrated age related changes to modularity (Chen et al., 2011). The 
groups were matched for age. Similarly, mental illnesses have shown to be 
associated with disruption to the modular architecture. A few studies have also 
examined this property in medical conditions like MS and epilepsy (He et al., 
2009, Vaessen et al., 2012).  
A number of studies have shown an association between socioeconomic 
deprivation and brain anatomy and function in both children and adults, though 
none have examined the association with network structure (Hanson et al., 
2011, Gianaros et al., 2010). A key question that remains is how these 
anatomical differences could contribute to poorer cognitive functioning and 
mental health. Interestingly, the MD group performed poorly on all cognitive 
tests, including NART (National adult reading test) – a test that is relatively 
stable through age, and often considered a test of measure of the peak achieved 
intellectual functioning. I did not examine if less modularity was directly 
associated with poorer cognitive functioning as utilizing correlation coefficients 
to construct the matrix meant that indices of modularity could not be calculated 
at an individual level. However, change in network structure is a potential 
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mechanism by which regional anatomical brain deficits may contribute to global 
network topology, thereby resulting in poorer cognitive function. Previous 
studies have examined the relationship between intelligence quotient (IQ) and 
network properties. For example Li et al found a significant positive correlation 
between number of edges and IQ. They also found that those with greater IQ had 
shorter path lengths, greater clustering coefficient (similar to my findings) and 
in general greater global efficiency of structural networks in the brain (Li et al., 
2009). Similarly using resting state fMRI to examine the overall organization of 
the brain network using graph analysis, van den Heuvel et al showed a strong 
negative association between characteristic path length of the resting-state 
brain network and IQ (van den Heuvel et al., 2009). They suggest that human 
intellectual performance is likely to be related to how efficiently the brain 
integrates information between various brain regions. 
5.5.1 Inflammation and network structure 
The finding that the difference between the two groups disappeared, when I 
used a correlation matrix of cortical thickness that was corrected for the 
inflammation index, suggests that at least in part, the difference in network 
structure between two groups was driven by greater inflammatory factor in the 
most deprived group. While no previous study has examined the effect of 
inflammation in cortical covariance network structure in humans, a few studies 
have examined patient groups where inflammation may have played a role. 
Inflammation is thought to play a role in the pathophysiology of cancer including 
the initiation, promotion, invasion and metastasis. Inflammation also affects and 
is affected by cancer therapy(Grivennikov et al., 2010, Tili et al., 2011). 
Hosseini et al examined modularity in patients with acute lymphoblastic 
leukemia (Hosseini et al., 2012a). They found for a given number of modules, 
the degree of network modularity was significantly smaller in the networks from 
ALL survivors. The smaller network modularity in the ALL network suggested a 
reduction in the balance between network segregation and integration in ALL 
patients. The same group also demonstrated that the clustering coefficient – the 
cliquishness of the network or the network segregation - was significantly 
smaller in the structural covariance networks from breast cancer patients than 
in the control network (Hosseini et al., 2012b).  Although the authors did not 
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examine the role of inflammation in this group, they postulate that 
inflammatory processes may contribute to the difference in these structural 
properties. Indeed, acute leukemia and breast cancer has been associated with 
inflammatory processes (Montesano et al., 2005, Tsukasaki et al., 2001).  
The relationship between inflammation and brain structural networks however, 
is far from clear. Interestingly, Hess et al used graph theoretical analysis to see 
if anti-inflammatory medications decrease pain, by directly suppressing the 
brain networks responsible for pain, rather than having an effect on joints.  In a 
mouse model of arthritis, they constructed a matrix of cross-correlation of BOLD 
signals from structures that showed significant activation in response to 
nociceptive stimuli. This network showed increased clustering and modularity in 
arthritic mice compared to wild type mice. These changes largely resulted from 
the formation of tight clusters of a number of sub-cortical structures including 
the thalamus, periacqueductal grey and the amygdala. Interestingly, treatment 
with TNF- α blockade led to a rapid dissolution of this cluster, which resulted in 
a clustering and modularity similar to that of wild type mice. The authors 
suggest that neutralization of TNF-α directly affects nociceptive brain activity 
and network architecture in the context of arthritis, and that this occurs long 
before it achieves anti-inflammatory effects in the joints(Hess et al., 2011).  
5.5.2 Neighbourhood level vs Individual level SES 
Socio-economic status (SES) refers to a multidimensional construct that is usually 
measured using a number of economic (e.g. income) and noneconomic (e.g. 
education) indicators (Hackman et al., 2010). SES can be measured at an 
individual/household or at a neighbourhood level. Regardless of the level of 
measurement (individual/neighbourhood), SES has been associated with 
significant health disparities (Diez Roux and Mair, 2010). Most of the studies 
previously mentioned have examined the association between individual level 
SES and brain morphology. But individual level explanations for poor health do 
not capture significant social and structural determinants of ill health (Diez Roux 
and Mair, 2010). It is well established that social circumstances have direct 
biological consequences, as well as impact on health behaviours. However, 
relatively small number of studies have explored the contributions of individual 
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level SES indicators with neighbourhood level indicators to health inequalities. 
Neighbourhood level deprivation has been associated with poor health outcomes 
due to inequalities in resource distribution. These neighbourhoods have physical 
(e.g. access to food) and social (e.g. violence) attributes that are contributors to 
health outcomes. In the present study, individual level SES covaried significantly 
with neighbourhood level SES. Due to the nature of the sampling technique, 
people from the most deprived neighbourhoods also had poorer individual SES. 
This is partly because neighbourhood deprivation scores (SIMD) are derived from 
data pertaining to individuals in the area. Since the groups differed inherently in 
their individual SES, it was deemed inappropriate to co-vary for the effects of 
individual SES (Miller and Chapman, 2001).  The study’s relatively small sample 
size was also not sufficiently powered to examine if individual SES contributed 
significant variance over and above that explained by neighbourhood SES or vice 
versa. The extreme group sampling technique prevented us from examining any 
dose-response effect of either individual or neighbourhood level deprivation in 
the sample. 
5.5.3 Effect of parcellation scheme on network structure 
Zalesky et al have previously shown that network topology vary considerably as a 
function of the spatial scale of the atlas used (Alexander-Bloch et al., 2013, 
Zalesky et al., 2010).  Previous reports that have examined cortical thickness 
covariance network structure in clinical and nonclinical populations have used 
the same parcellation scheme (Desikan-Killiany atlas) used in the present study 
(van Wijk et al., 2010, Romero-Garcia et al., 2012, Hanggi et al., 2011, Raj et 
al., 2010, Yang et al., 2012). Of note,  Romero-Garcia et al in order to examine 
the effect of network resolution on topological properties, compared the 
Desikan-Killiany atlas based parcellation with finer parcellation schemes of up to 
1494 parcellations .  Interestingly they found that highly grained cortical scales 
showed enhanced local connectivity (clustering coefficient), and local 
efficiency, but increased path length and decreased global efficiency (Romero-
Garcia et al., 2012). My findings resonate that of Romero-Garcia et al, in that, at 
different parcellation schemes, the network topologies differed . For fine-
grained parcellation schemes that did not follow sulcogyral boundaries, the LD 
brain network and MD brain network were similar. At a modularity threshold of 
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around 0.3, both network structural properties looked similar to their random 
counterparts (suggesting a decrease in global properties at more fine grained 
schemes). (figure 1 a and 1b) 
Anatomically, since cortical thickness is a continuous measure, regions that lie 
close to each other will show very similar cortical thickness and hence high 
correlation. Here, a fine parcellation schemes, may uncover local connection (or 
a forking-U fiber connection), while a coarse may not (see figure 1 in Zalesky et 
al)(Zalesky et al., 2010). In addition, regions close to each other are likely to be 
anatomically connected by the tangential neurons and dendrites. It is possible 
that in our case, the group differences disappeared when geometrically close 
connections were exposed at the finer parcellation schemes. In addition, at finer 
parcellation, where the number of parcels far exceed the number of subjects in 
the study, the study may have been significantly underpowered to show 
significant differences between groups (Zalesky et al., 2010).  
It is also possible that network structure derived from relatively coarse 
parcellations are more representative of large scale cortical networks, while the 
networks derived from the fine-grained parcellations also include the 
meso/microscale connections representing regional/local connections. Whatever 
the case, it is clear that the granularity of chosen parcellations may affect the 
results of the network analysis. The present data suggest that when exploring 
connectivity, choosing the right granularity that is best suited to answer the 
question of interest is vital. However clear cut guidelines pertaining to this are 
absent. One suggestion is that in order to answer clinical questions, anatomically 
relevant atlases like AAL or the sulcogyral parcellations (FreeSurfer) as used in 
the present study may be more relevant.  Interestingly for a finer (than Desikan 
atlas) parcellation that follows the sulcogyral boundaries (the Destreaux atlas - 
149 parcellations), the difference between the brain and random networks in 
the most deprived group disappear at around a modularity threshold of around 
0.2 (figure 11a).  
5.5.4 Sparsity (density) and modularity 
Although I found significant differences between the networks and their 
corresponding random graphs, I did not perform a direct comparison of the 
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network structure between the two groups, as the thresholds imposed by the 
FDR correction led to matrices that were significantly different in their sparsity 
(density). Thresholding a matrix is a problem when comparing networks that 
have different sparsity for a given correlation coefficient . While the reason for 
the sparsity difference between the groups is not known, revealing topological 
differences gives deeper insights into the difference in networks than just 
revealing the sparsity difference.   
One recommended way to solve this problem is by fixing the sparsity (density) of 
a matrix, and comparing the networks at the same fixed sparsity threshold (van 
Wijk et al., 2010). This approach will however increase the false negative or 
false positive correlations at a given threshold.  For instance, in our case, at 
more than 90% of correlation thresholds, the LD network was more sparse (less 
edges – k) than the MD. i.e. for a given correlation threshold, the networks from 
both the groups were different in their size (the number of edges). The 
difference in modularity between groups may therefore be k dependent. This 
difference in correlation threshold may have arisen from anatomical difference 
in the bilateral perisylvian cortical thickness I found between groups. While 
these morphological differences could have led to a reduction in correlation 
between regions that are actually connected, this could also have led to an 
increase in the number of spurious correlations (false positive), between regions 
that are not biologically connected, thereby contributing to noise within the 
network. Therefore, introducing false edges by fixing the sparsity was not 
thought to be meaningful.  
5.5.5 Cortical thickness correlation as a measure of connectivity 
While the biological meaning of structural covariance is not clear, structural 
covariance networks have been found to be genetically heritable, associated 
with cognitive function, recapitulate functional networks, and change over the 
life span. See Alexander-Bloch (2013)  for a detailed recent review of this 
literature (Alexander-Bloch et al., 2013). Cortical volume is a construct that is 
derived from two distinct properties of the cortical sheet: cortical thickness and 
surface area and have distinct cellular and genetic basis(Rakic, 2007). Rakic’s 
radial unit hypothesis proposes that symmetrical cell division within the neural 
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stem cell pool in the ventricular zone causes an exponential increase in the 
number of radial columns – that result in surface area (SA) expansion. This is 
independent of asymmetrical cell division in the founder cells that is responsible 
for a linear increase in the number of neurons within a radial column, 
contributing to cortical thickness (CT) (Rakic, 2007).  
Complex network analysis using graph theory using cortical structural covariance 
networks derived from CT and cortical SA shows different structural properties, 
suggesting that they contribute to different properties within cortical networks 
(Sanabria-Diaz et al., 2010). Cortical grey matter volume is almost entirely 
driven by differences in the cortical SA rather than CT  (Im et al., 2006).  
Secondly, recent large scale studies have shown that these two parameters – CT 
and SA- have independent genetic basis (Panizzon et al., 2009).  
Thirdly, life course trajectories of these cortical parameters seem to be 
different. While gyrification – a ratio of total SA to pial SA remains fairly stable 
post childhood through to early adulthood, CT changes dynamically through this 
period (Raznahan et al., 2011, Rathbone et al., 2011, Salinas et al., 2012). 
However, more recent studies suggest that the relation between age and 
cortical parameters in adulthood, are complex (Hogstrom et al., 2012). CT in 
addition appears to be highly susceptible to various environmental influences 
over the life course such as smoking, alcohol dependence, and marijuana use 
while SA appears to be influenced by various unique developmental factors 
(Kuhn et al., 2010, Lopez-Larson et al., 2011, Momenan et al., 2012). I restricted 
our analysis to cortical thickness as I was examining the association between 
what an environmental variable (deprivation) and a cortical parameter (cortical 
thickness) that has previously shown to be influenced by environmental factors. 
Further analysis using other parameters may reveal differences in structural 
properties that are contributed by factors that may be influenced early in life.  
In summary, people from the MD population show less modular and overlapping 
modular architecture of the brain networks derived from cortical morphology 
compared to their corresponding random graphs at a coarse sulcogyral 
parcellation scheme. At fine-grained parcellation scheme that did not follow 
sulcogyral boundaries, this difference disappeared. While the difference in 
network structure at the coarse level may be the result of anatomical 
Chapter 5  140 
 
differences at a large scale level, the exact aetiopathogenesis and the 
consequence of this difference is not clear. Taken together I propose that brain 
networks associated with MD group may be less efficient in information and 
signal processing at a large-scale level. Greater inflammatory markers within the 
MD group may drive these differences. Future studies should look at longitudinal 
functional and effective connectivity studies using MRI and EEG/MEG to explore 
the effect of socioeconomic status on development.
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6 Chapter 6 - A composite measure of circulating 
inflammatory markers mediates the relationship 
between neighbourhood deprivation and 
morphological changes within the limbic stress 
circuit 
In this chapter, I explore if the same circulating inflammatory index - that was 
found to mediate cortical thickness difference pertaining to the Wernicke’s 
region and the network structure difference associated with neighbourhood 
deprivation in the previous chapters – mediated the association between 
neighbourhood deprivation and a putative limbic stress circuit. I used the same 
dataset I examined earlier, to explore the relationship between neighbourhood 
deprivation and volumes pertaining to a group of limbic forebrain structures -
hippocampus, amygdala and medial prefrontal cortex - implicated in the top-
down regulation of the stress response. Then I go on to explore if an index of 
peripheral inflammation mediated the relationship between neighbourhood 
deprivation and the stress circuitry volumetry. The findings of these chapters 
have been submitted for publication. 
6.1  Introduction 
The social and physical environments of disadvantaged neighbourhoods impinge 
adversely upon individual health outcomes (Diez Roux, 2001, Aneshensel, 2009, 
Pickett and Pearl, 2001) over and beyond the effects of individual-level 
socioeconomic status (SES) (Schwartz et al., 1999, Susser, 1994, Haan et al., 
1987, Pickett and Pearl, 2001). Chronic psychosocial stress associated with 
socioeconomic disadvantage has been proposed as the pathway mediating the 
effects of lower SES on increased disease risk (Schulz et al., 2012, Steptoe and 
Marmot, 2002, Baum et al., 1999, Brunner, 1997). Chronic stress enhances the 
excitability of the hypothalamic-pituitary-adreno-cortical (HPA) and 
sympathoadrenomedullary (SAM) axes and leads to the prolonged secretion of 
stress hormones (Ulrich-Lai and Herman, 2009). An influential model – Allostatic 
Load (McEwen and Stellar, 1993) - proposes that the cumulative effects of 
biological adjustments induced by stress hormones result in a cascade of multi-
systemic physiological dysregulations that culminate in higher morbidity and 
mortality (Juster et al., 2010). 
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A group of limbic forebrain structures - the hippocampus, the amygdala and the 
medial prefrontal cortex - are implicated in the top-down regulation of the HPA 
axis and autonomic nervous system (ANS), in response to environmental stressors 
(Ulrich-Lai and Herman, 2009). These regions also process aversive and 
appetitive environmental cues and condition the HPA axis and ANS to 
motivationally salient stimuli (Smotherman et al., 1981, Sullivan et al., 2004, 
Ulrich-Lai and Herman, 2009). McEwen and Gianaros recently summarised a large 
body of evidence from both animal and human studies indicating that chronic 
stress is associated with structural remodelling of the limbic stress circuitry 
(McEwen and Gianaros, 2010). Consistent with the idea that lower 
socioeconomic status influences neuroplasticity in the limbic stress circuitry, a 
few neuroimaging studies have documented an association between lower 
individual-level SES and the hippocampus and amygdala volumes (Staff et al., 
2012, Noble et al., 2012, Hanson et al., 2011, Butterworth et al., 2011).  
The mechanistic pathways underlying the restructuring of the limbic stress 
circuitry in the context of neighbourhood deprivation remain unclear. So far, 
animal studies of chronic stress have implicated corticosteroids, neurotrophins, 
excitatory neurotransmitters and other endogenous mediators in the structural 
remodelling of the hippocampus and to a lesser extent of the amygdala, with 
divergent patterns of dendritic arborisation (Vyas et al., 2002). Additional 
evidence from human data suggests that immune mechanisms (Kohman and 
Rhodes, 2013) and metabolic factors (Gold et al., 2007) impair hippocampal 
neuroplasticity. 
I have already reported that living in a designated deprived urban area as per 
the Scottish Index of Multiple Deprivation is associated with a significantly higher 
inflammatory load compared with an affluent neighbourhood (Krishnadas et al., 
2013c). In addition, I found that greater peripheral levels of inflammatory 
markers such as C reactive protein (CRP) and intercellular adhesion molecule-1 
(ICAM-1) were associated with cortical thinning pertaining to perisylvian regions 
in the left hemisphere (Krishnadas et al., 2013c). 
Based on the aforementioned evidence of neurobiological correlates of 
socioeconomic deprivation, I explored the relationship between neighbourhood-
level SES and limbic stress network morphology. In order to better understand 
the mechanistic pathways that link socioeconomic deprivation with brain 
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morphology, I examined whether the above relationship was mediated by an 
index of peripheral inflammation. 
6.2 Methods and Materials 
6.2.1 Participants 
Participants were recruited as part of a larger study (Psychological, social and 
biological determinants of ill health [PSoBiD]) 
(http://www.gcph.co.uk/work_programmes/psobid). The details have been 
presented in chapter 4, section 4.2.1. 
6.2.2 Mediators of interest 
6.2.2.1 Cardio-metabolic risk markers 
For this analysis, I once again, as in the previous chapters, I examined the role of 
9 blood markers - C-reactive protein (CRP), Interleukin-6 (IL-6), Intercellular 
Adhesion Molecule-1 (ICAM),Triglycerides, High density lipoprotein (HDL), Very 
low density lipoprotein (VLDL), Fibrinogen, D-dimer and Insulin – and an 
anthropometric measure- BMI.  The details are given in chapter 4 section 
4.2.2.1. 
6.2.2.2 Principal components analysis and dimension reduction of 
cardio-metabolic markers 
This step is same as the step in chapter 4, section 4.2.2.2.  
6.2.3 Image acquisition 
This has been previously described in chapter 3 section 3.2.5.  
6.2.4 FreeSurfer cortical morphology construction and 
parcellation 
The automated procedures for cortical reconstruction, sulcogyral parcellations 
and volumetric measurements were performed with the FreeSurfer image 
analysis suite, which is documented and freely available online 
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(http://surfer.nmr.mgh.harvard.edu/) (Fischl et al., 1999a, Dale et al., 1999, 
Fischl et al., 2002, Walhovd et al., 2005). The preprocessing steps are detailed 
in chapter 3, section 3.2.6. Following preprocessing, the following procedure 
automatically assigns a neuroanatomical label to each voxel in an MRI volume 
based on probabilistic information automatically estimated from a manually 
labelled training set. Brieﬂy, the segmentation is carried out as follows. First, an 
optimal linear transform is computed that maximizes the likelihood of the input 
image, given an atlas constructed from manually labelled images. Next, a 
nonlinear transform is initialized with the linear one, and the image is allowed 
to further deform to better match the atlas. Finally, a Bayesian segmentation 
procedure is carried out, and the maximum a posteriori (MAP) estimate of the 
labelling is computed. The segmentation uses three pieces of information to 
disambiguate labels: (1) the prior probability of a given tissue class occurring at 
a speciﬁc atlas location; (2) the likelihood of the label given that tissue class; 
and (3) the probability of the local spatial conﬁguration of labels given the tissue 
class. This latter term represents a large number of constraints on the space of 
allowable segmentations, and prohibits label conﬁgurations that never occur in 
the training set (e.g. hippocampus is never anterior to amygdala). The technique 
has been previously shown to be comparable in accuracy to manual labeling 
(Fischl et al., 2002). In the present paper, I report the volumes for both 
subcortical and cortical gray matter of the regions of interested mentioned 
below. The parcellations were obtained using the Destrieux sulcogyral-based 
atlas, which follows the anatomical conventions of Duvernoy (Destrieux et al., 
2010).  
6.2.5 Regions of interest  
The regions of interest (ROIs) were identified from a network of limbic 
structures involved in regulating and coordinating the stress response (Ulrich-Lai 
and Herman, 2009, McEwen and Gianaros, 2010) (Figure 6-1). This limbic 
network comprises the hippocampus, the amygdala, the ventromedial 
prefrontal/orbitofrontal cortex (vmPFC/OFC) and the perigenual and subgenual 
ACC (pg/sg ACC). Based on the Destrieux sulcogyral-based atlas, I defined the 
vmPFC/OFC as a cortical region comprising the gyrus rectus (G_rectus, 31) and 
orbital gyri (G_orbital, 24) (Destrieux et al., 2010). The sg/pg ACC was 
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comprised of the subcallosal area (G_subcallosal, 32) and anterior part of the 
cingulate gyrus and sulcus (G_and_S_cingul-Ant, 6) (Destrieux et al., 2010).  
 
Figure 6-1: Representative figures of the regions of interest in the current analysis  
 
 
6.2.6 Statistical analysis 
In order to examine the difference in ROI volumes between the least and the 
most deprived groups, a repeated measures analysis of covariance (rmANCOVA) 
was performed using the ROI volumes as dependent variables and socioeconomic 
group (least deprived versus most deprived) as the predictor variable of interest. 
Intracranial volume (ICV), age and number of alcohol units consumed per week 
were considered as nuisance covariates. Statistical tests were corrected for 
multiple testing corrections using Dunn-Sidak correction (Šidák, 1967). An 
independent sample t test was performed to examine if inflammatory markers 
and other covariates differed between the least and the most deprived groups. 
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A mediation analysis was conducted in order to ascertain whether the 
inflammatory index mediated the effect of neighbourhood-level SES on the 
volumes of the ROIs, which were significantly related to neighbourhood-level SES 
in the rmANCOVA. The mediation analysis here tests the hypothesis that a 
proportion of the variance in brain volumes that is predicted by variance in 
neighbourhood-level SES can be accounted for by the mediator variable. That is, 
the neighbourhood-level SES accounts for variance in the mediator variable of 
interest and in turn, this variance in the mediator variable of interest accounts 
for a proportion of the variance of the ROIs’ brain volumes. In other words, the 
mediation analysis partitions the variance explained by the predictor into a part 
that is independent of the mediating variable, and a part that is accounted for 
via the mediating variable (Palaniyappan and Liddle, 2012). I used the bootstrap 
method of Preacher and Hayes to estimate the indirect effect and bias-corrected 
95% confidence interval (CI) for each individual mediator based on 20,000 
bootstrap samples using an SPSS macro. (8) I also obtained effect ratios for 
indirect effects (IE ratio), which express the proportion of the total effect that 
can be explained by the indirect (mediated) effects. In other words, an indirect 
effect ratio of 0.25 would mean that a quarter (25%) of the total effect of the 
deprivation status on the cortical morphology is explained by the mediator. This 
analysis requires no assumption regarding the underlying distributions since the 
statistical significance level is determined non-parametrically. Since only the 
inflammatory index differed between groups (a path), I only examined this 
relationship. 
 
6.3 Results 
On the multivariate analysis, there was a significant effect of neighbourhood 
deprivation on the grey matter volumes of the ROIs [F (1,37) = 10.33; p = .003; 
η2p = .22]. At the univariate level, the most deprived group had smaller right 
hippocampus (t = 3.252; p= .002; η2p = .22) and right vmPFC/OFC (t = 2.275; p= 
.029; η2p = .12) volumes. The other ROIs volumes did not differ between groups 
(Table 6-1). 
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Table 6-1: Between comparison of grey matter volumes of regions of interests 
 Least 
deprived 
Mean 
volume 
mm3 (s.d.) 
Most 
deprived 
Mean 
volume 
mm3 (s.d.) 
 
t 
 
p 
 
η2p 
Right 
Hippocampus 
3901.81 
(474.61) 
3410.72 
(588.33) 
3.252 .002 .222 
Left 
Hippocampus 
3648.75 
(546.46) 
3416.70 
(439.03) 
1.46 .153 .054 
Right 
Amygdala 
1139.82 
(229.82) 
1086.29 
(274) 
0.517 .608 .007 
Left  
Amygdala 
1162.2 
(243.87) 
1101.36 
(202.88) 
0.632 .532 .011 
Right sg and 
pg ACC 
6567.3 
(913.71) 
6338.76 
(998.32) 
0.386 .702 .004 
Left sg and 
pg ACC 
6070.42 
(803.01) 
5658.90 
(941.69) 
1.427 .162 .052 
Right 
vmPFC/OFC 
8620.61 
(1138.07) 
8001.38 
(947.27) 
2.275 .029 .123 
Left 
vmPFC/OFC  
9011.09 
(1004.42) 
8501.80 
(859.87) 
1.776 .084 .079 
Standard deviation (s.d.); Unpaired t test (t); Significance (p); Partial eta squared (); 
Subgenual and perigenual anterior cingulate cortex (sg and pg ACC); ventromedial 
prefrontal/orbitofrontal cortex (vmPFC/OFC) Covariates appearing in the model are 
evaluated at the following values: Age (years) = 50.9, alcohol (units per week) = 17.21, 
Intracranial volume (mm
3
) = 1557805.39 
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The most deprived group had a greater inflammatory index (t = -4.366; p < 
.001). Results of between group comparisons for individual inflammatory 
markers are shown in Table 4-2. 
Since both the BMI-HDL-Insulin factor and TAG factor did not differ between 
groups, I examined only the mediating effects of the inflammatory index. As 
shown in Table 6-2 on the mediation analysis, the inflammatory index mediated 
the relationship between neighbourhood-level SES and grey matter volume in the 
right vmPFC/OFC (B = -0.37; SE = .18; 95%CI = -0.83 to –0.06) but not in the right 
hippocampus (B = -0.05; SE = 0.29; 95%CI = -0.68 to 0.49). 
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Table 6-2:  Results of the mediation analysis 
ROI Coefficient SE p Boot 
strap  
95% CI 
Effect 
ratio 
Right   
Ventral/Orbitofrontomedial  
cortex 
 r2 = 0.19 ; F(5,36)=1.6; p=0.06 
a path 1.06 0.26 0.0003   
b path -0.35 0.20 0.09   
Total effect -0.68 0.29 0.028   
Direct effect -0.30 0.36 0.4   
Indirect effect -0.37 0.18  -0.83 to 
-0.06 
54.46% 
Right Hippocampus r2 = 0.48 ; F(5,36)=6.7; p<0.0002 
a path 1.06 0.26 0.0003   
b path -0.04 0.17 0.79   
Total effect -0.76 0.23 0.002   
Direct effect -0.71 0.29 0.02   
Indirect effect -0.05 0.29  -0.68 to 
0.49 
6.5% 
Bootstrap samples for bias corrected bootstrap confidence intervals: 20000. Covariates in 
the model for the dependent variable include age, ICV and number of alcohol units; the 
initial r
2
 statistic shows the fit of the model with all variables including the mediator. 
Mediating variable – Inflammation factor; details of the path are shown in Figure 2. 
Coefficients are interpreted as Betas. Indirect effect is the product of coefficients of ‘a’ and 
‘b’ paths.  
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6.4 Discussion 
In the present study, I have shown an association between greater 
neighbourhood deprivation and smaller right hippocampal and vmPFC/OFC 
volumes. Neighbourhood deprivation accounted for 22% of the variance in the 
volume of the right hippocampus and 10% of the variance in the right 
vmPFC/OFC. Greater inflammatory load mediated the association between 
greater neighbourhood deprivation and smaller right vmPFC/OFC volume. 
6.4.1 Comparison with previous findings 
Our findings are consistent with previous reports demonstrating an association 
between early-life and current individual-level SES and smaller hippocampi. In 
the PATH study, Butterworth et al found current financial hardship to be 
associated with smaller bilateral hippocampi in middle-aged adults(Butterworth 
et al., 2011). Others have found early-life socioeconomic disadvantage to be 
associated with smaller hippocampal volumes in children  and adults (Staff et 
al., 2012, Noble et al., 2012, Hanson et al., 2011). Two of the above mentioned 
studies failed to find an association between parental education (an estimate of 
individual-level early-life SES) and hippocampal volume (Noble et al., 2012, 
Hanson et al., 2011). They however found an association between household 
income and hippocampal volumes. The authors therefore concluded that as 
household income was an indirect measure of limited access to basic goods, this 
and not parental education was particularly relevant for hippocampal 
development. Although our sample was comprised of middle-age adults, this 
observation appears to be consistent with our data given that the deprivation 
indicators used in our study are representative of inequalities in area-level 
material resource distribution. It should be noted that hippocampal neurogenesis 
continues throughout adulthood (Eriksson et al., 1998, Spalding et al., 2013). In 
addition, in adult rodents, chronic stress has been associated with hippocampal 
atrophy, through suppression of neurogenesis (Gould et al., 1997), remodelling 
of the CA1 and CA3 hippocampal subfields with loss of dendritic spines (Pawlak 
et al., 2005) and diminished dendritic arborisation (McKittrick et al., 2000).  
To the best of our knowledge, this is the first human study to find an association 
between neighbourhood deprivation and smaller volume in the right 
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vmPFC/OFC. Our findings are strikingly similar to those documented by Gianaros 
et al who used prospectively measured chronic life stress and not SES as 
predictor variable (Gianaros et al., 2007b). The right-lateralized effect of 
chronic stress on hippocampal and OFC morphology is in accord with both animal 
and human data supporting a dominant role of right-sided limbic structures in 
the activation and coordination of stress regulatory systems (Sullivan and 
Gratton, 2002, Wittling, 1997). It has been proposed that disruptions in this right 
sided asymmetry of stress regulation may predispose to psychopathology and 
physical ill health (Wittling and Schweiger, 1993a, Wittling and Schweiger, 
1993b). Finally, it is worth noting that whereas the hippocampus exerts 
inhibitory feedback on HPA axis function, the vmPFC upregulates HPA axis and 
sympathetic activity (Sullivan and Gratton, 1999) and mediates hippocampal 
influences on autonomic function (Ruit and Neafsey, 1990).  
There are no data on the cellular correlates of socioeconomic deprivation in the 
vmPFC/OFC. Of potential relevance are previous conflicting accounts from 
animal studies regarding the effects of chronic stress on neural plasticity in the 
vmPFC/OFC. Murmu et al reported that prenatal stress was associated with 
reduced spine densities on basal and apical dendrites in both female and male 
rat pups and atrophy of apical dendrites only in male rats (Murmu et al., 2006). 
However, in another rat experiment chronic restraint stress resulted in a 43% 
increase of apical dendritic arborization in the lateral orbitofrontal cortex but a 
20% retraction of apical dendritic arbors in the mPFC (Liston et al., 2006). 
While the hippocampus is involved in associative learning and retrieval of recent 
memories (Squire and Zola-Morgan, 1991, Squire et al., 2004), the vmPFC/OFC 
supports adaptive decision making and long-term memory storage (Noonan et 
al., 2012, Rangel et al., 2008, Walton et al., 2011, Padoa-Schioppa and Cai, 
2011, Euston et al., 2012). The coordinated activity in these two structures are 
necessary for early and late memory consolidation (Euston et al., 2012). It is 
therefore, tempting to speculate that the observed structural abnormalities in 
the above regions may provide a neurobiological account of the cognitive and 
behavioural deficits which have been linked to lower SES (Farah et al., 2006). 
I found no association between neighbourhood deprivation and amygdalar 
volumes. Previous research in animals has shown chronic stress to be associated 
with increased dendritic branching within the basolateral amygdala (Vyas et al., 
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2002). In keeping with this, lower parental education (a proxy measure of 
individual-level parental nurturance and warmth) has been associated with 
greater amygdalar volume . Based on this account and bearing in mind our data 
represent an adult sample, it could be argued that our findings are reflective of 
the fact that neighbourhood deprivation fails to capture the effects of 
individual-level deprivation and parenting style.  
I found no association between neighbourhood deprivation and sg/pACC volume. 
Previously Gianaros et al demonstrated that lower perceived social standing, but 
not conventional indicators of SES, was associated with smaller pgACC grey 
matter volumes (Gianaros et al., 2007a). They proposed a dissociation between 
the neural substrates of subjective (perceived) and conventional indicators of 
SES (as used in our study). I however did not measure perceived social standing 
in our sample.  
6.4.2 The role of circulating inflammatory markers.  
Our result of an association between neighbourhood deprivation and 
inflammatory index is consistent with earlier accounts (Schulz et al., 2012, 
Gruenewald et al., 2009, Alley et al., 2006). Indeed, exposure to stressful 
neighbourhood conditions is associated with elevated systemic inflammatory 
burden both in children (Broyles et al., 2012) and adults (Pollitt et al., 2007, 
Petersen et al., 2008, Pollitt et al., 2008). Psychological stress and subsequent 
activation of ANS and HPA axis have been shown to result in the production of 
pro-inflammatory cytokines and activation of mononuclear cells (Bierhaus et al., 
2003). This finding has been replicated in a number of studies and provides a 
viable mechanistic molecular pathway by which lower neighbourhood-related 
chronic stress may give rise to increased peripheral inflammatory load. 
Of particular interest is our finding that peripheral inflammation mediates the 
effect of chronic stress on the morphology of the right vmPFC/OFC. Only two 
previous studies have documented that activation of inflammatory pathways 
mediates structural brain changes (i.e. reduced white matter integrity and 
smaller cortical thickness) in relation to living in disadvantaged neighbourhoods 
(Gianaros et al., 2012). Moreover, complementary evidence from functional 
neuroimaging data has revealed that experimentally induced elevation of 
peripheral pro-inflammatory cytokines correlates with abnormal neural 
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reactivity within brain regions subserving psychomotor activity, mood regulation 
and interoception (Brydon et al., 2008, Harrison et al., 2009b). It is worth noting 
that, given the correlative nature of our data, I cannot exclude that pre-existing 
structural abnormalities in the vmPFC/OFC gave rise to poor decision making 
strategies, ultimately leading to maladaptive and unhealthy behaviours which 
are associated with increased peripheral inflammation and social drift. 
In spite of overwhelming evidence that inflammation has a detrimental effect on 
hippocampal neurogenesis (Kohman and Rhodes, 2013), I detected no mediation 
effect of inflammation between lower neighbourhood SES and smaller right 
hippocampus. Contrary to our finding a previous study reported that higher 
serum levels of IL-6 were associated with smaller grey matter volume in the left 
but not right hippocampal volume in middle aged adults (Marsland et al., 2008). 
At a molecular level, other mechanisms such as stress-induced surges in 
circulating corticosteroids (Sousa et al., 2000), plasminogen and tissue 
plasminogen activator (Pawlak et al., 2005), reduced levels of brain derived 
neurotrophic factor (McEwen and Gianaros, 2010), corticotrophin-releasing 
factor (Chen et al., 2004), decreased binding to serotonin receptors and 
transporters in Ammon's horn (McKittrick et al., 2000), NMDA receptor activation 
(Gould et al., 1997) or decreased density in the hippocampus (Pawlak et al., 
2005) have been implicated in mediating neurodegenerative changes in 
hippocampal morphology. I can only speculate that one or more of the 
aforementioned mechanisms and not inflammatory mediators may have played a 
role in determining the observed smaller hippocampal grey matter volume. 
In conclusion, I have provided evidence that in a sample of middle-aged healthy 
male adults neighbourhood deprivation was significantly associated with smaller 
grey matter volumes in the right hippocampus and right vmPFC/OFC. Moreover, 
an index of peripheral inflammation mediated the effects of neighbourhood 
deprivation on the right vmPFC/OFC grey matter volume. The results expand the 
existing body of knowledge on the neurobiology of socioeconomic deprivation 
and provide novel insights into the pathways mediating the impact of lower SES 
on brain morphology. 
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7 Chapter 7 - Relationship between circulating 
inflammatory markers and midbrain serotonin 
transporters  
In this chapter, I present the methods and results of an experimental study that 
explore the relationship between circulating inflammatory markers, and 
serotonin transporter (SERT) availability and their modulation by biologics. I 
tested a sample of patients with psoriasis and psoriatic arthritis, who were about 
to receive Etanercept, a specific TNF-α blockade agent. Using a test-retest 
design, I explored the relationship between circulating inflammatory markers 
and midbrain SERT availability before and after Etanercept. 
7.1 Introduction 
7.1.1 Psoriasis and Psoriatic arthritis 
Autoimmune diseases are conditions where the body’s adaptive immune 
response targets a cell-mediated antigen (Ag) of the host. While SLE is the 
prototype autoimmune illness that has been associated with neuropsychiatric 
symptoms, more prevalent illnesses like autoimmune arthritis are associated 
with significant neuropsychiatric morbidity and mortality (González et al., 
2012). Psoriasis affects around 1.5% to 3 % of the population in North America 
and Europe. Psoriatic arthritis affects up to 30% of people with psoriasis. 
Although not fully clear, most of the evidence suggests that both psoriasis and 
psoriatic arthritis are autoimmune diseases that may share common pathogenic 
mechanisms (Fitzgerald and Chandran, 2012, Gladman, 1998, Gladman, 2012, 
Gottlieb et al., 2008, Hayes and Koo, 2010, Rieder and Tausk, 2013).  
Although abnormal epidermal keratinocyte proliferation was initially considered 
to be the primary pathology in psoriasis, it is now thought that inflammation 
(particularly T cells) play an important role in initiation and maintenance of 
psoriasis (Coimbra et al., 2012). In addition to the T cells, number of other cells 
and inflammatory mediators (cytokines and chemokines) are thought to play key 
roles in the pathogenesis of psoriasis (Nestle et al., 2009).  
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In brief, the immune system is thought to consist of two components, innate and 
adaptive immunity.  Innate immunity is primarily mediated by macrophages that 
have receptors that recognise families of “pathogens” and provide an early 
response mechanism against harm to the host (González et al., 2012). Adaptive 
immunity is primarily mediated by lymphocytes and recognises a host of 
“antigens” that are presented to them, including self-antigens. This response is 
usually a late / slow process. Although lymphocytes recognise self-antigens, in 
healthy conditions, they do not initiate an immune response towards the self, as 
they are either removed or inactivated – a process called tolerance(González et 
al., 2012).  
Earlier views considered that the process, by which the immune cells responsible 
for adaptive immunity develop tolerance to the self-antigens, is inactive in 
individuals with autoimmune diseases. However, it is now known that even the 
innate immune system is dysregulated in psoriasis (Coimbra et al., 2012, 
González et al., 2012, Nestle et al., 2009). It is not clear as to what triggers the 
etio-pathogenic processes involved in psoriasis/psoriatic arthritis.  However, it is 
thought that events like physical trauma or bacterial products or even stressful 
life events, may lead to the formation of cathelicidin-DNA complexes (this is 
usually triggered in response to an infection by a microbe) that activate 
plasmacytoid dendritic cells (macrophages) and secretion of interferon alpha 
(Nestle et al., 2009). The activated cells, enter the lymphatic system, where 
they release IL12 and IL23. These cytokines induce the differentiation of naïve T 
cells into effector cells like Th17 and Th1 cellls (Coimbra et al., 2012). Effector 
cells then enter the skin, produce IL17, IFN gamma and TNF-α. These mediators 
then go on to act on keratinocytes, and production of a number of downstream 
proteins, which in turn trigger an inflammatory response, thus maintaining the 
cycle (Figure 7-1).   
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Figure 7-1:  Key Cells and Mediators in the Transition from Innate to Adaptive Immunity in 
Psoriasis.  
  
Innate immune cells produce key cytokines (tumor necrosis factor α [TNF-α ], interferon-α
, interferon-γ, interleukin-1β, and interleukin-6) that activate myeloid dendritic cells. 
Activated dendritic cells present antigens and secrete mediators such as interleukin-12 and 
interleukin-23, leading to the differentiation of type 17 and type 1 helper T cells (Th17 and 
Th1). T cells, in turn, secrete mediators (e.g., interleukin-17A, interleukin-17F, and 
interleukin-22) that activate keratinocytes and induce the production of antimicrobial 
peptides (e.g., LL-37 cathelicidin and β-defensins), proinflammatory cytokines (TNF-α, 
interleukin-1β, and interleukin-6), chemokines (CXCL8 through CXCL11 and CCL20), and 
S100 proteins. These soluble mediators feed back into the proinflammatory disease cycle 
and shape the inflammatory infiltrate. Reused with permission from Nestle FO, Kaplan DH, 
Barker J. N Engl J Med 2009; 361:496-509. Copyright Massachusetts Medical Society. 
7.1.2 Depression in psoriasis and psoriatic arthritis 
A recent systematic review of studies examining psychological morbidity in 
patients with psoriasis suggest that the prevalence rates of depression in 
psoriasis range between 10% and 62%, largely determined by the difference in 
sample examined and methodology used. Table 7-1 shows the recent studies 
from 2005, that showing the prevalence of depression in psoriasis (Rieder and 
Tausk, 2013).  
Similar rates of depression have been shown in patients suffering from psoriatic 
arthritis. A recent study by Kotsis et al found prevalence rates of 21.7% in 
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patients with psoriatic arthritis (Kotsis et al., 2012). Another study that used a 
self rated measure of HADS found a prevalence of 17.6% (Freire et al., 2011). In 
a cross sectional observational survey, we found that 30% of patients suffering 
from psoriatic arthritis fulfilled the criterion for caseness for depression, using 
HADS (Krishnadas et al., 2011).  
Table 7-1: Studies that have explored the prevalence of depression in patients with 
psoriasis since 2005.  
Study n Study design Measures 
Presence of 
depression 
 (Consoli et 
al., 2006) 
93 
(France) 
Cross-
sectional – no 
control 
PASI and 
questionnaires: 
MINI, HADS 
11.8–25.8% of 
patients with 
symptoms of 
depression on 
HAD-D 
(Picardi et 
al., 2006)  
80 (Italy) 
Cross-
sectional – no 
control 
Questionnaires: 
GHQ-12, Skindex-
29, PHQ 
No psoriasis-
specific statistics 
reported 
(Sampogna 
et al., 
2007)  
414 (Italy) 
Cross-
sectional – no 
control 
Questionnaires 
during 
hospitalization and 
1 month after 
discharge: SAPASI, 
GHQ-12, Skindex-29 
No statistics 
reported 
(Schmitt 
and Ford, 
2007)  
265 (USA) 
Cross-
sectional – no 
control 
Questionnaires: 
DLQI, CES-D, PLSI, 
SAPASI 
33% of patients 
with history of 
depression 31–
48.7% screened 
positive for 
depression on 
CES-D 
(Magin et 
al., 2009)  
27 
(Australia) 
Cross-
sectional – 96 
unmatched 
controls 
without skin 
disease 
GHQ-12, HADS, 
Fenigstein Self-
Consciousness 
Scale, Eysenck 
Personality 
Inventory 
No psoriasis-
specific statistics 
reported 
(Schmitt 
and Ford, 
2010)  
3147 
(Germany) 
Case–control 
ICD-10 codings of 
depression 
Independent 
association 
between psoriasis 
and depression 
(OR 1.49; 95% CI 
1.20–1.86) 
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Study n Study design Measures 
Presence of 
depression 
(Kurd et 
al., 2010)  
149 998 
(UK) 
Cohort 
Clinical diagnoses 
of depression, 
anxiety, and 
suicidality 
1.39 HR for 
depression (95% CI 
1.37–1.41) 1.31 
HR for anxiety 
(95% CI 1.29–1.34) 
1.44 HR for 
suicidality (95% CI 
1.32–1.57) 
Reproduced with permission from Rieder E, Tausk F. Psoriasis, a model of dermatologic 
psychosomatic disease: psychiatric implications and treatments. Int J Dermatol. 2012 
Jan;51(1):12-26. Copyright John Wiley and Sons 
 
7.1.3 Pathogenesis of depression in psoriasis and psoriatic 
arthritis 
The association between inflammatory conditions and depressive illness cannot 
be solely explained by pain or disability, because a number of people who have 
severe disability are not clinically depressed. More recently it has been 
postulated that the mediators of inflammation may be directly responsible for 
the pathogenesis of depression in the context of medical illness. Inflammatory 
processes have also been implicated in the pathophysiology of major depressive 
disorder in the absence of medical illnesses. At least 3 meta-analyses and 1 
longitudinal study have shown an association between raised proinflammatory 
cytokines and depressive illness in the absence of medical illnesses (Dowlati et 
al., 2010, Howren et al., 2009, Liu et al., 2012a). Recent data have shown that 
treatments directed towards arthritis, have been associated with improvement 
in depression. There is also some evidence that the improvement in depression 
may precede the improvement in arthritis, suggesting that these two processes 
may be independent of each other (Gelfand et al., 2008, Langley et al., 2010, 
Langley et al., 2011, Tyring et al., 2006).  
Of direct relevance to the link between Ps/PsA and depression is the proposal 
that pro-inflammatory cytokines, that mediate inflammation, also provoke 
changes in brain structure and function that lead to the development of co-
morbid major depression (Krishnadas and Cavanagh, 2012, Capuron and Miller, 
2011). Not surprisingly, most of the evidence for the effects of proinflammatory 
Chapter 7  159 
 
cytokines in the proposed pathogenesis of depression come from animal studies. 
There is now evidence that peripheral cytokines signal the brain through various 
mechanisms as discussed in chapter 1. This “signalling” is thought to contribute 
to a number of changes that may be considered responsible for the pathogenesis 
of depression. (Figure 1-3) 
From the above, it is clear that pro-inflammatory cytokines play a crucial role in 
mediating the pathogenesis of psoriasis and psoriatic arthritis. Indeed, TNF-α  is 
thought to play a central role within the cytokine network and a number of anti-  
TNF-α therapies have been shown to be successful in treating Psoriasis and 
psoriatic arthritis.  TNF-α  is a pro-inflammatory cytokine, that occur in two 
forms - a soluble form sTNF (17kDa) and a transmembrane form tmTNF (26kDa). 
TNF-α has been shown to bind to at least two receptors TNFR1 and TNFR2 
(Waters et al., 2013). While TNFR1 is expressed in most tissues, including 
neurons and glia, TNFR2 is restricted to cells of the immune system. TNFα 
binding to its ligands causes conformational changes in the receptors, leading to 
the initiation of at least 3 intracellular signalling pathways of interest(Chen and 
Goeddel, 2002, Wajant et al., 2003).  It activates NF-kB pathways, hereby 
releasing a transcriptional factor – NFkB, which mediates the transcription of a 
vast number of proteins including cell surface receptors and intracellular 
receptors like glucocorticoids that are involved in mediating inflammatory 
response (Berthold-Losleben and Himmerich, 2008). Secondly, it activates MAPK 
pathways – particularly the stress related JNK groups and the p38 MAPK 
pathways. Thirdly, TNFR1 is also involved in death signalling – apoptosis. 
However, the signalling pathways show significant cross talk and other factors 
mediate the balance of activity within and between the pathways (Gaur and 
Aggarwal, 2003).  
Newly developed therapeutic agents for inflammatory arthritides target 
proinflammatory cytokines like TNF-α (Feldmann and Maini, 2001, Feldmann and 
Maini, 2003, Feldmann and Maini, 2010, Feldmann et al., 2010). Blocking the 
activity of TNF-α, using either specific antibody or TNF-α  receptor fusion 
constructs is highly effective in controlling inflammation and altering the course 
of Psoriasis/psoriatic arthritis. A common observation during anti-TNF-α  
treatment, which has been confirmed in trials, is a hedonic response, consistent 
with some antidepressant effect. For example, Etanercept (TNF-α  receptor Fc 
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fusion protein) has been shown to relieve the symptoms / signs of psoriasis and 
the depression and fatigue associated with psoriasis (Tyring et al., 2006). This 
improvement in mood seems to occur even before any improvement in joint 
inflammation, suggests that this is more than an epiphenomenon associated with 
arthritic symptom improvement. Rather, here, I postulate that blocking 
circulating TNF-α  (using anti-inflammatory drugs like Etanercept) would reduce 
the signalling of the cytokines to the CNS, thus reversing the effects of 
proinflammatory cytokines on the brain, which in turn, improves the mood. 
7.1.4 Rationale and need for the study  
The use of these anti TNF-α agents give us the ideal opportunity to explore the 
effect of proinflammatory cytokines on potential molecular pathways implicated 
in the pathophysiology of depression in the medically ill population. This study 
exploited the availability of these new therapeutic agents to explore specifically 
the relationship between circulating inflammatory markers and one such marker 
- SERT. A number of preclinical studies have shown that inflammatory markers 
(particularly IL1B and TNF-α) may have a direct effect on SERT availability 
through activation of MAPK pathways as shown in Figure 7-2 (Baganz and Blakely, 
2013, Ramamoorthy et al., 1995, Samuvel, 2005, Couch et al., 2013, Malynn et 
al., 2013, Morikawa et al., 1998, Tsao et al., 2008, Katafuchi et al., 2006). Both 
TNF-α and IL1β up-regulate SERT expression in in-vitro cells and animal models. 
The mono-amine theory of depression first proposed by Schildkraut in 1965, 
states that depression may the result of a functional deficit in mono-amine 
neurotransmission - particularly serotonin and norepinephrine(Schildkraut, 
1965).  SERT plays a major role in serotonin neurotransmission, and increased 
availability/function of SERT has been associated with depressive 
symptoms(Meyer, 2008, Savitz and Drevets, 2013). Indeed, the most commonly 
used antidepressants, show 80% SERT occupancy at therapeutic doses and inhibit 
SERT, thereby increasing synaptic serotonin availability(Meyer, 2012). Given the 
above, a key question is, will blocking TNF-α result in changes in SERT 
availability.  
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Figure 7-2:  Interleukin-1 β (IL-1 β ) stimulates SERT activity through an interleukin-1 
receptor (IL-1R)- and p38 MAPK-dependent signalling pathway. 
 
Reused with permission from Baganz N, Blakely RD. A Dialogue between the Immune 
System and Brain, Spoken in the Language of Serotonin ACS Chem. Neurosci., 2013, 4 (1), 
pp 48–63 
 
7.2 Aim of the study  
1. To study the association between circulating inflammatory markers and 
serotonin transporter availability in humans. 
2. To ascertain whether anti-inflammatory treatment targeting TNF-α  will be 
associated with changes in serotonin transporter availability in humans. 
7.2.1 Hypothesis 
Based on previous studies, I hypothesised that greater pro-inflammatory 
cytokines will be associated with greater SERT availability in the brain. I also 
hypothesise that treatment with Etanercept will be associated with a reduction 
in SERT availability.  
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7.2.2 Objectives 
1. To examine the association between peripheral pro-inflammatory cytokines 
and SERT density in the brain measured using [123I] -beta-CIT SPECT in a group of 
patients with Psoriasis and Psoriatic arthritis. 
2. To examine the association between pro-inflammatory cytokines and change 
in SERT in response to treatment with Etanercept  
7.3 Methods 
7.3.1 Subjects  
Fifteen subjects clinically diagnosed with psoriasis/psoriatic arthritis aged 30-65 
years, were recruited into the study. Those who incidentally fulfilled the criteria 
for major depression were included in the study. Three patients dropped out - 
one withdrew consent, and the other two had incidental findings, and hence 
their data were excluded from analysis. Therefore, data from 12 individuals 
were analysed. All patients met disease activity criteria set by the NICE advice 
pertaining to the use of TNF-α  blocking biologic agents for Psoriasis and 
psoriatic arthritis. The treating clinicians decided this. These patients were 
given information sheets about the study, and were contacted if they gave 
consent for the study. Those with a history of antidepressant intake in the 
previous 3 months; history of CVA, documented head trauma or neurological 
disorders, lifetime history of DSM Axis I psychiatric diagnoses other than 
depression (measured using SCID), alcohol and/or substance misuse, pregnancy, 
other connective tissue or systemic inflammatory disease were excluded from 
participation in the study. Patients with contraindications to TNF-α  blockade as 
per NICE guidelines were also excluded. Subjects with contraindications to any 
type of imaging procedures in the study were not included. The study was 
approved by the West of Scotland Research ethics committee and the NHS 
Greater Glasgow and Clyde Research and Development departments. In addition, 
the use of ionising radiation for SPECT was approved by the regional ARSAC. 
7.3.2 Sample size 
Based on a pilot study by Cavanagh et al, in order to demonstrate an effect size 
of reduction in SERT binding of Cohen’s d=1.2, with 80% power, with an alpha of 
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0.05, with a power of 90%, the total sample size required was 10 subjects. 
However that study did not look at the relationship between circulating 
inflammatory markers and SERT. The details of the power calculation are shown 
below. 
Analysis: A priori: Compute required sample size  
Input:   Tail(s)                        = Two 
   Effect size d                = 1.23 
   α err prob                     = 0.05 
   Power (1-β err prob)          = 0.9 
Output:  Non-centrality  δ      = 3.88 
   Critical t                     = 2.26 
   Df                             = 9 
   Total sample size              = 10 
Actual power          = 0.93 
 
7.3.3 Study design 
A single study group design was employed with 2 conditions (pre- and post-
treatment with Etanercept). All subjects underwent clinical, and SPECT 
assessments twice during the study. Clinical, blood and SPECT measures were 
made before and after the commencement of treatment. The post treatment 
scans and clinical measurements were performed 6 - 8 weeks after commencing 
treatment with etanercept.  
7.3.4 The study drug 
The drug used to achieve TNF-α  blockade in this study was Etanercept(Strober 
et al., 2008, Tan et al., 2007). Etanercept is a recombinant human TNF-α -
receptor fusion protein with 934 aminoacids and weighs 150kDa. It interferes 
with the inflammatory cascade by binding to TNF-α , thereby blocking its 
interaction with cell-surface receptors (Feldmann and Maini, 2001, Feldmann 
and Maini, 2010). Etanercept is licensed for use in adults with active Psoriasis/ 
Psoriatic arthritis who responded inadequately to previous treatments (Fantuzzi 
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et al., 2008). All participants recruited into the study were then commenced on 
a weekly Etanercept 50 mg intramuscularly. 
7.3.5 Inflammatory markers 
Blood was collected and serum extracted on the same day as the SPECT scans, 
just before the administration of the ligand. The serum was stored in -80ºC.  
Cytokines were measured in plasma in duplicates using sandwich immunoassays, 
with all samples from the same volunteer on the same plate. The cytokines 
measured included TNF- α (sensitivity = 4 pg/mL), IL-1b (sensitivity = 4 pg/mL), 
IL-10 (sensitivity =2 pg/mL) and IL-6(sensitivity = 2 pg/mL) (Ready-set-go ELISAs, 
eBioscience, UK) and hsCRP (sensitivity = 1.9 ng/ml) (ELISA, Invitron, UK). 
The CV% for all assays were as follows: TNF-α - 3.6% (250pg/mL) - 7.1% 
(3.9pg/mL) - median CV%:5.0% ; IL10 - 2.4% (150pg/mL) - 4.8% (2.34pg/mL) - 
median CV%:11%; IL6 - 0.4% (100pg/mL) - 3.9% (1.56pg/mL) - median CV%:7%; 
IL1b - 2.4% (250pg/mL) - 8.2% (3.9pg/mL) - median CV%:18%; hsCRP - 0.3% 
(150ng/mL) - 2% (1.9ng/mL) - median CV%:3%.  
7.3.6 Clinical measures 
7.3.6.1 Beck's depression inventory BDI II (Beck et al., 1996) 
Beck's depression inventory II is a 21 item self-rated Likert questionnaire that 
measures depressive symptoms over the past 2 weeks. Each question is answered 
and scored on a scale of 0 to 3. Total score ranges from 0 to 63, with higher 
scores indicating more severe depressive symptoms.  Cut off scores have been 
used to indicate levels of depression. However, in this study, the scores have 
been used as a continuous scale.  
7.3.6.2 The functional assessment of chronic illness therapy (FACIT) - 
Fatigue scale (Webster et al., 2003) 
FACIT - Fatigue scale is  a short 13 item self rated scale that measures an 
individual's fatigue during their daily activities over the past week. The level of 
fatigue is measured on a four point likert scale with total greater scores 
indicating less fatigue. In a 2007 study, the FACIT Fatigue Scale was found to 
have high internal validity (Cronbach’s alpha = 0.96) and high test-retest 
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reliability (ICC = 0.95)(Chandran et al., 2007). The FACIT has demonstrated 
reliability and sensitivity to change in clients with a variety of chronic health 
conditions and in the general population. 
7.3.6.3 The Health assessment questionnaire - HAQ pain scale (Fries et al., 
1982) 
The HAQ Pain Scale assesses pain severity over the past week on a double-
anchored VAS (a horizontal line where each end represents opposite ends of a 
continuum). It obtains data on how pain has usually been over the past week, 
even though pain may be reported to vary over the course of a day or from day 
to day. The VAS line is standardized to 15 centimeters in length, which is 
convenient for the page and the patient. The scale is labeled from zero (no pain) 
at the left anchor point and 100 (severe pain) at the right anchor point. Patients 
are instructed to place a vertical mark on the line to indicate the severity of 
their pain. The distance between 0 and the mark left by the patient is then 
multiplied by 0.2 to get a score between 0 and 3, with greater scores 
representing greater pain(Bruce and Fries, 2003b, Bruce and Fries, 2003a).  
7.3.7 SPECT measurement of serotonin transporter (SERT) 
7.3.7.1 Serotonin transporter (SERT) 
Serotonin (5-hydroxytryptamine, 5-HT), a monoamine neurotransmitter, has 
been implicated in many behaviours, including sleep, appetite, sexual 
behaviour. It has also been implicated in cognitive and emotional function. More 
importantly, it is implicated in the mono-amine theory of 
depression(Schildkraut, 1965). In short, this hypothesis suggests that depressive 
states are caused due to a decrease in monoamine neurotransmitters – 
particularly Serotonin in the synaptic cleft (Canli and Lesch, 2007, Hornung, 
2010, Maximino, 2012, Savitz and Drevets, 2013, Sghendo and Mifsud, 2012).  
Serotonin that is released into the synaptic cleft is either metabolised or 
actively transported back into the neuron by a protein in the neuronal cell 
membrane. This protein is called the Serotonin transporter / reuptake 
transporter (SERT).  
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7.3.7.2 SERT location and Structure  
In humans, SERT has been clearly identified in a number of brain regions, 
including the brain stem, hypothalamus, occipital and frontal cortices. In the 
neurons, SERT is located in the presynaptic terminus – i.e. the axonal nerve 
endings. See Figure 7-3. SERT plays a key role in scavenging serotonin 
transporter from synaptic cleft back to the axonal nerve ending. Surprisingly 
SERT is found in neuronal cells and non-neuronal cells(Hornung, 2010). In 
humans, SERT has been found in glia, platelets, the GIT, monocytes and the 
placental syncitioblast (Maximino, 2012). 
Serotonin levels in the brain are controlled by a number of factors including rate 
of synthesis, rate of release into the synaptic cleft, rate of enzymatic 
breakdown, rate of diffusion through the extracellular space and active 
reuptake. In the brain, SERT seems to be the predominant mechanism 
controlling the strength and duration of serotonergic neurotransmission. 
Therefore it is likely that SERT availability is directly related to serotonergic 
neurotransmission(Paterson et al., 2013, Paterson et al., 2010, Savitz and 
Drevets, 2013, Sghendo and Mifsud, 2012).  
Serotonin gene that codes for the SERT protein is situated on chromosome 17 
(17q11.2).  This gene transcription is regulated by a polymorphic promoter 
region – 5HTTLPR. The promoter region has two alleles – a short and a long 
allele. The protein itself is 630 amino acids long with 12 transmembrane 
domains. They are mostly located at outer cell membranes peri-synaptically and 
transport serotonin into the cell (Canli and Lesch, 2007). SERT also plays an 
important role in the trophic organisation of the somatosensory cortex in the 
developing brain. The evidence for this comes from the fact that the foetal brain 
expresses SERT in the somatosensory regions during a small window in time 
during development – particularly during week 12 and 14 of gestation (Daws and 
Gould, 2011, Sodhi and Sanders-Bush, 2004). 
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Figure 7-3: Shows the serotonin transporter, its genes and its promoter region alleles.  
 
 
 
Reused with permission. Turhan Canli & Klaus-Peter Lesch. Long story short: the serotonin 
transporter in emotion regulation and social cognition. Nature Neuroscience 10, 1103 - 1109. 
Copyright Nature Publishing Group. 
 
7.3.7.3 Measuring serotonin transporter using SPECT – [123I] -beta-CIT 
Brain imaging techniques, like PET and SPECT, allow us to measure SERT 
availability in the living human brain.  While SPECT has been used extensively to 
assess the availability of SERT, fewer studies have used PET. It is generally 
considered that PET measurement give a better quantification of SERT(Paterson 
et al., 2013). In addition, the property of the ligand used to measure SERT also 
contributes to the noise in the findings. For example, a very commonly used 
ligand in SPECT – [123I] -beta-CIT, has affinity for both SERT and DAT in the brain. 
Therefore it is difficult to quantify SERT completely using this ligand (Ruhe et 
al., 2009). Newer SPECT ligands like ADAM and MZIENT seem to be much better 
in quantifying this(Paterson et al., 2013, Paterson et al., 2010, Nicol et al., 
2012). [123I] -beta-CIT is a cocaine analogue that binds to the SERT and DAT with 
equal affinity(Brucke et al., 1993). However, these two transporter bindings can 
be differentiated due to their differential localisation. For example, DAT is more 
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concentrated in the striatum while SERT in the midbrain(de Win et al., 2005). In 
addition, there are kinetic differences that also contribute to the differential 
binding of [123I] -beta-CIT[123I] -beta-CIT to DAT and SERT. For example, DAT 
uptake is thought to be maximal at 20 - 24 hours of administration of Beta-CIT, 
while SERT binding is thought to be maximal at between 2 to 4 hours post 
administration (Brucke et al., 1993, de Win et al., 2005).  
7.3.7.4 Radioligand [123I] -beta-CIT preparation for the study 
[123I] -beta-CIT was prepared via electrophilic iododestannylation of the 
corresponding tributylstannyl precursor (Baldwin et al., 1993).  Briefly, reagents 
were added to carrier free Na123I (370-740 MBq) in approximately 10-20 μl of 
0.05 M NaOH, in the following order: 30 μg tributylstannyl precursor in 300 μl 
glacial acetic acid followed by 10% V/V peracetic acid. The reaction proceeded 
for 20 minutes at room temperature. 500 μl of NaOH was then added. The 
mixture was purified by reverse-phase HPLC and the solvent removed by rotary 
evaporation. The [123I] -beta-CIT was formulated as 150 MBq in 5 ml ≤6% ethanol 
in isotonic citrate acetate buffer and filtered through a 0.22 μm filter.  
Pyrogenicity tests and sterility tests were performed.   
7.3.7.5 SPECT Imaging 
This protocol has been previously validated and described (Cavanagh et al., 
2006).  [123I] -beta-CIT binds with high affinity in vitro to both Dopamine 
transporter (DAT) and SERT.  In vivo studies in both humans and nonhuman 
primates have shown that [123I] -beta-CIT accumulates in two distinct brain 
regions.  In the striatum, where the density of DAT is much higher than that of 
SERT, [123I] -beta-CIT binding mainly reflects DAT density, whereas in the 
brainstem and diencephalon binding seems to be specific for SERT. 
The kinetics of [123I] -beta-CIT binding differs markedly between the DAT-rich 
and SERT-rich regions.  The slow uptake in the striatum, which reaches a peak 
after 20-30 hours, is in contrast to the faster kinetics seen in the brainstem and 
the diencephalon, where peak activity is attained after 2-4 hours after 
administration.  In this study, early imaging of SERT regions was performed to 
minimize any possible effect of DAT on the SERT measurement because DAT 
uptake is proportionally lower at 3 hours(de Win et al., 2005). 
Chapter 7  169 
 
Brain SPECT imaging was performed with a dedicated state of the art, 12 headed 
Neurofocus 900 SPECT scanner (spatial resolution 7mm full width at half 
maximum with a line source in air; NeuroPhysics, Shirley, Massachusetts), which 
acquires sequential single transaxial brain sections.  Up to 25 axial sections 6 
mm apart were scanned and the energy window (140-178 keV) was placed 
symmetrically around the 123I gamma energy of 159 keV.  A linear attenuation 
correction was applied, based on an automatically detected ellipse matching the 
outer head surface. 
Subjects were scanned starting 3 – 4 hours after IV administration of [123I] -beta-
CIT.  To minimize thyroid uptake of radioactive iodine, 120mg of potassium 
iodide was administered orally to each subject at least one hour prior to [123I] -
beta-CIT injection.  Scanning time was approximately 50 min per scan. 
7.3.7.6 SPECT Image analysis 
Region of interest (ROI) analysis, carried out by an investigator blinded to the 
subject’s clinical and demographic history, was used to extract data from the 
[123I] -beta-CIT scans.  A standard ROI template was constructed with the aid of 
two image templates: (1) the standard magnetic resonance imaging template 
known as ICBM152, which is based on 152 normal MRI scans and is available from 
the Statistical Parametric Mapping web site of the Functional Imaging Laboratory 
(http://www.fil.ion.ucl.uk/spm/); and (2) and in-house cerebral perfusion 
template based on 32 normal SPECT scans of cerebral perfusion. 
The ROI template consisted of manually drawn regions representing the striatum 
ROI, the brain stem/diencephalon ROI (referred to as the brain stem ROI below 
for brevity), and a reference ROI).  The striatum ROI (7.6 cm3 on each side) was 
drawn on three axial sections 5 mm apart and encompassed the head of caudate 
and putamen in both hemispheres.  The brain stem ROI (23 cm3) was drawn on 
seven axial sections 5mm apart and comprised the thalamus-hypothalamus, mid-
brain, and pons.  The reference ROI (35 cm3) was drawn on three axial sections 5 
mm apart in the medial and lateral occipital lobe bilaterally.  The occipital 
region was chosen to represent nonspecific and non-displaceable [123I] -beta-CIT 
uptake (i.e., activity not associated with binding to transporters) because it has 
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a negligible density of both dopamine and serotonin transporters, as does the 
cerebellum. 
The [123I] -beta-CIT uptake in each ROI was expressed as mean counts per pixel, 
and the specific uptake in each transporter ROI was calculated as mean counts 
per pixel in the ROI minus mean counts per pixel in the occipital ROI.  
Transporter binding ratio for SERT was then defined as the ratio of specific 
uptake to uptake in the occipital reference region.  Under equilibrium conditions 
the binding ratio is proportional to transporter binding potential, and provided 
transporter affinity and nonspecific binding are invariant across subjects, the 
ratio is then a measure of transporter availability. 
7.3.8 Statistical analysis.  
All data were tested for normality. Where data were not normal, appropriate 
transformations were performed. Non-parametric tests were performed 
wherever possible, in order to be conservative. Differences between two 
independent groups were tested using unpaired t test (or Mann Whitney U Test). 
Differences between dependent variables were tested using paired t test (or 
Wilcoxon signed-rank test). Linear regression was performed to examine the 
relationship between variables. In addition, a mediation analysis was conducted 
to examine the relationship between inflammatory markers, SERT and BDI 
scores. All p values mentioned are 2-tailed. 
7.4 Results 
7.4.1 Sample demographics 
We analysed data from 12 subjects. They consisted of 6 males and 6 females 
(mean age = 47.58; s.d.=8.8), who were initially scanned using SPECT following 
intravenous administration of [123I] -beta-CIT (average dose = 150.08mBQ) after 
an average of 218.9 (s.d. = 18.5) minutes. Blood for  measuring TNF-α , hsCRP, 
IL6, IL1B and IL10 were collected just before the [123I] -beta-CIT injection.  
All patients were then commenced on a weekly Etanercept 50 mg 
intramuscularly. All participants received the medication for an average of 6 to 8 
weeks (6.58 weeks; s.d. = 0.79), and underwent a second scan using the same 
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protocol with [123I] -beta-CIT (average dose = 148.5 mBQ) after an average of 
220.4 minutes. There was no significant difference between the dose of [123I] -
beta-CIT between the two scans or the average delay of scan after the injection. 
In addition, neither the dose of [123I] -beta-CIT nor the time of scan after 
administration, showed a correlation with SERT data.  
7.4.2 Descriptive statistics 
The descriptive statistics of the measures are shown in Table 7-2. Normality of 
continuous data was tested using normality plots and Shapiro-Wilk tests (Table 
7-3). Since most of the data were not normally distributed, data were log or 
inverse transformed. Where data were normally distributed, they were left as it 
is. As shown the table below log transformation of the data rendered most of the 
variables normal. However, where possible, I performed non-parametric tests. 
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Table 7-2: Descriptive statistics of the variables measured 
 Mean Std. 
Deviation 
Median Percentiles 
25 50 75 
Age 47.58 8.8 49.00 41.25 49.00 55.25 
sIL1B_1 5.93 5.14 3.39 2.21 3.39 7.73 
sIL1B_2 8.03 5.40 7.30 2.68 7.30 12.19 
IL10_1 5.83 4.52 4.81 3.04 4.81 6.81 
IL10_2 6.64 5.77 4.72 3.68 4.72 6.80 
TNF-α _1 61.53 108.79 12.76 2.00 12.76 85.56 
TNF-α _2 198.67 147.61 248.88 20.64 248.88 293.98 
hsCRP_1 8823.58 13475.50 3909.50 966.00 3909.50 10166.75 
hsCRP_2 7049.58 13001.49 3264.00 781.25 3264.00 6354.00 
IL6_1 16.14 42.70 2.84 1.41 2.84 6.82 
IL6_2 12.23 32.63 1.79 1.06 1.79 3.23 
SERT_1 1.13 .23 1.08 .99 1.08 1.18 
SERT_2 1.00 .19 1.02 .81 1.02 1.14 
BDI_1 11.42 7.66 10.00 5.00 10.00 16.75 
BDI_2 8.08 8.05 5.00 3.25 5.00 10.00 
FACIT_1 27.08 13.70 27.50 14.75 27.50 39.50 
FACIT_2 33.66 13.70 38.00 23.75 38.00 44.50 
Pain_1 1.31 0.64 1.42 .80 1.42 1.77 
Pain_2 .74 .42 .65 .32 .65 1.10 
1 refers to pre-treatment levels and 2 refers to post-treatment levels. Lower FACIT 
scores suggest lower fatigue. All circulating cytokine levels measured as pg/ml; hsCRP 
as ng/ml 
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Table 7-3: Normality distribution of the variables and the log transformed variables.  
 Shapiro-Wilk Shapiro-Wilk (post log 
transformation) 
Statistic df Sig. Statistic df Sig. 
sIL1B_1 .82 12 .02 .95 12 .70 
sIL1B_2 .93 12 .43 .92 12 .30 
IL10_1 .73 12 .002 .96 12 .91 
IL10_2 .57 12 .000 .81 12 .01 
TNF-α _1 .63 12 .000 .91 12 .24 
TNF-α _2 .90 12 .19 .76 12 .01 
hsCRP_1 .65 12 .000 .98 12 .99 
hsCRP_2 .52 12 .000 .96 12 .90 
IL6_1 .39 12 .000 .94 12 .51 
IL6_2 .39 12 .000 .97 12 .91 
BDI_1 .93 12 .39 .95 12 .66 
BDI_2 .77 12 .01 .98 12 .99 
FACIT_1 .95 12 .65    
FACIT_2 .87 12 .07    
Pain_1 .97 12 .96    
Pain_2 .94 12 .49    
Note : p<0.05 suggests data significantly deviates from normality. 1 refers to pre-
treatment levels and 2 refers to post-treatment levels 
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7.4.3 Relationship between diagnosis and baseline variables 
Table 7-4 shows the difference in baseline continuous variables between 
participants with psoriasis and psoriatic arthritis. Only the fatigue scores and 
pain scores differed between the two groups. Fatigue (U=0.00; p=0.004) and pain 
(U=5.00; p=0.07) was greater in those with psoriatic arthritis.  
 
Table 7-4: Difference in baseline variables between participants with psoriasis and psoriatic 
arthritis 
 
Psoriasis 
(4) 
Mean rank 
Psoriatic 
Arthritis 
(8) 
Mean rank 
Mann-
Whitney U Z 
Exact Sig. 
[2 tailed] 
SERT 6.75 6.38 15.00 -.17 .93 
TNF-α 5.25 7.13 11.00 -.84 .46 
IL6 6.63 6.44 15.50 -.08 .93 
hsCRP 6.25 6.63 15.00 -.17 .93 
IL10 6.50 6.50 16.00 .00 1.00 
IL1B 5.00 7.25 10.00 -1.01 .36 
BDI 5.00 7.25 10.00 -1.02 .36 
FACIT (fatigue) 10.50 4.50 0.00 -2.71 0.004 
Pain 3.75 7.78 5.00 -1.87 0.07 
Lower FACIT scores suggest greater fatigue 
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7.4.4 Relationship between sex and baseline variables 
Table 7-5 shows the difference in baseline variables between males and female 
participants. As can be seen, sex was not significantly associated with any of the 
baseline variables.  
 
Table 7-5: Difference in baseline variables between males and females 
 
Males (6) 
Mean rank 
Females (6) 
Mean rank 
Mann-
Whitney U Z 
Exact Sig. 
[2 tailed] 
SERT 5.67 7.33 13.00 -.80 .48 
TNF-α 7.00 6.00 15.00 -.48 .69 
IL6 6.83 6.17 16.00 -.32 .81 
hsCRP 6.50 6.50 18.00 .00 1.00 
IL10 7.33 5.67 13.00 -.80 .48 
IL1B 6.67 6.33 17.00 -.16 .93 
BDI 5.33 7.67 11.00 -1.12 .31 
FACIT (fatigue) 6.00 7.00 15.00 -.48 .69 
Pain 6.17 6.83 16.00 -.32 .81 
Lower FACIT scores suggest greater fatigue 
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7.4.5 Correlation between baseline variables  
Table 7-6 shows the results of the spearman’s correlation analysis used to 
examine if there was significant correlation between the baseline variables. As 
can be seen, IL1B, IL6, IL10 and CRP showed significant correlation at baseline. 
TNF-α did not show significant correlation with other inflammatory markers. Age 
correlated negatively with SERT and FACIT score and positively with BDI scores 
(non-significant). In addition, it can be seen that TNF-α  showed a positive 
correlation with SERT.  
 
Table 7-6: Correlation between baseline variables 
 SERT TNF-α IL6 hsCRP IL10 IL1B BDI FACIT Pain Age 
 SERT rho 1          
TNF-α rho .66* 1         
IL6 rho .004 .17 1        
hsCRP rho -.21 -.22 .69* 1       
IL10 rho .12 .42 .64* .28 1      
IL1B rho .25 .35 .67* .44 .25 1     
BDI rho .16 .12 -.61* -.19 -.21 -.27 1    
FACIT rho -.09 -.28 .21 .04 .16 -.04 -.49 1   
Pain rho .12 .37 -.07 -.26 .33 .07 .46 -.41 1  
Age rho -.52 -.04 -.18 -.09 -.17 .13 .32 -.59* .33 1 
*. Correlation is significant at the 0.05 level (2-tailed); Lower FACIT scores suggest greater 
fatigue.  
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7.4.6 Relationship between TNF-α , SERT and BDI scores at 
baseline 
Since there was a significant association between TNF-α  and SERT in the above 
analysis, we explored the relationship between TNF-α , SERT and BDI further. 
Since age, gender and diagnosis shows some association with the above 
variables, I corrected TNF-α , SERT and BDI for age, gender and diagnosis, using 
linear regression. I also corrected FACIT and Pain scores for age and diagnosis. 
We used the standardised residuals for further analysis.   
 
Figure 7-4: Correlation between SERT and TNF-α  levels at baseline. The dotted lines show 
the 95% confidence interval  
 
 
From Figure 7-4, it can be seen that baseline TNF-α  explained almost 61.5% of 
the variance in SERT levels (rho=0.76;p=0.004).  hsCRP (r2=0.03), IL1B 
(r2=0.018), IL10(r2=0.01) and IL6 (r2=0.10) did not explain significant variance in 
SERT levels.   
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Figure 7-5: Correlation between SERT and BDI scores at baseline. The dotted lines show the 
95% confidence interval  
 
From the Figure 7-5 it can be seen that SERT explained almost 33% of the 
variance in BDI (rho=0.57;p=0.05).  
Figure 7-6: Correlation between TNF-α  and BDI scores at baseline. The dotted lines show 
the 95% confidence interval  
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However, as can be seen from Figure 7-6, TNF-α  accounted only for around 2% 
of the variance in BDI scores (rho=0.15;p = 0.63).  
Although TNF-α  explained only around 2% of the variance in BDI, since TNF-α  
explained significant variance in SERT and SERT in turn explained significant 
variance in BDI, a question was whether, the variance explained by SERT and 
TNF-α  on BDI overlapped significantly.  
We therefore conducted a mediation analysis to explore this relationship. To 
explore the relationship between TNF-α , SERT and BDI scores, I conducted a 
mediation analysis with TNF-α  levels as independent (explanatory/predictor) 
variable, SERT as mediator and BDI scores as dependent variable. Here, I aimed 
to examine if a proportion of variance in SERT could explain the relationship 
between TNF-α  and BDI scores. It should be noted that in classic mediation 
analysis, causal models are tested using longitudinal data; such an assumption is 
not made here. The analysis here, tests the hypothesis that the TNF-α  levels 
accounts for variance in the mediator (SERT) and in turn, this variance in the 
mediator accounts for a proportion of the variance in BDI scores. “The 
adjustable parameters of the model represent the unidirectional influence 
between pairs of variable in the model. The best fitting values of the parameters 
are estimated by using the General Linear Model to solve the linear equations 
that describe the relationships within the model. This analysis differs from 
multiple regression which estimates the proportion of variance in the dependent 
variable accounted for by each of several independent predictor variables while 
allowing for the variance accounted for by the other predictors in the 
model(Palaniyappan and Liddle, 2012).” In other words, the mediation analysis 
partitions the variance explained by the predictor into a part that is 
independent of the mediating variable (direct), and a part that is accounted for 
via the mediating variable (indirect)(Figure 7-7). 
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Figure 7-7:  The relationship between the predictor, mediator and the outcome variables. 
 
 
 
 
 
 
 
 
 
The mediation analysis partitions the total variance (total effect) explained by the predictor 
into a part that is independent of the mediating variable (direct effect), and a part that is 
accounted for via the mediating variable (indirect effect). a represents the ‘a’ path and b 
represents the ‘b’ path. 
 
I used the bootstrap method of Preacher and Hayes to estimate the indirect 
effect and bias-corrected 95% confidence interval (CI) for each individual 
mediator based on 20,000 bootstrap samples using an SPSS macro(Preacher and 
Hayes, 2008). It should be noted that this analysis requires no assumption 
regarding the underlying distributions since the statistical significance level is 
determined non-parametrically.  
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Figure 7-8: Indirect effect analysis shows that SERT mediates the association between TNF-
α  and BDI scores at baseline 
 
 
 
Figure 7-8 shows that SERT was a significant mediator of the relationship 
between TNF-α  and BDI scores (Indirect effect: Beta=0.94; SE =0.50; 95% CI = 
.32 to   2.12).  It should also be noted that neither pain scores nor fatigue scores 
mediated the relationship between TNF-α  and BDI scores. 
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7.4.7 TNF-α , SERT and FACIT-fatigue 
 
Figure 7-9 shows the relationship between SERT levels and FACIT scores. Greater 
SERT was associated with lower FACIT scores (greater fatigue) (r2= 0.17; rho= -
0.46  ; p=0.1). 
Figure 7-9: Correlation between SERT and FACIT-F scores. The dotted lines show the 95% 
confidence interval  
 
As shown in Figure 7-10 , TNF-α  levels explained around 6% of variance in FACIT 
scores ( rho=-0.25 p=0.43).  
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Figure 7-10: Correlation between TNF-α   and FACIT scores. The dotted lines show the 95% 
confidence interval  
 
 
However, a mediation analysis as in the previous step, showed that SERT did not 
mediate the relationship between TNF-α  and FACIT scores (Beta=-0.47; SE=0.75; 
95%CI = -1.6 to 1.2).  
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7.4.8 TNF-α , SERT and Pain scores 
Figure 7-11: Correlation between SERT and pain scores. The dotted lines show the 95% 
confidence interval  
 
 
As can be seen in Figure 7-11, SERT explained only around 8% of variance in pain 
scores (rho=0.28;p=0.37). 
Figure 7-12: Correlation between TNF-α  and Pain scores. The dotted lines show the 95% 
confidence interval  
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Figure 7-12 shows that TNF-α  explained around 12 % of variance in pain scores 
(rho=0.35;p=0,26).  SERT levels did not mediate the relationship between TNF-α  
levels and pain scores (Beta= 0.009; SE=0.65; 95%=-0.93 to 1.37). 
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7.4.9 Effect of TNF-α blockade using Etanercept  
Table 7-7: Paired t test exploring difference between the two conditions (before and after 
Etanercept) 
 Paired Differences (Pre - Post Etanercept) t 
(d.f. =11) 
p 
(2-tailed) 
Mean 
differe
nce 
Std. 
Deviatio
n 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
SERT 0.12 0.20 0.06 -0.01 0.24 2.07 0.06 
TNF-α -1.94 1.97 0.57 -3.19 -0.69 -3.41 0.01 
IL6 0.06 0.19 0.06 -0.06 0.18 1.10 0.30 
CRP 0.31 0.35 0.10 0.08 0.53 3.00 0.01 
IL 10 -0.14 0.48 0.14 -0.45 0.16 -1.04 0.32 
IL 1B -0.37 0.76 0.22 -0.85 0.12 -1.67 0.12 
BDI 0.48 0.57 0.17 0.11 0.84 2.87 0.02 
FACIT -6.58 5.75 1.66 -10.34 -2.92 -3.95 0.002 
Pain 2.86 2.22 0.64 1.44 4.28 4.45 0.001 
 
As can be seen in the Table 7-7, SERT levels decreased following TNF-α  
treatment. However, this difference failed to reach statistical significance on a 
2-tailed test. Interestingly, TNF-α  blockade resulted in a significant increase in 
TNF-α levels detected using ELISA. IL 1B and IL 10 also showed minimal increase 
however did not reach statistical significance. Among the inflammatory markers, 
only hsCRP showed a significant decrease with treatment. BDI, FACIT and Pain 
scores also showed a reduction following treatment with Etanercept. The 
average reductions in the 3 variables are shown in below Table 7-8.  
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Table 7-8: Percentage Change in variables following treatment with Etanercept 
Descriptive Statistics 
 N Minimum Maximum Mean Std. 
Deviation 
BDI reduction 12 -66.67 82.35 28.5862 39.13654 
SERT reduction 12 -13.29 36.66 9.5522 17.32771 
CRP reduction 12 -12.42 66.75 22.4441 23.90788 
FACIT change 12 -78.95 9.09 -29.39 28.07 
Pain reduction 12 0 78.57 39.14 25.24 
 
 
Figure 7-13: Individual SERT binding before and after treatment with Etanercept. 
 
As can be seen in Figure 7-13, the first 5 candidates showed an increase in SERT 
binding. However the mean increase in SERT was 8.3%. The mean reduction in 
SERT binding among the 7 people who showed a reduction in SERT was 22.3%.  
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Figure 7-14: Individual BDI scores before and after treatment with Etanercept 
 
 
 
Figure 7-14 shows the individual BDI scores before and after TNF-α  blockade. At 
baseline, 3 people met the criteria for mild mood disturbance, one person met 
the criteria for borderline clinical depression, and two people  met the criterion 
for moderate depression. However, on SCID examination, none of them met the 
criteria for major depression requiring treatment with an antidepressant. None 
of them endorsed significant suicidal ideas. 
As can be seen, the first 5 candidates who showed an increase in SERT binding 
showed a decrease in BDI scores. Among the 7 people who showed a reduction in 
SERT binding, two of them showed an increase in BDI scores.  
Among the two people who showed an increase in BDI scores, their fatigue 
scores also showed some worsening. One of them did not show any change in 
pain scores (Figure 7-15). 
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Figure 7-15: Individual change in variables 
 
 
As shown in the Table 7-9, there was no significant association between change 
in BDI, FACIT, Pain, SERT reduction and CRP reduction. 
 
Table 7-9:  Correlation between percentage change in scores following Etanercept treatment 
 FACIT 
change 
Pain 
reduction 
SERT 
reductio
n 
CRP 
reductio
n 
BDI 
reducti
on 
 
FACIT change Rho 1.00     
Pain reduction Rho -.32 1.00    
SERT reduction Rho .007 .02 1.00   
CRP reduction Rho .13 -.29 .08 1.00  
BDI reduction rho -.19 .40 -.41 -.38 1.00 
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7.4.10 Predictors of SERT reduction 
Only 7 of them showed a reduction (mean reduction = 22.3%; s.d. =9.15).  Those 
who showed a reduction in SERT had greater BDI scores at baseline. Greater 
baseline TNF-α  predicted greater SERT levels at follow up. Not all participants 
showed a reduction in SERT. As can be seen in Table 7-10, the best predictor of 
SERT reduction was lower score on FACIT (greater fatigue). In addition, greater 
BDI scores predicted greater SERT reduction. Greater inflammatory markers at 
baseline - IL6, IL1B and hsCRP predicted lower SERT reduction.  
Table 7-10: Association between baseline variables and change in SERT 
 FACIT Pain SERT TNF-α  IL6 hsCRP IL10 IL1B BDI 
 
SERT 
change  
rho -.65* .09 .37 .23 -.53 -.26 -.21 -.48 .55 
p .02 .77 .23 .45 .07 .41 .51 .11 .06 
 
Among those who showed a reduction in SERT binding (7 individuals), greater 
baseline TNF-α predicted greater SERT reduction (rho=0.61; r2=0.35; p=0.1).   
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7.5 Discussion 
In this chapter, I have shown a significant association between circulating TNF-α  
and central SERT levels pre-treatment. Greater circulating TNF-α  was 
associated with greater SERT. In addition, the greater SERT levels mediated the 
relationship between inflammation and depression scores (but not fatigue or 
pain scores). It should be noted that only a very small variance in BDI was 
explained by TNF-α levels. However, whatever variance was explained by TNF-α 
, overlapped significantly with that explained by SERT. This finding should be 
interpreted with caution, as all three variables were measured at the same 
time, and therefore, the data cannot be assumed to implicate a causal 
relationship. In addition, within the mediation relation tested, the direction of 
the relationship is speculative (but theoretically motivated). Here we are 
assuming that variance in TNF-α  (the predictor variable) is what drives the 
other factors including SERT (mediator) and mood (outcome variable). However, 
it could be that mood is the primary driver and the other two variables may be 
epiphenomena (not mediated). Or  SERT is the primary driver, thereby affecting 
mood and inflammation (not mediated). It should be noted that neither pain nor 
fatigue scores mediated the relationship between TNF-α and BDI scores. 
The relationship between TNF-α , SERT and fatigue suggest that although SERT 
was significantly associated with fatigue scores, the variance in SERT did not 
mediate the relationship between TNF-α  and fatigue. In other words, there was 
no significant overlap between the variance in fatigue explained by TNF-α  and 
SERT. A similar situation obtains with pain scores.  
Interestingly, TNF-α  levels did not correlate significantly with the other 
proinflammatory cytokines. The correlation between TNF-α  and IL1B was 
r=0.35, but did not reach statistical significance – perhaps due to the small 
sample size. However, it is also possible that TNF-α  and IL1B have significant 
variance that is independent of each other. Interestingly, the anti-inflammatory 
cytokine, IL10 levels also correlated positively with TNF-α  levels. It could be 
argued that greater inflammation was associated with a compensatory increase 
in anti-inflammatory levels. As expected, IL6 levels showed a significant 
association with CRP, IL1B and IL10. However, IL6 levels did not correlate with 
TNF-α  levels.  
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Surprisingly, IL6 also showed a negative correlation with BDI scores. This is 
opposite to what was expected, in that greater inflammation was associated 
with lower scores on BDI. In fact, the BDI scores showed a positive association 
with only TNF-α . It showed a negative association with CRP, IL1B and IL10 
levels. BDI scores however showed significant correlation with pain and fatigue 
scores. 
With regards to the sample, those with psoriatic arthritis had greater fatigue and 
pain. However, they did not differ significantly in terms of depression scores or 
other inflammatory markers. A number of other measures showed an association 
with age and gender and diagnosis. Those variables were corrected for these, in 
order to account for the variance examined by these variables.  
Treatment with Etanercept was associated with a reduction in SERT levels. 
However, not everyone showed a reduction in SERT. Those who showed a change 
in SERT had greater depression scores and fatigue at baseline. Those with 
greater baseline IL1B and IL6 showed lesser reduction in SERT. Interestingly, 
TNF-α  levels increased following treatment with TNF-α  blockade. This is in 
keeping with a number of previous reports(Tsimberidou et al., 2003, Suffredini 
et al., 1995, Zou et al., 2003, Madhusudan et al., 2004, Nowlan et al., 2006). 
The possible explanation for this is that the ELISA detects both bound and 
unbound forms of TNF-α and does not differentiate biologically active and 
inactive TNF-α  (Bhatia and Kast, 2007). In other words, the TNF-α  that was 
bound to Etanercept (but inactive) was also detected. This is also perhaps why, 
we did not find any association between TNF-α levels and SERT post-treatment. 
7.5.1 The association between inflammatory markers and SERT 
7.5.1.1 Comparison with preclinical studies 
Most of the studies that have examined the relationship between inflammation 
and SERT are in animals. The relationship between circulating/peripheral 
inflammation and serotonergic system has been shown in a number of studies.  
Clement et al found that peripheral treatment with TNF-α  and IL6 was 
associated with increased release of 5HT in the rat dorsal raphe nucleus 
(Clement et al., 1997). As the peripheral application of interferon gamma was 
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not associated with an increased release of serotonin, they suggested that the 
effect of peripherally elevated cytokine concentration on serotonin metabolism 
in the dorsal raphe nucleus was cytokine dependent.  Zhang et al  studied the 
response of peripheral administration of IL6 on in vivo microdialysis and in vivo 
amperometry (Zhang et al., 2001). Intraperitoneal injection of IL6 resulted in an 
increase in the concentration of serotonin in rat striatum associated with 5HT 
signals obtained from striatum, following electrical stimulation of the dorsal 
raphe nucleus. This in vivo amperometry signal had previously been shown to 
reflect specific increase in synaptic 5HT release.  
We did not measure synaptic serotonin concentrations in our sample. However, 
it could be argued that greater SERT in at least some cases could be attributed 
to an up-regulation secondary to greater availability of SERT in the synaptic 
cleft. However, the relationship between synaptic 5HT and SERT is not clear. 
There is evidence to say that at least in some cases, greater synaptic 5HT results 
in downregulation of SERT that results in a reduction in SERT levels.  
A number of studies have shown that inflammatory mediators may have a direct 
effect on SERT availability and activity in cell systems and in adult animals. 
Ramamoorthy et al showed that interleukin-1β (IL-1β) stimulates the activity of 
SERT in human JAR choriocarcinoma cells (Ramamoorthy et al., 1995). The 
stimulation was associated with an increase in the steady state levels of 
transporter mRNA and transporter density. They also showed that this increase 
in SERT mRNA was blocked by actinomycin D – a transcription inhibitor, thus 
suggesting that the increase in mRNA may be due to increased transcription of 
the SERT DNA. They in addition showed that this regulation may be independent 
of the cAMP pathway. However, they found no effect of IL-6 on SERT function. 
Morikawa et al examined the effects of interferon alpha and gamma on the 
transcriptional regulation of serotonin transporter in human choriocarcinoma 
cells(Morikawa et al., 1998).  They showed that treatment with the interferons 
for around 30 minutes, led to an increase in SERT mRNA for upto 3 hours. This 
was found to be inhibited by treatment with the transcription inhibitor - 
actinomycin D. They found that treatment of the cells for a longer period (3 to 6 
hours) rather than shorter period (30 minutes) was also associated with an 
increased SERT uptake activity. Tsao et al  examined the effect of IFN alpha on 
MAPK phosphorylation, 5HTT mRNA expression and 5HT uptake in Jurkat T 
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cells(immortalized cell lines)(Tsao et al., 2008). They found that following 
treatment with IFN alpha, these cells showed an increase in the levels of MAPK 
phosphorylation, 5-HTT mRNA expression and 5-HT uptake. This was blocked in 
the cells that that were pretreated with MAPK inhibitors and fluoxetine. They 
claimed these results were evidence for an IFN-α-induced 5-HT uptake that 
reduces the 5-HT levels and IFN-α-regulated transcription of 5-HTT. Katafuchi et 
al, showed that induction of fatigue by intraperitoneal injection of polyI:C in 
rats, led to an increase in interferon alpha expression in the brain and an 
increase in 5HTT expression (Katafuchi et al., 2006). This was directly related to 
a reduction in 5HT in medial prefrontal cortex. All of the above are in keeping 
with our findings of greater association of TNF-α with SERT availability. 
While the above reports suggest a SERT trafficking dependent pathway that 
mediate the relationship between inflammatory cytokines and SERT, there are 
studies, which show that the relationship between inflammation and SERT may 
also occur through SERT trafficking independent mechanisms. Mossner et al 
showed that the cytokine TNF-α modulates 5-HTT functions (Mossner et al., 
1998). Using the same cell line, as Ramamoorthy et al, they found that TNF-α 
enhances 5-HT uptake, with a doubling of the maximal velocity of uptake. 
Furthermore, they showed that this effect was dose- and time- dependent, with 
a maximum observed after exposure to TNF-α for 48 hours. Zhu et al.showed, 
that both IL-1β and TNF-α cause rapid activation of SERT in raphe neuron 
derived RN46A cells (Zhu et al., 2006). They also found that this increase in 
activity was p38 MAPK dependent. Given p38MAPK has an important role in 
sustaining SERT expression at the plasma membrane , immune factors that 
operate via this signalling mechanism could have marked effects on serotonergic 
neurotransmission (Samuvel, 2005). More recently, the same group showed that 
intraperitoneal injection of the cytokine inducer, LPS, stimulated SERT activity 
in vivo and increased immobility in both the tail suspension test (TST) and the 
forced swim test (FST) in adult mice (Zhu et al., 2010). They found that this 
mechanism was mediated via IL-1R and p38MAPK dependent mechanisms. They 
suggest that unlike previous results, which examined the direct effect of 
proinflammatory cytokines on SERT activity, their data provide evidence for a 
relationship between induction of peripheral inflammation and central 
expression of proinflammatory markers and SERT activity. It should be noted 
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that these experiments used low levels of inflammation, in order to avoid the 
effect of fever on behaviour.  
In addition to neuronal SERT, it is recognised that SERT is also expressed in glial 
cells. Malynn et al showed that C6 glioma cells and primary astrocytes treated 
with TNF-α showed a sustained and significant increase in SERT mediated 5HT 
uptake(Malynn et al., 2013). They showed that this increase was due to an 
increase in the transporter capacity without any significant alteration in the 
affinity. They also found an increase in expression of SERT mRNA levels. Taken 
together, they argue that the increase in SERT mediated uptake was due to 
increased expression of the SERT gene, that is at least in part mediated through 
p38 MAPK dependent pathways.   
We did not measure SERT activity. While it could be argued that at least some of 
SERT activity is dependent on its availability, there clearly exists  mechanisms by 
which 5HT levels in the synaptic cleft is controlled by SERT activity that is 
independent of the availability –as described above. It is likely that at least some 
of the relationship between TNF-α  and 5HT is mediated by changes in uptake 
that is independent of SERT availability.  
While all the above studies have been done in animals/ human cell lines, very 
few studies have examined the relationship between inflammation and midbrain 
SERT in humans.  In a pilot study, Cavanagh et al examined the effect of TNF-α  
blockade on midbrain SERT availability using Beta CIT SPECT(Cavanagh et al., 
2010). They used adalimumab, a drug that binds to tumour necrosis factor-alpha 
(TNFα), preventing it from activating TNF-α  receptors in patients with 
rheumatoid arthritis. In this study, following treatment with adalimumab, for 
just 4 days following last treatment, 5 out of 6 individuals showed a reduction in 
SERT binding of an average 20%. In their study, one participant showed an 
increase in SERT following treatment. They however did not measure the 
relationship between SERT and circulating inflammatory markers. Our findings 
resonate with this. However, the average binding reduction was much less. This 
is because 5 out of the 12 people showed an increase in SERT availability. Among 
those who did show a reduction, the average reduction was similar to that of 
Cavanagh et al(Cavanagh et al., 2010). It should however be noted that the 20% 
reduction in availability is far lower than that usually occurs with 
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antidepressants (80%). This may partly explain why a reduction in SERT 
availability did not correlate with reduction in BDI scores. It is likely that the 
reduction in depressive symptoms in our study was mediated through pathways 
independent of SERT availability. 
Raison et al examined if anti TNF-α  treatment using Infliximab reduced 
depressive symptoms in patients with treatment-resistant depression, and if 
inflammatory marker levels predicted treatment response(Raison et al., 2013). 
The found that after 3 infusions of infliximab vs placebo over a period of 12 
weeks, there was no difference in depression scores between the two treatment 
groups. However, they found that those who responded to infliximab had a 
baseline concentration of hsCRP of more than 5mg/ l. 62% of those with a CRP of 
greater than 5 showed a response to infliximab, compared to only 33% who 
showed who showed a response to placebo. Baseline concentrations of TNF-α  
and its soluble receptors were also greater in infliximab responders.  
7.5.2 Studies examining the relationship between inflammation 
and other brain markers  
Two recent studies have examined the relationship between circulating 
inflammatory markers and other markers in the brain in the context of arthritis.  
Lampa et al examined the levels of intrathecal proinflammatory cytokines in 
cases of rheumatoid arthritis(Lampa et al., 2012). They found that IL1B was 
elevated in the CSF of patients with rheumatoid arthritis, compared to healthy 
controls and patients with multiple sclerosis (in remission). Interestingly, they 
also found that CSF levels of IL1B were greater than serum levels. This suggests 
that at least in case of serum IL1B, serum levels may not represent levels in the 
brain. In addition, the presence of soluble and cell bound TNF-α  in the brain, 
makes it difficult to reach conclusions about the CSF levels of this cytokine. 
They suggest that activated microglia produce cell bound TNF-α  which mediate 
cell-cell interaction, and hardly release any soluble TNF-α  detectable in the 
CSF. They did not find any significant difference in TNF-α  levels or IL6 levels.  It 
should also be noted that IL6 and TNF-α  are very low in CSF in general. They 
also found that levels of anti-inflammatory cytokines – IL1Ra and IL 4 were lower 
in the CSF of patients with rheumatoid arthritis. They found a significant 
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correlation between IL1B levels and fatigue, but not with sleep/pain in these 
patients. In an animal model of fast-developing arthritis (serum-transferred 
K/BxN arthritis), they found that the spinal cord showed an increased expression 
of IL1B and TNF-α   (but not IL6) mRNA on the day the arthritis peaked. 
In another study, Hess et al aimed to establish why people with RA, who undergo 
TNF-α  antagonist treatments perceive rapid improvement of symptoms in spite 
of chronic joint inflammation with structural changes(Hess et al., 2011). In 
patients with RA, they demonstrated that treatment with infliximab (a 
monoclonal antibody TNF-α  blocker) was associated with reduction of 
nociceptive and limbic CNS activity measured using bold fMRI, as early as after 
24 hours. This was independent of joint swelling and changes in acute phase 
reactants. They used a mouse model to show that TNF-α  blockade was directly 
related to rapid reduction of nociceptive BOLD signals associated with thermal 
and mechanical hyperalgesia induced by arthritis. They used graph theoretical 
complex network analysis of bold signal cross-correlation to show that the pain 
related regions showed an increased degree of connectivity, clustering and 
modularity in the arthritic mice compared to the wild type mice. This tight 
cluster partially dissolved on TNF-α  blockade administration. Their data suggest 
that TNF-α leads to intensive, widespread and prolonged activity on nociception, 
which is reversed with TNF-α  blockade. They suggest that the nociceptive 
changes precede anti-inflammatory action of the TNF-α  blockade agents.  
Felger et al, examined the effect of interferon alpha treatment in rhesus 
monkeys(Felger et al., 2013). They treated the monkeys with interferon alpha or 
saline for 4 weeks. They used in vivo microdialysis to investigate dopamine 
release in striatum. They also used PET (C raclopride) to examine D2 receptor 
binding after amphetamine use, and 18F- FECNT to examine DA transporter 
binding. The in vivo microdialysis showed a reduction in DA release in the IFN 
group, compared to saline. This was associated with reduction in DA release in 
following amphetamines and reduced D2R binding, but no change in dopamine 
transporter availability. Anhedonia-like behaviour (reduced sucrose 
consumption) correlated with the reduction in DA release at 4 weeks. 
Capuron et al measured presynaptic dopamine function in patients with hepatitis 
C virus who went on interferon alpha treatment (average 35 days)(Capuron et 
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al., 2012). They used F-dopa to measure dopamine turnover in the caudate and 
putamen using PET. The patients showed a significantly increased F-dopa uptake 
and decreased F-dopa turnover in caudate and putamen. Baseline and 
percentage signal change in  F-dopa turnover correlated with changes in 
depression, fatigue and neurotoxicity. Serotonin release in the hypothalamus has 
been shown to be modulated by  inflammatory cytokines in animal models (Wu 
et al., 1999). This release is thought to mediate behavioural changes associated 
with sickness behaviour (Guijarro et al., 2006).Raison et al demonstrated a 
direct relationship between cytokine levels and serotonin turnover was 
demonstrated in humans (Raison et al., 2009). They examined the CSF of 
patients being treated with interferon alpha for hepatitis C. They found that 
greater IL6 levels correlated negatively with 5HIAA concentrations in the CSF. 
This reduction in 5HIAA correlated negatively with depression severity in those 
who received the treatment . Higher TNF-α  levels at baseline has been 
associated with somatic symptoms of depression in patients receiving IFN alpha 
treatment (Loftis et al., 2013). 
Drake et al used PET tracer PK 11195 to examine the relationship between 
cerebrovascular risk factors (but no stroke) and brain inflammation. They found 
that people with greater risk factors showed greater microglial activation in the 
brain, compared to normal controls (Drake et al., 2011). Similarly, a few studies 
have shown that modulating circulating inflammation is associated with both 
functional and structural changes in the brain. Harrison et al showed that 
inducing a circulating inflammatory response using typhoid vaccine in normal 
adults is associated with change in BOLD signals in regions pertaining to 
modulation of mood in the brain (Harrison et al., 2009a) . Craig suggests that 
interoceptive signals from the body have a “primary viscero-cortical 
representation” within the Insula/SN (Craig, 2009). Essentially, interoceptive 
signals from vagal afferents, spinal afferents and sensory circumventricular 
organs are integrated in the ‘viscero-sensory hubs’ within the brainstem 
(Critchley and Harrison, 2013). Information from this hub is then relayed to the 
SN. In the case of inflammation, activated immune cells release inflammatory 
mediators, particularly cytokines, which activate vagal afferents and the sensory 
circumventricular organs (Harrison et al., 2009b). The brain stem ‘viscero-
sensory hub’ responses evoke visceral reflexes that result in “sickness 
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behaviour”, including fatigue, malaise, weight loss and anorexia. Inflammatory 
challenge using typhoid vaccine activates the ‘brainstem hubs’ and insula and 
disrupts affective network connectivity within the first 3 hours of 
administration, suggesting an early/fast neural mechanism in inflammation 
related viscero-cortical representation (Brydon et al., 2008, Strike et al., 2004). 
These changes also predict fatigue/psychomotor and sickness behaviour 
(Harrison et al., 2009b). 
More recently, Hannestad et al found that systemic inflammation induced by 
endotoxin in humans was associated with higher normalised glucose metabolism 
in the insula. This change was associated with change in peak cytokine levels 
and also changes in social interest, suggesting that these may be linked to each 
other (Hannestad et al., 2012b). Hannestad et al , examined microglial 
activation using a PET TSPO ligand - PBR 28 in non-human primates. They found 
that following an intravenous administration of E Coli lipopolysaccharide, which 
induced systematic inflammation; PBR 28 binding was increased by 29% and 62% 
at 1 hour and 4 hours respectively(Hannestad et al., 2012a). Increased PBR 
binding also correlated significantly with serum IL1Beta and IL 6 levels. They 
conclude that systemic inflammation is associated with an increase in TSPO 
binding in non-human primates. The same group, however found no difference in 
PBR 28 binding in individuals with mild to moderate depression compared to 
healthy control subjects (Hannestad et al., 2013).  
Functional gene polymorphisms of SERT have been examined in inflammatory 
cytokine-associated depression. A recent review by Felger and Lotrich, examined 
the relationship between the long and short allele of the SERT promoter regions 
and depressive symptoms in those who were receiving pegylated IFN-alfa-2a 
(PEGAYS) or IFN-alfa-2b (PEGINTRON) plus ribavirin for chronic hepatitis C virus 
(HCV) infection(Felger and Lotrich, 2013). Two studies showed no association, 
while two studies showed that the L/L alleles were associated with lower 
depressive symptoms and one study reported an association between L allele and 
higher depression scores in non-Hispanics, but an association between S allele 
and depression scores in Hispanic Caucasians (Table 7-11). In addition, this 
suggests that ethnicity may be a covariate of interest when examining this 
relationship. 
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Table 7-11: Relationship between functional polymorphisms of the SERT promoter region 
and depressive symptoms in patients receiving interferon treatment 
(Bull et 
al., 2009) 
5-
HTTLPR 
(L/S) 
N = 98, depression and 
fatigue monitored at 4, 
8, 12, 24 weeks by BDI, 
SDS, CFQ 
The L/L genotype was 
associated with fewer 
depressive symptoms, and 
this ‘protective’ effect was 
evident only in the presence 
of the ‘low expression IL-6’ 
genotype. 
(Kraus et 
al., 2007) 
5-
HTTLPR 
(L/S) 
N = 139, depression 
monitored by HADS 
No significant association with 
cytokine-induced depressive 
symptoms 
(Lotrich et 
al., 2009) 
5-
HTTLPR 
(LG, LA, 
and S) 
N = 71, depression and 
related symptoms 
monitored by SCID, 
BDI, PSQI, NEO-Five 
Factor Inventory, CIRS-
G at weeks 2, 4, 8, 12, 
and 16 weeks 
treatment 
The LA allele was associated 
with a decreased rate of 
depression, with the LA/LA 
genotype being the most 
resilient. This genotype was 
also associated with better 
sleep quality 
(Pierucci-
Lagha et 
al., 2010) 
5-
HTTLPR 
(L/S) 
N = 1,015, depression 
monitored by CIDI and 
BDI-II for 24 or 
48 weeks 
The L allele was associated 
with higher depression scores 
in non-Hispanic Caucasians 
and S allele associated with 
depression scores in Hispanic 
Caucasians 
(Su et al., 
2010) 
5-
HTTLPR 
(L/S) 
N = 132, depression 
monitored by M.I.N.I., 
BDI and HDRS for 
24 weeks 
No significant association with 
cytokine-induced depressive 
symptoms, however there 
were only IL-6 G/G subjects in 
this Chinese sample and the 
effects of the “at risk” allele 
on the 5-HTTLPR could not be 
assessed 
Reused with permission from Felger, J, Lotrich FE. Inflammatory cytokines in depression: 
Neurobiological mechanisms and therapeutic implications (Felger and Lotrich, 2013) 
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7.5.3 Reduction of SERT on Etanercept treatment 
7.5.3.1 Does SERT play a role in the pathophysiology of depression? 
The serotonin system has long been associated with depression. It is perhaps one 
of the most widely studied neurotransmitter systems in the context of 
depression. It is also the system that is most commonly affected by anti-
depressants. A vast number of studies have examined the serotonin system in 
depression. They have demonstrated alterations in a wide range of aspects of 
the serotonin system. Serotonin levels in the brain are controlled by a number of 
factors including rate of synthesis, rate of release into the synaptic cleft, rate of 
enzymatic breakdown, rate of diffusion through the extracellular space and 
active reuptake. In the brain, SERT seems to be the predominant mechanism 
controlling serotonergic neurotransmission. Therefore it is likely that SERT 
availability is directly related to serotonergic neurotransmission (Meyer, 2008, 
Meyer, 2012).  
Although a number of studies have examined the relationship between serotonin 
transporter and depression, due to the heterogeneity of the populations 
examined, only a few studies have the methodological rigour to address these. 
Meyer in a recent review of literature concluded that finding from studies that 
exclude subjects that have been on medications for at least 2 months, exclude 
those with co-morbidities, suggest either no change or an increase in regional 
SERT binding potential(Meyer, 2008, Meyer, 2012). Studies that have included 
participants, who have been recently medicated or included participants with 
co-morbidities, tend to report a reduction in SERT BP. More recently, Savitz and 
Drevets synthesised the data on SERT binding in mood disorders (Savitz and 
Drevets, 2013). They focused on PET studies that used 11C-DASB as the ligand, 
as the other ligands showed non-specific binding. Similar to Meyer, they reached 
the conclusion that PET based data on SERT binding in mood disorders are not 
definitive. However, similar to Meyer, they offer an interim summary, based on 
imaging studies of depression-related phenotypes, preclinical studies and the 
neuroimmunology literature, that SERT function is likely to be increased in 
depression. They then go on to provide a simplified hypothesis of SERT 
dysfunction in mood disorders. They suggest that increased serotonergic 
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neurotransmission in response to elevations in CRF and inflammation, results in 
an increase in SERT function, leading to chronic over-activity and decreased 
serotonin neurotransmission.  
In our study, interestingly, we found a significant correlation between BDI scores 
and SERT levels. Those with greater SERT levels had greater BDI scores. SERT 
availability did not correlate with Fatigue scores or pain scores. It should be 
noted that the mean scores on BDI were below what would be considered clinical 
depression.  
The data from the current literature reveal the complexity of this area of 
research. A difference in SERT binding seen in patients with depression may be 
due to a number of reasons (Meyer, 2008). Firstly, there may be differences in 
the number of serotonergic neurons  - a lesion model similar to the loss of 
dopaminergic neurons on Parkinson’s disease.  Secondly, the radio-active ligands 
may be displaced by differences in serotonin levels. For example, an excess of 
serotonin can displace the radioactive ligand. Thirdly, SERT may also have 
undergone up/down regulation – i.e. there are differences in the number of 
transporters on the presynaptic neuron. Therefore, an increase in SERT binding 
can directly result in increased reuptake and a reduction of serotonin in the 
synaptic cleft. However, it can also represent a state of upregulation in response 
to an increase in serotonin levels. It is therefore not clear whether these are 
epiphenomenon or actually related to the pathophysiology of depression. In 
Recent research in humans have measured 5HT2A levels as a surrogate marker of 
extracellular serotonin in the brain. These data suggest that the relationship 
between SERT and 5HT2A levels seems to follow an inverted U shape. In other 
words, a reduction in SERT binding may represent low or high synaptic serotonin 
levels (Erritzoe et al., 2010). In addition to the above, serotonin levels may be 
regulated by SERT in two ways.  Trafficking dependent activity - where the 
concentration of SERT molecules on the cell surface of the neurons are 
controlled, and a trafficking independent activity where only the activity of 
SERT, i.e. the substrate affinity and maximal transport is affected. There is 
evidence that inflammation may directly affect serotonin concentration through 
regulation SERT availability as well as activity, through both the above 
mechanisms(Ramamoorthy et al., 1995, Zhu et al., 2006).    
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7.5.3.2 What does a reduction in SERT availability mean? 
The change in scores with treatment was more difficult to interpret. While we 
found no association between change in SERT and change in behavioural 
measures, we found that greater baseline BDI scores and greater fatigue 
predicted greater reduction in SERT. Interestingly, in our sample, greater 
inflammatory markers predicted smaller reduction in inflammatory markers. This 
is perhaps due to the fact that those who had greater inflammation to begin 
with, also showed greater inflammation (and hence SERT) following treatment, 
as there were no significant reductions in the inflammatory markers, except 
with CRP. However, CRP levels did not correlate with either pre or post 
etanercept SERT levels.  
The reduction in SERT binding, could be due to a number of processes. It could 
mean that there is a direct effect of reduction of inflammation on transcription, 
and hence, SERT expression. It could be that greater serotonin availability (due 
to release of 5HT secondary to a reduction in inflammation) in the synapse, led 
to a down regulation of SERT. It should be noted that the relationship between 
SERT and 5HT follows an inverted U shape. It could also be that the greater 
serotonin availability just led to the displacement of beta-CIT from the 
transporter. It is also possible that a combination of the above factors may have 
led to our findings. However, using our data, the exact reason for the reduction 
cannot be ascertained.  
7.5.3.3 How does the reduction in SERT and BDI scores compare with 
antidepressant treatments. 
At least 3 recent studies have directly examined the effect of treatment with 
anti TNF-α  biological agents on mood. See Table 7-12 (Rieder and Tausk, 2013). 
They also show the results of antidepressant trials that have directly examined 
the effect of antidepressants on mood in patients with psoriasis. Four studies 
that directly examined the effect on mood, showed significant improvement in 
mood scores, similar to those with antidepressant treatments. 
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Table 7-12: Studies examining the effect of treatment with anti-TNF-α  agents or antidepressants on mood in Psoriasis 
Study n 
Control 
group 
Experimental 
group 
Double-
blind 
Premorbid 
depression 
Results 
(experimental vs. 
placebo) 
P value 
(Alpsoy 
et al., 
1998) 
60 Placebo 
6 weeks of 
moclobemide, 
450 mg/d 
Yes Undisclosed 
Higher improvement 
rates in PASI, BDI, 
STAI-1, and HAM-A 
AllP < 0.05 
(Modell 
et al., 
2002) 
11 None 
6 weeks of 
bupropion-SR, 
150–300 mg/d 
then 3-week 
washout 
N/A None 
At 6 weeks, 8 of 10 
patients’ lesions had 
improved vs. 
baseline 
<0.001 for 
both 
(Tyring 
et al., 
2006) 
618 Placebo 
Etanercept 50 mg 
twice weekly 
Yes 
77 of 308 (25%) of 
experimental group 
as measured by 
HAM-D 80 of 305 
(26%) of placebo 
group as measured 
by HAM-D 
At week 12, 42% 
more patients 
achieved 75% 
improvement in PASI 
At week 12, greater 
improvement in HAM-
D and BDI 
<0.0001 
<0.0012 for 
both 
(Gelfand 
et al., 
2546 Interrupted 
Continued 
etanercept 50 mg 
No Mean BDI scores 8.1 
and 8.3 in 
Mean BDI scores 
improved by 29% at 
None 
Chapter 7  205 
 
Study n 
Control 
group 
Experimental 
group 
Double-
blind 
Premorbid 
depression 
Results 
(experimental vs. 
placebo) 
P value 
2008)  etanercept once weekly for 
second 12 weeks 
continuous and 
interrupted 
treatment arms 
week 12. 
Improvement 
sustained in both 
arms at week 24 
provided 
(Langley 
et al., 
2010) 
1230 Placebo 
Ustekinumab 
45 mg or 90 mg at 
weeks 0, 4, and 
every 12 weeks 
through week 52 
Yes 
227 of 814 (28%) of 
combined 
experimental group 
by HADS-D 98 of 405 
(24%) of placebo 
group by HADS-D 
At week 12, greater 
improvement in 
HADS-A (13.9%) and 
HADS-D (29.3%) 
<0.001 for 
both 
Reused with permission from Rieder E, Tausk F. Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and 
treatments. Int J Dermatol. 2012 Jan;51(1):12-26. Copyright John Wiley and Sons. 
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Recent reviews suggest that the usual minimal effective dose for SSRIs produce a 
SERT occupancy of around 70 to 80% measured using SPECT. Higher occupancy 
than this does not increase efficacy(Preskorn, 2012). de Win et al, using Beta-CIT 
showed that treatment with Citalopram was associated with a reduction in SERT 
binding of about 72% in the midbrain(de Win et al., 2005). Meyer suggest that at 
therapeutic doses, SSRIs and other antidepressants show SERT occupancy of 
around 80% (Meyer, 2012). However, the literature is not always consistent. 
Cavanagh et al found that SERT availability measured using Beta CIT did not 
differentiate treatment responders from non-responders(Cavanagh et al., 2006).  
Therefore the relationship between reduction SERT availability and reduction in 
depressive symptoms may not be linear. 
In our case, the average reduction of SERT binding following TNF-α  blockade 
was only around 9%. Among those who showed a reduction, the average 
reduction was around 20% and in our best case, the reduction was only 36.6%. 
Compared to Citalopram, the reduction in SERT binding with TNF-α  treatment 
was considerably smaller.  In our case, SERT reduction was not associated with a 
change in any of the clinical variables, including pain and fatigue. It was also not 
associated with a change in CRP levels, suggesting that this was not directly 
related to changes in disease/clinical state.  
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7.5.4 Pain and central serotonin 
Figure 17: Pain modulatory pathway: The green arrows show descending inhibitory pain 
pathways, while the red arrows show ascending pain pathways 
 
Figure 17 gives a simplistic representation of the afferent and modulatory pain 
pathways. Afferent neurons (A delta and C fibres) from the joints and the skin, 
contain nociceptors can be stimulated by inflammatory mediators like 
prostaglandins and cytokines(Reddi and Curran, 2013). These fibres synapse with 
secondary afferent neurons in the dorsal horn of the spinal cord. The primary 
fibres release a number of excitatory neurotransmitters including glutamate and 
substance P. They ascend through the spinothalamic and the spino-reticular 
pathways to the thalamus and third order neurons from thalamus pass on the 
primary somatosensory areas of the brain. These ascending pathways also 
project to the periaqueductal and raphe nuclei in the brain stem/midbrain.  Pain 
also activates a number of other cortical and subcortical regions of the brain. 
Inhibitory pathways from the peri-aqueductal gray and the dorsal raphe nuclei, 
descend along the dorsal funiculus, to activate the inhibitory interneurons in the 
dorsal horn. These in turn interact with the afferent fibres, thereby inhibiting 
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further ascending neurotransmission. It can be seen that serotonin plays a major 
role in pain inhibition.  
The reduction in pain in response to anti-inflammatory drugs could either be due 
to reduced stimulus of the nociceptor at the peripheral level due to reduction in 
inflammatory stimulus of the nociceptor, or it may be a direct central action 
through serotonin receptors. Anecdotal evidence say that serotonergic 
antidepressants have analgesic and anti-inflammatory effects. In addition, 
recent fMRI findings have directly examined the effect of TNF-α  blockade on 
pain pathways in the brain(Hess et al., 2011). They suggest that the rapid 
reduction in pain may be modulated through pain pathways in the brain. In our 
data, it was difficult to interpret the relationship between changes in 
inflammatory markers and changes in SERT and behavioural measures. 
Critchley and Harrison suggest that inflammation may communicate with centres 
in the brain though neural interoceptive pathways (Critchley and Harrison, 
2013). These pathways include those regions that are consistently activated in 
pain paradigms. Therefore in conditions where pain and inflammation coexist, 
the neural basis of pain and inflammatory signalling are difficult to differentiate.  
It should be noted that all patients were also taking other NSAIDS as required, 
and this may have affected their pain scores and may have interfered with anti-
inflammatory levels.  
7.5.5 Fatigue and central serotonin 
Fatigue is a common but debilitating symptom in inflammatory conditions 
(Capuron and Miller, 2011). While peripheral fatigue is due to neuromuscular 
factors, central fatigue is thought to represent a failure to complete physical 
and mental tasks that require self-motivation and internal cues in the absence of 
cognitive failure and motor weakness (Chaudhuri and Behan, 2000). Fatigue is 
commonly associated with sickness behaviour associated with infections, 
inflammatory conditions and also as a part of depressive illness (Capuron and 
Miller, 2011).  
FACIT scores correlated with BDI scores and Pain. However, this did not reach 
statistical significance. Similarly, BDI scores correlated with pain scores. The 
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correlations suggest that they were associated, however, not fully explained by 
each other. Similarly inflammatory markers did not correlate significantly with 
BDI scores, Pain scores or Fatigue scores, suggesting that disease activity as 
measured using these inflammatory markers, did not significantly predict these 
clinical variables. It should be noted that circulating inflammatory markers have 
been shown to serve as a good measure of disease severity in both psoriasis with 
and without arthritis (Beygi et al., 2013, Dowlatshahi et al., 2013, Enerback, 
2011, Fitzgerald and Chandran, 2012, Strober et al., 2008) 
Although central serotonergic pathways have been linked to fatigue, the 
literature is not very clear about the relationship between the two. Studies in 
humans suggest that central fatigue correlates with an increase in serotonin in 
the CNS. This is somewhat counterintuitive, as 5HT is thought to boost the 
activity of motor neurons in the CNS.  
Cotel et al suggest that the central component of the fatigue induced by 
serotonin is thought to be mediated by serotonergic 5HT1A receptors present in 
the axon initial segments (AIS) of the motor neurons(Cotel et al., 2013). They 
showed that focal activation of these receptors, led to inhibition of the action 
potential in the motor neurons. However, they also found that the AIS segments 
are not innervated by 5HT neurons. They found that the activation of AIS 5HT1A 
receptors occur only on repeated stimulation of the raphe nuclei, which leads to 
a spill over effect of excess serotonin into the AIS regions. In general, they 
suggest that during low activity, 5HT promotes the excitability of motor neurons, 
but during prolonged activity, this can lead to a spill over effect on the AIS, 
leading to greater fatigue (Cotel et al., 2013).  
However, not all studies are consistent with this theory. The effect of cytokines 
on the relationship between serotonin and fatigue was recently examined by 
Katafuchi et al (Katafuchi et al., 2006). They showed that induction of fatigue by 
intraperitoneal injection of poly I:C in rats, led to an increase in interferon alpha 
expression in the brain and an increase in 5HTT expression. This was directly 
related to a reduction in serotonin levels in medial prefrontal cortex. This was 
shown to be linked to fatigue in these rats. In addition, they showed that a 
5HT1A agonist reversed the fatigue in these rats. Our findings resonate with that 
of Katafuchi et al, in that we found an association between inflammation and 
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SERT and fatigue, and treatment with anti-TNF-α  agent led to a reduction in 
fatigue. However, it is not clear whether the reduction in fatigue was part of a 
general improvement in mood, or an independent reduction. Although the 
correlations did not reach statistical significance, there seems to be significant 
overlap between the two.  
In summary,  I have shown a significant association between circulating TNF-α  
and central SERT levels. Greater circulating TNF-α  was associated with greater 
SERT. In addition, the greater SERT levels mediated the relationship between 
inflammation and depression scores (but not fatigue or pain scores). Treatment 
with Etanercept was associated with a reduction in SERT levels. Future 
experimental studies will explore the relationship between inflammation and 
SERT in those who are being treated with interferons or LPS.  
Chapter 8  211 
 
8 Chapter 8 – General Discussion  
 
In this chapter, I will first summarise the findings of all the above chapters. Then 
I will discuss findings of recent studies that have explored the relationship 
between circulatory inflammatory markers in the context of mental illnesses.  
8.1 Summary of findings presented in this thesis 
In the first chapter, I reviewed the literature proposing an association between 
circulating inflammatory markers and the brain that may contribute to the 
pathophysiology of major mental illnesses, particularly major depressive 
disorder. I discussed findings from preclinical and clinical studies that suggest 
psychiatric illnesses, particularly major depressive disorder, are associated with 
inflammatory processes. Here I discussed that there is now evidence to suggest 
that inflammation may play a subtle role in the pathophysiology of major 
depressive disorder. Most of the evidence that links inflammation to major 
depressive disorder comes from three observations - a) one third of those with 
major depression show elevated peripheral inflammatory biomarkers, even in 
the absence of a medical illness; b) inflammatory illnesses are associated with 
greater rates of major depressive disorder; c) patients treated with cytokines 
are at greater risk of developing major depressive illness. I explored theoretical 
mechanistic pathways through which inflammatory mediators have been found 
to affect various substrates thought to be important in the aetiopathogenesis of 
major depressive disorder. These included an altered monoamine (serotonin and 
dopamine) and glutamate neurotransmission, glucocorticoid receptor resistance 
and adult hippocampal neurogenesis. At a higher level, I discussed how 
inflammation might affect brain signalling patterns, cognition and the 
production of a constellation of symptoms, termed “sickness behaviour”.  I 
discussed findings, which suggest, how inflammation may play a role in the 
aetiology of depression, at least in a “cohort” of vulnerable individuals. I 
discussed potential pathways through which inflammation may contribute to the 
development of major mental illness in high-risk conditions - socioeconomic 
deprivation and general medical conditions. Both these conditions have been 
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associated with greater inflammation, and greater psychiatric morbidity, 
particularly major depressive disorder.  
In the further chapters, I went on to present findings pertaining to observational 
analyses of the relationship between circulating inflammatory markers and 
structural MRI of the brain.  
In chapter 3, I presented the results of my first observational analysis. I aimed to 
explore the relationship between cardio-metabolic risk factors and cortical 
thickness in a neurologically healthy middle aged population-based sample. T1-
weighted MRI was used to create models of the cortex for calculating regional 
cortical thickness in adult males, selected from the PSOBID study. I examined 
the association between cardio-vascular risk markers – classic risk markers like 
BMI and lipid markers, and “emerging” markers like inflammatory markers - and 
cortical thickness across the whole brain, using the general linear model. I found 
that greater C reactive protein (CRP) and Intercellular adhesion molecule (ICAM-
1) levels were associated with cortical thinning pertaining to perisylvian regions 
in the left hemisphere.  
In chapter 4, I extended my findings from chapter 3. I examined if greater 
inflammatory markers mediated the relationship between neighbourhood 
deprivation (a high risk condition for mental illnesses) and the brain. I first 
compared the cortical morphology of neurologically healthy adult men from the 
least deprived and most deprived neighbourhoods of Glasgow.  I demonstrated 
that the most deprived group had significantly smaller left posterior parietal 
cortex surface area and fusiform cortex surface area. They also had thinner left 
Wernicke’s area and its right homologue. I then used mediation analysis to 
demonstrate that a composite factor comprised of circulating inflammatory 
markers mediated the relationship between neighbourhood deprivation and 
cortical thickness pertaining to the Wernicke’s area. Here, I provided some 
preliminary evidence for a mechanistic pathway that may explain the 
relationship between neighbourhood-level socioeconomic deprivation and the 
brain.  
In chapter 5, I used complex network analysis using graph theory to explore the 
relationship between neighbourhood deprivation, inflammation and the 
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structural properties, of cortical thickness covariance brain networks in the 
above sample. The premise of the analysis was that complex cognitive functions 
are widely recognized to be the result of a number of brain regions working 
together as large-scale networks. Here, I aimed to examine the association 
between neighborhood level deprivation and brain network structure 
(organisation) – modularity and grey nodes. I compared the structural properties 
of cortical thickness covariance networks derived from the  same groups as 
described in chapter 4.  I demonstrated that for a given number of modules, 
networks derived from the least deprived group had stronger modules and had 
greater proportion of  grey nodes – a measure of overlapping modular structure. 
In other words, the structural organization of the cortical covariance brain 
networks from the least deprived group was consistent with a more robust and 
efficient information processing system compared to that of the least deprived 
group. More interestingly, I  demonstrated  that once the cortical thickness 
covariance networks were constructed after accounting for differences in 
circulating inflammatory markers, the difference in structural properties of 
between the groups disappeared. In other words, the structural difference was 
driven by differences in inflammatory markers. This is a novel finding, and one 
of the first studies to show an association between socioeconomic deprivation 
and brain network structure. In addition, I suggest that differences in circulating 
inflammatory markers may drive the difference in network structure in the most 
deprived group.  
In chapter 6, I examined the potential pathways that mediate the relationship 
between socioeconomic deprivation and limbic stress pathways. Here, using the 
same sample as in the previous chapters, I investigated whether neighbourhood-
level deprivation was associated with volumetric differences in a group of limbic 
forebrain structures -hippocampus, amygdala and medial prefrontal cortex - 
implicated in the top-down regulation of the stress response. I demonstrated 
that greater neighbourhood deprivation was associated with smaller grey matter 
volumes in the right hippocampus and right ventromedial and orbitofrontal 
cortices. I also showed that  circulating inflammatory markers mediated the 
relationship between neighbourhood-level deprivation and the right 
ventromedial and orbitofrontal cortex volumes, but not hippocampal volumes. I 
discussed how  inflammatory pathways  may serve as a potential mechanism 
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underlying  the theory of biological embedding of adverse physical and social 
environments.  
In chapter 7, I presented the findings of an experimental study that explored the 
relationship between circulating inflammatory markers and serotonin transporter 
in the brain.  The rationale for the analysis was the findings from a number of 
preclinical studies that have shown a direct relationship between inflammatory 
markers and serotonin transporter in the brain. Of particular interest in this 
analysis was the trafficking dependent mechanisms mediated through MAPK 
dependent pathways. I explored the relationship between circulating 
proinflammatory cytokines and serotonin transporter availability in the midbrain 
of 12 patients with psoriasis/psoriatic arthritis. In  a group of patients suffering 
from psoriasis / psoriatic arthritis, I demonstrated  that those who had greater 
circulating TNF-α  had greater midbrain serotonin transporter availability. 
Although circulating TNF-α accounted only for a very small variance in 
depression scores, I found that the relationship between TNF-α and depression 
scores was mediated by greater serotonin transporter availability. In the next 
step of the analysis, I demonstrated that experimentally blocking the action of  
TNF-α  (using Etanercept) was associated with a reduction in SERT availability. 
Here, I present some of the first evidence that show an association between 
inflammatory markers and SERT availability in humans. These findings provide a 
mechanistic pathway through which inflammatory pathways contribute to the 
pathogenesis of depression.  
8.2 Limitations of the studies 
With regards the findings from the observational study (chapter3,4,5 and 6), 
while the positive feature of the study was that I examined a well-characterized 
community based cohort, there are a number of limitations to be acknowledged.  
The cross-sectional design means that causal inferences cannot be made. This is 
firstly true with regards the relationship between socioeconomic deprivation and 
cortical parameters. While theoretically it is possible that greater deprivation, 
due to various adverse factors associated with it, led to changes in cortical 
parameters, it could be argued that differences in cortical parameters were 
present even before the exposure to neighbourhood deprivation. Longitudinal 
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studies are required to see if these differences are present early in life, and 
whether they progress over the life course. Indeed, some of the recent 
longitudinal studies have confirmed an effect of childhood poverty on the brain 
and cognitive functioning in adulthood (Evans and Schamberg, 2009, Kim et al., 
2013). This limitation is also crucial when considering the association between 
inflammation and cortical thickness. For example, throughout the literature 
review and discussions, I have made the assumption that inflammation drives the 
cortical/ subcortical parameters. However, such a causal assumption is rather 
speculative. Theoretically, even though this may be the direction of causality, 
the direction could be the other way. For example, cortical parameters can 
control inflammatory markers. It is known that the "inflammatory reflex", 
central autonomic networks and the stress (HPA axis) can have a significant 
impact on circulating inflammatory markers (Olofsson et al., 2012, Ulrich-Lai 
and Herman, 2009). Therefore, it is possible that cortical thickness/ volumes 
pertaining to a number of regions in the brain may influence circulating 
inflammatory markers. Even if we assume a direct effect of circulating 
inflammatory markers on cortical parameters, it is not clear how these changes 
are signalled. Potential pathways have been discussed in the introduction 
chapter, however, data from human studies are lacking (Capuron and Miller, 
2011). Therefore, a number of questions remain. Do circulating inflammatory 
markers provide a good marker for central markers? At least in humans the 
relationship does not seem to be straight forward.  
The observational study, reported in chapters 3, 4, 5 and 6 included only males. 
The rationale behind this was to decrease variability in cortical thickness that 
could be attributable to gender (Sowell et al., 2007). Similarly, cardio-metabolic 
risk factors co vary significantly with gender.  In the prospective multi-ethnic 
study of atherosclerosis, inflammatory markers like CRP levels have been found 
to be significantly higher in women compared to men. This gender difference 
was present even after taking into account BMI and oestrogen use (Lakoski et al., 
2006).  Similarly, during the third and fourth decade of life, cholesterol levels 
show a sharper increase in men than in women. In addition, the same 
cardiovascular risk factors may impact differently on men and women. For 
example, HDL cholesterol and Triglycerides have been found to have a greater 
impact on cardiovascular disease risk in women compared to men (Roeters van 
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Lennep et al., 2002). However, this meant that the findings of the study are less 
generalisable to the population. The parent study – PSOBID - was designed to 
explore the differences in a number of biomarkers between the least and most 
deprived groups with the greatest power(Velupillai et al., 2008) . Therefore, the 
nature of the sampling technique used for recruiting subjects led to a bimodal 
distribution of a number of independent variables used in this study. Indeed, the 
mean cortical thickness (contributed by the DV) was normally distributed. 
Nevertheless, a sampling technique with equal distribution from all 
socioeconomic status with a larger sample size may have been more 
appropriate, in order to explore a dose dependent relationship between cardio-
metabolic risk markers and cortical thickness.  
In chapter 3, with regards multiple testing correction, we used a cluster wise 
approach when examining the relationship between risk markers and cortical 
thickness. This approach has been validated and used in recent studies exploring 
variance in cortical thickness.(Ehrlich et al., 2012, Leritz et al., 2011) We opted 
for this approach, as the primary aim of the study was to look for any evidence 
for a “signal” in the cortex that could be attributable to the risk markers. For 
this, a cluster wise approach was thought to be sensitive and 
appropriate.(Poldrack et al., 2011) In this study, I was not primarily interested in 
the spatial specificity or location of the significant clusters, and hence did not 
opt for a voxel wise approach. While this is not a limitation per se, when I 
repeated the analysis using a voxel wise FDR (0.05) approach for multiple testing 
corrections, none of the above regions survived the FDR correction. In other 
words, the test statistic at none of the voxels crossed the required significance 
threshold after multiple testing corrections using the FDR procedure. This could 
be either due to the small sample size or may be because the association 
between the risk markers and the cortical thickness is spread across a large area 
of the cortex, but the magnitude of the relationship is modest at best.  Previous 
cross sectional studies suggest that cerebrovascular disease may mediate the 
relationship between cardiovascular risk factors like diabetes and hypertension 
and cortical thickness in cognitively impaired individuals. (Seo et al., 2012a, Seo 
et al., 2012b) It is therefore possible that the relationship between high CRP and 
ICAM and cortical thinning in our study was mediated by the presence of 
cerebrovascular pathology. None of our participants showed significant 
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pathology on the scans. Moreover, the small sample size and the cross sectional 
nature of our data precludes us from making any meaningful conclusions 
regarding the role of causal mediation or mediators pertaining to 
cerebrovascular pathology. In addition, greater LDL and TAG factor levels 
(generally associated with greater cardiovascular risk) were associated with 
greater cortical thickness. It is unlikely that this relationship was mediated by 
cerebrovascular pathology in our sample.  
The sample size of the observational studies were relatively small. This may 
have led to potential type 2 errors. For instance, in chapter 4 and 6, a number 
of comparisons that had an effect size traditionally considered to be medium to 
large did not survive multiple testing corrections. It is possible that studies with 
greater power would have identified many of these relationships as statistically 
significant. It should however be noted that the groups did not differ in global 
measures of cortical morphology. In addition, the direction of relationship 
between SES and cortical morphology was not always consistent. For example, 
although the right posterior parietal SA was significantly smaller in the most 
deprived group, the posterior parietal cortical thickness was greater (not 
statistically significant) in the most deprived group. While this finding is in 
keeping with Hogstrom et al who observed a negative correlation between 
cortical thickness and surface area throughout the life span, these findings 
suggest that cortical morphology is indeed a complex construct and that the 
relationship between SES and the cortex could be differential in terms of 
morphology and direction of relationship (Hogstrom et al., 2012). 
While the use of an extreme sampling technique led to a bimodal distribution of 
most of the variables, the mean cortical thickness (the dependent variable) did 
not differ between the SES groups. Therefore, the assumptions of a GLM analysis 
were not violated. However, most independent variables differed between the 
two  deprivation groups. This may have led to an inflation of effect sizes in the 
observational studies (chapter 3,4,5 and 6). Extreme group sampling (as in the 
observational studies) may have potential effects on the significance, reliability 
and generalizability of the true effects of interest(Gianaros and Hackman, 
2013).In addition, small samples can affect the statistical power to detect 
between-individual effects, especially when multiple comparisons are used.  
Yarkoni et al in a recent review, suggest that a combination of small sample size 
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and stringent alpha thresholds may inflate the effect sizes of relationships 
(Yarkoni, 2009).This is a limitation of our study. Future studies exploring these 
relationships should include larger sample sizes, and include participants from 
all socioeconomic classes. 
With regards the limbic stress networks,  given the lack of information on any 
experience of childhood trauma or other individual significant life event, which 
has been reported to be associated with hippocampal atrophy (McCrory et al., 
2010), I cannot exclude that these individual stressful life events may be partly 
account for the finding. So, for example, the relationship between 
neighbourhood deprivation and hippocampal and orbitofrontal cortex volumes 
could be because those from the poorest neighbourhood are at greater likelihood 
of experiencing life greater life events. Indeed, there is evidence to show that 
individual life events may explain variance in hippocampal volumes even after 
accounting for socioeconomic status (Teicher et al., 2012). I did not explore the 
components and pathways within the construct of SES that could have explained 
the variance in cortical parameters. The main aim of my thesis was to explore 
the relationship between circulating inflammatory markers and cortical 
parameters. In the context of SES, my analysis emphasised what I thought was 
the most proximal (biologically closest to cortical parameters) biomarker (i.e. 
circulating inflammatory marker) that could mechanistically account for the 
relationship between SES and the brain. With regard to the specificity of 
structural brain changes to neighbourhood-level SES, it has been argued that 
without controlling for individual socioeconomic variables, neighbourhood-based 
socioeconomic measures serve to proxy for unmeasured aspects of individual 
socioeconomic characteristics (Geronimus and Bound, 1998). Nonetheless, 
another view posits that measures of neighbourhood-level SES may be a more 
stable marker of lifelong accumulated wealth then early and adult individual-
level SES (Oakes, 2004).  
 Three subjects from the most deprived group and 1 person from the least 
deprived group were prescribed psychotropic medications during their lifetime. 
Although it can be argued that mental illness and its treatment are components 
of deprivation, removing these individuals from the analysis did not change the 
findings in chapters 3,4,5 and 6. None of our participants were acutely medically 
unwell, nor had they undergone recent surgery. However, those with chronic 
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physical illnesses (other than neurological conditions) were not excluded. This 
may have contributed to significant variance in inflammatory and cardiovascular 
markers. The small sample size meant that stratifying the sample further to 
examine these effects was not possible (Nicol et al., 2012).   
There are a number of methodological challenges when exploring the 
relationship between SES and the brain. Hackman and Farah have enumerated 
these in a recent review(Hackman and Farah, 2009). Of particular concern is the 
separation of what constitutes confounding factors and what constitutes 
mediators of the effect of SES. For example, in our study, we considered  
inflammatory markers as mediators of the effects of SES on the brain. However, 
we did not explore the effects of alcohol use or cigarette smoking. It is very well 
know that alcohol and cigarette smoking can have an effect on cortical thickness 
and subcortical volumes (dependent variable). It is also known that alcohol use 
and cigarette smoking can covary significantly with SES (the independent 
variable). In addition, these factors may potentially lie in the causal pathway 
linking SES to brain structure. Miller and Chapman suggest that when comparing 
groups, including variables that covary with the independent variable (SES in our 
case) may be inappropriate (Miller and Chapman, 2001). It is therefore 
imperative to decide which of these factors are mediators and which are 
confounding factors. In addition to this, many potential mediators covary with 
each other, and it is difficult to separate out the effect of individual mediators. 
Another potential problem is sample selection. Do we include participants with 
physical and mental ill health in our sample? This is of particular concern, as we 
know that physical and mental ill health covaries significantly with SES (Srireddy 
et al., 2012). While excluding may increase the internal validity of the study, 
excluding these participants would decrease the external validity and 
generalizability of our findings(Hackman and Farah, 2009). Exploring the effect 
of confounding factors also requires large sample sizes.  
The experimental study, presented in chapter 7, also had a small sample size. I 
calculated the required sample size based on the relationship between TNF-α  
blockade and SERT availability. However, the small sample size may have led to 
reduced power in calculating the correlations between circulating inflammatory 
markers and SERT. However, it should be noted that the presence of an 
association even with small numbers suggests that these results may be non-
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trivial. Perhaps more importantly, a limitation of this study was the absence of a 
control subject group. Firstly, a healthy control group that is matched for age 
and sex would have enabled us to compare SERT availability in 
psoriasis/psoriatic arthritis patients, with that of healthy controls at baseline. 
Although we showed an association between TNF-α and SERT availability in the 
patient group, we do not know if the relationship will be present in the healthy 
population. Our group was a mixed group consisting of PS and PSA patients who 
had quite severe illness and were going to be treated with etanercept, hence, 
these effects may not be generalised to those with a milder illness or to the 
general population. This is important, as TNF-α often exerts its effect in an 
inverted U shape fashion. Therefore, while an adequate level of TNF-α may be 
necessary for normal functioning, a lower or greater than normal level may be 
detrimental. However, administering Etanercept to healthy controls would have 
been both ethically and clinically difficult. A second possible control group 
would have examined the role of a placebo or another anti-inflammatory 
medication, firstly to see if the reduction in SERT is significantly greater than 
that would have achieved with placebo and also to see if the effect was specific 
to TNF-α blockade, compared to other antiinflammatory drugs/ SSRIs. Technical 
difficulties prevented us from completing the originally intended study of 
examining the effect of other disease modifying agents. Although Beta CIT has 
been used and validated in examining the SERT, there are better ligands now 
available that are more selective for SERT.  
I refer to the study presented in chapter 7 as "experimental", as there was 
manipulation of circulating inflammatory markers - using TNF-α blockade- to 
demonstrate changes in SERT availability. Here, I attempted to show a direction 
of causality. That is a direction from circulating inflammatory markers to central 
SERT.  However, this does not rule out a bidirectional relationship. In other 
words, central SERT can in turn have an effect on circulating inflammatory 
markers. For example, previous research has shown that 5HT2A receptor 
activation suppresses TNF-α induced inflammation with extraordinary potency 
(Yu et al., 2008). Another concern is whether the change in SERT availability was 
an epiphenomenon, rather than a direct effect of the manipulation of circulating 
inflammatory markers. Although treatment with Etanercept was associated with 
a reduction in SERT and improvement in mood, it should be noted that 
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inflammation and pain, also significantly improved with the treatment. It could 
therefore be argued that rather than there being a direct relationship between 
reduction in inflammation and reduction in SERT, the reduction in SERT was an 
epiphenomenon associated with improvement in the pain and the physical 
condition, thereby improving mood. It should be noted that we showed a 
significant association between TNF- α and SERT levels at baseline. This is very 
much in keeping with preclinical studies.   
It should also be noted that neither the reduction in pain, nor the reduction in 
CRP (a measure of disease activity) correlated significantly with the reduction in 
SERT. It should also be noted that the relationship between SERT and other 
markers of inflammation were not significant at baseline, suggesting that the 
relationship may have been unique to TNF-α, at least in my sample. However, it 
was not meaningful to examine the relationship between change in TNF-α and 
change in SERT, as the assay measured both active and inactive TNF-α in 
circulation, and therefore, would have not given a good picture of the 
relationship. Interestingly, although there was a reduction in SERT availability 
following TNF-α blockade, there was no association between reduction in 
inflammation and reduction in SERT availability. This could also be due to the 
fact that most circulating inflammatory markers did not show a reduction 
following treatment with etanercept. Only hsCRP showed a reduction. However, 
CRP levels did not significantly correlate with SERT even at baseline. Therefore, 
it is not surprising that change in CRP was not associated with changes in SERT. 
Interestingly, greater baseline TNF-α and IL1B also showed an association with 
greater SERT post treatment. This is in keeping with the fact that these two 
cytokines did not show significant reductions with treatment with etanercept. 
8.3 Update on research 
Since the start of this PhD project, a number of studies have examined the 
relationship between inflammation and depression. In this section, I will provide 
a brief and selected update. Firstly, I will review an update on the relationship 
between inflammatory markers and major mental illness/brain (explored in 
chapters 3,4, 5 and 6). Secondly,   I will review research that has added 
evidence for the use of TNF-α blockade in the treatment of potential major 
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mental illness and if there is a potential for inflammatory markers to help 
stratify major depressive disorder, in terms of treatment response. 
8.3.1 Relationship between inflammation and major mental illness  
As presented in the review of literature, a number of individual studies, and at 
least 3 meta-analyses of cross sectional studies have shown an association 
between raised circulating inflammatory markers (CRP and proinflammatory 
cytokines) and major depression (Dowlati et al., 2010, Howren et al., 2009, Liu 
et al., 2012a). In addition to the traditional circulating markers of inflammation 
- CRP and cytokines, recent studies have also examined the role of other 
potential markers of inflammation, and depression. For example, Naude et al 
examined the determinants of plasma neutrophil gelatinase-associated lipocalin 
(NGAL) - a protein thought to be a neuro-inflammatory marker that is triggered 
by TNF-α 1 receptor signaling (Naude et al., 2013).  They examined plasma 
levels of NGAL in older patients who are depressed. They found that depressed 
patients had significantly higher NGAL compared to healthy controls. They also 
found that those who had partially remitted had lower levels of NGAL and those 
with a history of recurrent depression had greater levels, compared to those who 
had just one episode. These levels were not affected by antidepressant 
medication or age of onset. Heringa et al examined the relationship between a 
composite score of serum inflammatory markers including CRP, SAA, IL6, IL8, 
TNF-α, ICAM and MPO on cognitive function in people aged 50 and 75 years 
(Heringa et al., 2014). They found that the composite measure of inflammation 
predicted poor cognitive function including information processing speed, 
attention and executive function, cross-sectional and prospectively. 
Although a number of classic and new inflammatory markers have been linked 
cross-sectionally to depression,  the question remains as to whether there is a 
causal relationship between raised inflammatory markers and major depression 
or even a subset of the syndrome. A few prospective studies have directly 
examined the relationship between depressive symptoms and inflammation. 
However the results are not conclusive. For example, Gimeno et al, using the 
Whitehall II study cohort (around 3000 participants), examined if inflammatory 
markers (IL6 and CRP) measured at baseline predicted cognitive symptoms of 
depression eleven years later (Gimeno et al., 2008, Gimeno et al., 2009). They 
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found that after adjusting for sociodemographic, behavioural and biological risk 
factors, health condition, medication use and baseline depressive symptoms, 
both IL6 and CRP predicted cognitive symptoms at follow up. However, in a more 
recent study, Stewart et al, examined the longitudinal associations between 
depressive symptoms and inflammatory markers (IL6 and CRP), in 263 healthy 
older men and women, over a period of 6 years (Stewart et al., 2009). They 
found that baseline BDI scores predicted changes in IL6 after 6 years. However, 
baseline IL 6 levels did not predict 6 year change in BDI scores. They concluded 
that depressive symptoms may precede and augment inflammatory processes, 
and that this may be a potential pathway through which depression may 
contribute to increased cardiovascular risk.  
In order to reach a consensus, Valkonoya et al undertook a systematic review of 
longitudinal studies  (including the study by Stewart et al) to investigate 
whether raised circulating inflammatory markers - CRP and IL6- was indicative of 
the development of subsequent depressive symptoms (Valkanova et al., 2013). 
They examined the relationship between CRP and IL6 on the subsequent 
development of depressive symptoms. They found a significant association 
between CRP and depressive symptoms at follow up (adjusted r=0.05). The 
relationship at best was thought to be modest (yet significant). As shown in 
Table 8-1, their results suggested that raised inflammatory markers precede the 
development of depressive symptoms. However, the pathways that lead from 
inflammation to depression remain unclear. It still remains unclear if circulating 
inflammatory markers represent an association, a  mediating or a causal factor 
for depression.  The relationship between circulating inflammatory proteins and 
those in the brain is also opaque. Their study also found moderate degree of 
heterogeneity among studies as well as some level of publication bias, suggesting 
that negative studies may have been under-reported. Once again, most of the 
studies examined depressive symptoms using validated scales, and not a 
structured clinical interview to diagnose major depression. This leaves us with a 
question if there are specific symptoms that are predicted by greater 
inflammation.   
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Table 8-1:  Meta-analysis of longitudinal studies examining relationship between circulating 
inflammatory markers and depression. 
 
Sub 
groups 
N 
studies 
Correlation 
(weighted mean 
mixed effects 
model) 
95% CI  
 p-value Heterogeneity 
     
Q-
value 
p-
value 
I-
squared 
CRP 
 
6 
0.069  
(0.036 - 0.103) <0.0005 19.23 0.002 74 
CRP* 
 
7 
0.046  
(0.021 - 0.07) <0.0005 11.22 0.08 46.5 
 
old 3 
0.079  
(0.012 - 0.144) 0.02 5.7 0.06 64.89 
 
young 4 
0.03  
(0.01 - 0.05) 0.003 3.19 0.36 6.09 
IL-6 
 
2 
0.045  
(0.013 - 0.078) 0.007 0.54 0.46 0 
IL-6* 
 
3 
0.097  
(-0.005 - 0.198) 0.06 5.2 0.08 61.37 
CRP—C-Reactive protein; IL—6-Interleukin-6; * fully adjusted (e.g. body-mass 
index, smoking, use of medication, chronic illness etc.). 
The weighted-mean effect sizes of studies and measures of heterogeneity of meta-analysis 
of longitudinal studies that have examined the relationship between raised circulating 
inflammatory markers and depression in longitudinal studies (Reused with permission from 
Valkanova, et al. CRP, IL-6 and depression: A systematic review and meta-analysis of 
longitudinal studies. Journal of Affective Disorders, Volume 150, Issue 3, 25 September 
2013, Pages 736–744) 
 
More recent studies have tried to examine whether the link between 
inflammatory markers and depression are driven by somatic symptoms of 
depression. Considering that low-grade inflammation is perhaps a link between 
depression and adverse outcomes in a number of medical conditions, Duivis et 
al, explored if the association with inflammatory markers were primarily driven 
by the somatic symptoms of depression and anxiety (Duivis et al., 2013). In a 
cohort of 2861 participants from the Netherlands Study of Depression and 
Anxiety, they examined if there was a differential association of somatic and 
cognitive symptoms of depression with inflammation. They used linear regression 
to examine the association between circulating inflammatory markers – CRP, IL6 
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and TNF-α . They found that the association between inflammatory markers and 
depressive symptoms were indeed driven by the somatic symptoms.  
While all the studies mentioned above examined the association between 
circulating inflammatory markers and depression, few studies have examined 
CSF cytokine variations associated with depressive illness in humans. This of 
course is difficult to examine. More than a decade ago, Levine et al (1999) 
examined CSF concentrations of cytokines in 13 un-medicated patients admitted 
with acute depression (Levine et al., 1999). Compared to a healthy control 
group, they found that those with depression had greater IL1B, but lower IL6 
levels. They found no difference in TNF-α levels.  Lindqvist et al more recently 
showed increased CSF IL-6 levels in suicide attempters compared to healthy 
controls (Lindqvist et al., 2009). They also found a significant association 
between IL6 levels and severity of depression (MADRS scores). What was most 
interesting in this study was that the authors did not find any association 
between CSF and plasma cytokine levels. This finding is in keeping with Lampa 
et al who found that patients with rheumatoid arthritis had greater levels of CSF 
IL1B compared to serum levels (Lampa et al., 2012). A fourth more recent study, 
Martinez et al, found no difference in CSF levels of inflammatory cytokines (IL1, 
IL6 and TNF-α a) between patients with depression and healthy controls. 
Interestingly they found that CSF IL1 levels correlated with a history of suicide 
attempts (r=0.53) (Martinez et al., 2012).  
While the above studies have measured cytokines in the CSF, even fewer have 
directly measured cytokine expression in human brain. Dean et al examined if 
TNF-α was altered in the frontal cortices from 10 subjects with major depressive 
disorder and control subjects (Dean et al., 2010). They measured 
transmembrane and soluble TNF-α from the post-mortem tissue homogenates 
from the left hemisphere. They found that transmembrane TNF-α was 
significantly increased in BA 46 of people who had a history of depression. 
Similarly Shelton et al examined the gene profiles of cytokines in BA 10 from 14 
subjects who had a history of major depressive disorder (Shelton et al., 2011).  
They found an up-regulation of a variety of pro- and anti-inflammatory cytokines 
in the region of interest. Steiner et al examined microglial HLA-DR expression 
using immunohistochemistry in the dorsolateral prefrontal cortex (DLPFC), 
anterior cingulate cortex (ACC), mediodorsal thalamus (MD) and hippocampus of 
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16 patients with schizophrenia, 14 with affective disorder and 10 matched 
healthy controls(Steiner et al., 2008). In addition, they included a subgroup of 
six patients with schizophrenia and seven patients with affective disorders who 
had committed suicide. While diagnosis was not associated with microglial 
density, suicide was associated with significant microgliosis in the DLPFC, ACC 
and thalamus. They claimed that this may represent pre-suicide stress, a causal 
link between the microglial activation and suicide remains speculative at best.  
A few observational and experimental studies have examined the relationship 
between inflammation, depression and the brain using PET. Hannestad et al in 
their first study,  showed that systemic inflammation induced by endotoxin in 
humans was associated with higher normalised glucose metabolism in the insula - 
a region thought to play a major role in inflammatory interoceptive pathways as 
well as key role in the central autonomic network (Hannestad et al., 2012b). 
This change was associated with change in peak cytokine levels and also changes 
in social interest, suggesting that these may be linked to each other (Hannestad 
et al., 2012b). Insula is also thought to play a key role as an outflow hub that 
sends control signals that activate frontoparietal networks in response to salient 
stimuli. These stimuli interestingly may be external (visual/auditory) or internal 
(interoceptive) stimuli. Deficient activation of insula has been shown in a recent 
meta-analysis of functional MRI studies of people with depression (Hamilton et 
al., 2012). More interestingly, the crucial role of insula as a biomarker of 
prediction of response was shown by McGrath et al, who found that reduced 
insula hypometabolism (relative to whole-brain mean) measured using FDG PET 
was associated with remission to cognitive behaviour therapy and poor response 
to escitalopram, while increased metabolism in the insula was associated with 
remission to escitalopram and poor response to cognitive behaviour therapy 
(McGrath et al., 2013).  
Hannestad et al, using PET, for the first time showed that systemic inflammation 
induced by LPS was associated with increased binding of TSPO ligand [11C]PBR28 
in the brains of baboons (Hannestad et al., 2012a). They found that the increase 
in [11C]PBR28 binding 4h after LPS administration correlated with serum IL-1β 
levels at 2hours and with IL-6 and TNFα levels at 3 hours. They also found in the 
increase in [11C]PBR28 expression occurred mostly in the microglia. Although 
experimental studies that induce an inflammatory state have found an 
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association between circulating inflammatory markers and neuronal activity in a 
number of regions implicated in depression, and depressive symptoms, the 
studies in major depression have not found consistent results (Capuron et al., 
2012). For example,  Hannestad et al, used positron emission tomography (PET) 
with [¹¹C]PBR28, to compare the level of TSPO between 10 individuals with mild 
to moderate depression and 10 healthy control subjects, matched for TSPO 
genotype (Hannestad et al., 2012a). They found no statistically significant 
difference in [¹¹C]PBR28 binding (VT) between the two groups. In fact, 7 of 10 
individuals with depression had lower [¹¹C]PBR28 binding in all the regions of 
interests compared to the control subjects.  
8.3.2 Anti-inflammatory medications (including TNF-α blockade 
agents) as a therapeutic option for major depression 
Given the numerous links that have been shown to exist between inflammation 
and depression, it would be reasonable to surmise that treatments with anti-
inflammatory agents may be beneficial in depression. There is tentative 
evidence that anti-inflammatory agents have antidepressant properties.  
A number of recent animal studies have shown that TNF-α blockade is associated 
with improvement in depressive phenotype. Using a rat model of depression 
(repeated restrained stress), Krugel et al showed that treatment with etanercept 
significantly reduced the depression like behaviour induced by the repeated 
restrained stress. The effect was similar to that of imipramine, and significantly 
greater than that induced by ringer solution (Krugel et al., 2013). Karson et al 
examined the effect of infliximab in a chronic mild stress (CMS) model of 
depression in rats (Karson et al., 2013). They divided rats into three groups no 
stress, saline-CMS and infliximab-CMS. The latter two groups, which were 
exposed to CMS for eight weeks, were either administered saline or infliximab 
concomitantly during the eight-week period. After the eight week period, they 
found that the infliximab treated rats had decreased depression-like behavior 
compared to the saline treated group. Similarly, Bayramgurler et al examined 
the effect of Etanercept treatment on anxiety and depression-like behavior in 
rats (Bayramgurler et al., 2013). They found that etanercept significantly 
decreased immobility time as assessed with elevated plus maze and forced swim 
test. Their data suggest that etanercept treatment reduced the anxiety and 
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depressive-like behavior in rats even in the absence of chronic inflammation or 
stressful condition.  
In humans, specifically, TNF-α blocking agents have been shown to improve 
mood, independent of improvement in the inflammatory condition. One of the 
first evidence is by Tyring et al who found that 55% of patients with psoriasis 
who were treated with etanercept showed a 50% reduction in Beck’s depression 
inventory (BDI) scores compared to 39% on placebo, an effect-size comparable to 
antidepressants (Tyring et al., 2006). This improvement was found to be 
independent of improvement in psoriasis. Since then a few studies have explored 
this, which I have reviewed in chapter 7 (Table 7-12).  
In a placebo controlled double blind cross over trial of 18 abstinent alcohol 
dependent male adults, Irwin et al found that a single dose of etanercept 25 mg 
produced significant decrease (normalisation) in the amount and percentage of 
REM sleep (Irwin et al., 2009). They also found that circulating concentration of 
soluble TNF-α receptor II, obtained 24 hours after the drug administration, 
correlated negatively with the percentage of REM sleep. They conclude that 
their data is consistent with the hypothesis that circulating TNF-α  may have a 
physiological role in the regulation of REM sleep in humans, and that 
pharmacologically blocking the effects of TNF-α may lead to the normalisation of 
REM sleep in abstinent alcohol dependent patients. They suggest that the sleep 
disturbance in alcohol use disorder may be due to ethanol induced production 
and release of TNF-α  into the circulation. This in turn, leads to rapid increase in 
the expression of brain TNF-α , which is then sustained in the brain, that leads 
to the sleep problems. However, what is not clear is, why do these patients have 
persistent increase in sleep disturbance even after abstinence from alcohol?  
One explanation is that the increase in brain expression of TNF-α  is sustained. If 
that is so, how could etanercept ( a large molecule that does not cross the blood 
brain barrier) have an effect on TNF-α  in the brain.  
In short, how peripherally administered Etanercept or any TNF-α blockade could 
cause changes in inflammation in the CNS is not clear. Bearing in mind that MDD  
is primarily an illness of the central nervous system, how these drugs bring about 
their antidepressant action is not clear (Krishnadas, 2010).  At least in animal 
models, manipulating peripheral inflammatory cytokines have shown to reflect 
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changes in cytokine expression central nervous system. A possible mechanism is 
that the trafficking of immune cells that are already affected by HPA axis 
dysregulation into the CNS is being blocked by these anti-inflammatory agents. 
This area of research is however not explored as much. Tobinick et al have 
earlier shown that peri-spinal delivery of Etanercept is associated with rapid 
amelioration of cognitive deficits associated with Alzheimer’s disease (Tobinick, 
2010, Tobinick and Gross, 2008). Surprisingly, this finding has not had significant 
translational implication. 
Raison et al examined if anti TNF-α treatment using Infliximab reduced 
depressive symptoms in patients with treatment-resistant depression, and if 
inflammatory marker levels predicted treatment response (Raison et al., 2013). 
They found that after 3 infusions of infliximab vs. placebo over a period of 12 
weeks, there was no difference in depression scores between the two treatment 
groups. However, they found that those who responded to infliximab had a 
baseline concentration of hsCRP of more than 5mg/ l. 62% of those with a CRP of 
greater than 5 showed a response to infliximab, compared to only 33% who 
showed who showed a response to placebo. The symptoms that were more 
responsive to infliximab were anhedonia, psychomotor retardation, psychic 
anxiety, depressed mood and suicidal ideation.  Baseline concentrations of TNF-
α and its soluble receptors were also greater in infliximab responders. Patients 
showed a greater improvement of around 3.1 points on the HAM-D in the 
infliximab + antidepressant group, which ‘corresponds to the average effect of 
antidepressants'. The number of needed-to-treat patients in the hs-CRP > 5mg/l 
group was 3.45 (as opposed to 8–10 for conventional antidepressants) (Undurraga 
and Baldessarini, 2012, Fond et al., 2013).  
Na et al conducted a meta-analysis of studies that have examined the efficacy of 
adjunctive celecoxib treatment for patients with major depressive studies (Na et 
al., 2014). They found four relevant studies with 75 patients in the NSAID group 
and 75 on the placebo group. The celecoxib group showed greater mean changes 
in depression scores (weighted mean difference = 3.26) compared to the placebo 
group. Those in the celecoxib group were also more likely to show remission 
(OR=6.58) and response (OR=6.49) than placebo group. They suggest that NSAIDS 
like celecoxib could be promising treatment strategy for patients with 
depressive disorder.  
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Fond et al reviewed the effectiveness and tolerance of anti-inflammatory add on 
treatment for major depression (Table 8-2)(Fond et al., 2013). They reviewed 
the efficacy of drugs from four major antiinflammatory drug classes, 
particularly, COX inhibitors, TNF-α  inhibitors and minocycline in depression. In 
particular, they reviewed the benefit/risk ratios of these groups of medications. 
With regards TNF-α blockade agents, they suggest that extreme care should be 
taken with regards the patient developing "survival compromising complication". 
These include immunosuppression related infectious diseases, neoplastic 
processes including lymphomas and hypersensitivity reactions. With regards cox-
inhibitors, the major risks being serious complications like stroke, 
cardiovascular, raised liver enzymes, renal toxicity and gastrointestinal risks. 
A continuing challenge in MDD is the lack of “stratification”, i.e. a clear way of 
classifying what is a highly heterogeneous disorder, in order to aid diagnosis or 
predicting treatment response. There has recently been an emphasis on the 
need to develop a “biomarker” panel for depression that aims to profile diverse 
peripheral factors, including cytokine levels and peripheral growth factors that 
may provide a “biological signature” that may help predict treatment response 
(Schmidt et al., 2011).  Anti-inflammatory response has been associated with 
antidepressant effects, Persoons et al finding that those with Crohn’s and MDD 
with higher pre-treatment CRP levels, and had greater remission from MDD with 
infliximab (Persoons et al., 2005).   
Some studies that have assessed the usefulness of cytokine levels in predicting 
treatment response in depression. Some of these studies have shown interesting 
patterns of findings(Janssen et al., 2010).  O’Brien et al. found that raised pre-
treatment plasma levels of IL-6 and TNF-α were suggestive of poor response to 
antidepressants (O'Brien et al., 2007). Similarly, Lanquillon et al. found greater 
pre treatment IL-6 levels was associated with treatment resistance (Lanquillon 
et al., 2000).  Eller et al found that higher levels of TNF-α predicted non-
response to treatment with escitalopram (Eller et al., 2008).  In a more recent 
study that combined pharmacogenetics and imaging, Baune et al found an 
association between rs114643 variant of the IL1B gene and non-remission after 
antidepressant treatment and decreased amygdala and ACC function(Baune et 
al., 2009). 
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Table 8-2: Summary of clinical trials (open-label and double-blind randomized placebo controlled trials (RCT)) on add-on therapy of anti-inflammatory 
drugs in major depressive disorder (MDD) 
Author Study design 
Treatment + 
trial duration 
Outcome 
measures 
Results 
(Abbasi et al., 
2012)  
RCT N = 40 patients 
with HAM-D 
score > 17 
Sertraline 
200 mg/day +
 (celecoxib 
400 mg or 
placebo) 
6 weeks 
Serum IL-6 
concentrations at 
baseline and 
week 6, 
HAM-D scores at 
baseline and 
weeks 1, 2, 4, 
and 6 
The celecoxib group showed significantly greater reduction in serum IL-6 
concentrations (mean difference (95%CI) = 0.42(0.30–0.55) pg/ml, 
t(35) = 6.727, P < 0.001) as well as HAM-D scores (mean difference 
(95%CI) = 3.35(1.08–5.61), t(38) = 2.99, P = 0.005) than the placebo group. 
The patients in the celecoxib group experienced more response (95%) and 
remission (35%) than the placebo group (50% and 5%, P = 0.003 and 0.04 
respectively). Baseline serum IL-6 levels were significantly correlated with 
baseline HAM-D scores (r = 0.378,P = 0.016). Significant correlation was 
observed between reduction of HAM-D scores and reduction of serum IL-6 
levels at week 6 (r = 0.673, P < 0.001) 
(Muller et al., 
2006) 
RCT N = 40 patients 
with acute MDD 
Reboxetine 
4 mg+ 
(Celecoxib 
400 mg or 
placebo) 
HAM-D 
The celecoxib group showed significantly greater improvement compared to 
the reboxetine-alone group. (F = 3.220; df 2.434; P = 0.035) 
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Author Study design 
Treatment + 
trial duration 
Outcome 
measures 
Results 
6 weeks 
(Akhondzadeh et 
al., 2009) 
RCT N = 40 out-
patient with MDD 
(baseline HAM-D 
score > 17) 
Fluoxetine 
40 mg + (Cel
ecoxib 
400 mg or 
placebo) 
6 weeks 
HAM-D (weeks 
0,1,2,4,6) 
The combination of fluoxetine and celecoxib showed a significant superiority 
over fluoxetine alone in the treatment of symptoms of major depression. The 
difference between the two treatments was significant at the endpoint (week 
6) (t = 3.35, df = 38, P < 0.001). There was a significant difference between 
two treatments in terms of the percentage of responders (at least 50% 
reduction in the HAM-D score) (celecoxib group: 90%, 18 of 20 and placebo 
group: 50%, 10 of 20; P < 0.01). Thirty-five per cent of the patients in the 
celecoxib group and 5% in the placebo group were remitted after 6 weeks 
(HAM-D < 7). The difference was significant (P = 0.04). 
There were no significant differences in the two groups in terms of observed 
side-effects 
(Mendlewicz et al., 
2006)  
Open-label 
N = 24 non-responder 
patients with MDD 
SSRI + aspiri
n 160 mg/day 
4 weeks 
HAM-D 
The combination SSRI-ASA was associated with a response rate of 52.4%. 
Remission was achieved in 43% of the total sample and 82% of the 
responder sample. In the responder group, a significant improvement was 
observed within week 1 (mean HAM-D at day 0 = 29.3 ± 4.5, at day 
7 = 14.0 ± 4.1;P < 0.0001) and remained sustained until day 28. These 
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Author Study design 
Treatment + 
trial duration 
Outcome 
measures 
Results 
preliminary results are in favour of an accelerating effect of ASA in 
combination with SSRIs in the treatment of major depression 
 
(Raison et al., 
2013) 
RCT N = 60 out-
patients with stable 
depression (37 with 
antidepressant and 23 
medication free) 
Three 
infliximab 
administratio
ns (week 
0,2,6) 
12 weeks 
HAM-D at weeks 
0 (baseline), 1, 2, 
3, 4, 6, 8, 10 and 
12. 
-high-sensitivity 
C-reactive protein 
(hs-CRP), TNF-α, 
and its soluble 
receptors at 
weeks 0 
(baseline), 1, 2, 3, 
4, 6, 8, 10 and 12 
No overall difference in change of HAM-D scores between treatment groups 
across time was found. However, there was a significant interaction between 
treatment, time, and log baseline hs-CRP concentration (P = 0.01), with 
change in HAM-D scores (baseline to week 12) favouring infliximab-treated 
patients at a baseline hs-CRP concentration >5 mg/l and favouring placebo-
treated patients at a baseline hs-CRP concentration of 5 mg/l or less. 
Exploratory analyses focusing on patients with a baseline hs-CRP 
concentration >5 mg/l revealed a treatment response (≥50% reduction in 
HAM-D score at any point during treatment) of 62% (eight of 13 patients) in 
infliximab-treated patients vs. 33% (three of nine patients) in placebo-treated 
patients (P = 0.019). Baseline concentrations of TNF-α and its soluble 
receptors were significantly higher in infliximab-treated responders vs non-
responders (P < 0.05), and infliximab-treated responders exhibited 
significantly greater decreases in hs-CRP from baseline to week 12 
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Author Study design 
Treatment + 
trial duration 
Outcome 
measures 
Results 
compared with placebo-treated responders (P < 0 .01). Drop-outs and 
adverse events were limited and did not differ between groups. 
This proof-of-concept study suggests that TNF-α antagonism does not have 
generalized efficacy in treatment-resistant depression but may improve 
depressive symptoms in patients with high baseline inflammatory biomarkers 
(Miyaoka et al., 
2012) 
Open-label 
N = 25 adult in-
patients with major 
depression with 
psychotic features 
(psychotic depression) 
according to DSM-IV-
TR 
Fluvoxamine, 
paroxetine, or 
sertraline + m
inocycline 
150 mg/day 
6 weeks 
HAM-D (baseline 
and week 6) 
CGI (baseline 
and week 6) 
BPRS (baseline 
and week 6) 
Minocycline in combination with antidepressants provided significant 
improvement in depression. Mean (±SD) HAM-D was reduced to 6.7 ± 1.9 at 
week 6 from a baseline value of 40.4 ± 2.5. Significant improvement of 
psychotic symptoms (mean ± SD) was indicated by the decrease in BPRS 
scores from baseline (63.3 ± 8.7) to week 6 (4.6 ± 2.4) (P < 0.001). No 
serious adverse events occurred 
Hs-CRP, highly sensitive C-reactive protein; 95% CI, 95% confidence interval. 
All diagnoses were carried out according to the DSM-IV or DSM-IV-TR (Chronic inflammatory diseases were excluded). HAM-D Hamilton Depression Rating 
Scale. CGI clinical Global Impression score. BPRS Brief Psychiatric Rating Scale (Reused with permission from Fond G, Hamdani N, Kapczinski 
F, Boukouaci W, Drancourt N, Dargel A, Oliveira J, Le Guen E,Marlinge E, Tamouza R, Leboyer M. Effectiveness and tolerance of anti-inflammatory drugs' 
add-on therapy in major mental disorders: a systematic qualitative review. DOI: 10.1111/acps.12211)
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These findings imply that raised inflammatory parameters in patients with MDD 
may be biological markers of poor treatment response. More importantly, 
tackling this state of “inflammation” may be important in treating MDD in those 
with high pre-treatment levels of inflammatory markers. It is tempting here to 
hypothesise that addition of an anti-inflammatory medication may be a 
treatment option, and as discussed below, this seems to be the back bone of a 
number of translational endeavours. A few studies indeed have been successful 
in showing this as shown in Table 8-2. However, the evidence pointing towards 
this direction is inconsistent.  
In fact, at least one recent study has shown that adding an anti-inflammatory 
drug may actually attenuate the antidepressant actions of SSRIs. Warner-Schmidt 
et al recently in a mouse model, showed that antidepressant treatment was 
associated with an increased expression of cytokines - particularly interferon 
gamma and TNF-α (Warner-Schmidt et al., 2011). This in turn led to an increased 
expression of protein p11, a member of the S100 family of proteins that interact 
with specific serotonin receptors to regulate their trafficking. This protein has 
previously been associated with behavioural markers of depressive states. For 
example p11 knockout mice show depression-like phenotype and over-expression 
of p11 has been associated with antidepressant-like responses. The authors 
showed that an antidepressant response to SSRIs were mediated by an increase 
in the above cytokines and a resultant increase in p11 expression. More 
interestingly they showed that treatment with NSAIDS prevented the increase in 
cytokines, thereby preventing the increase in p11 and the behavioural response 
to depression. They went on to test this hypothesis in humans. They analysed 
data from STAR D to show that those people who were prescribed NSAIDS had a 
reduced response to SSRIs taken for depression. In keeping with this , Harley et 
al (2010) found that patients that were treated with antidepressants with 
baseline CRP levels above 10 mg/L showed significantly better improvement 
than those who were within the normal range (Harley et al., 2010).  
Anti-inflammatory agents targeting novel neurotransmitter systems (including 
glutamate) have been found to have some efficacy in treating psychiatric 
conditions. Two drugs of note are riluzole and ketamine, both of which have 
significant anti-inflammatory effects, and have been found to be effective in 
treating depression. Riluzole is a glumatergic modulator, which has both neuro-
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protective and anticonvulsant properties, due to its ability to inhibit glutamate 
release and enhance both glutamate reuptake and AMPA trafficking. The non-
competitive, high-affinity NMDA antagonist ketamine is a phencyclidine 
derivative that prevents excess calcium influx and cellular damage, by 
antagonising NMDARs(Zarate et al., 2010).  Ketamine has been shown to have a 
very fast onset of action in relieving depressive symptoms, and is currently the 
focus of a number of studies in mood disorders. Other novel anti-inflammatory 
agents that may have promise include dietary omega 3 fatty acids, particularly 
eicosapentanoic acid and docosahexaenoic acid, which have been found to have 
significant anti-inflammatory action. Clinically important anti-inflammatory 
effects are suggested by trials demonstrating benefits of n-3 fatty acids in 
rheumatoid arthritis, psoriasis, asthma, and inflammatory bowel disorders. 
Addition of n-3 fatty acids to existing antidepressant therapy has been found to 
be effective in recurrent major depressive disorders(Logan, 2004).  Finally, drugs 
targeting the kynurenine pathway have shown preliminary encouraging results in 
phase 1 trials(Malpass, 2011). Studies are also currently underway, that aim to 
clarify the clinical and neurobiological phenotype of depressed patients with 
increased inflammation. It is hoped that if an “inflammatory phenotype” of 
depression does emerge, this will help to individualise the diagnosis and 
treatment of patients with this particular phenotype.  
8.4 Conclusion 
In this thesis, I have shown some evidence that circulating inflammatory markers 
explain significant variance in brain substrates - particularly cortical thickness 
and serotonin transporters. I also show that inflammatory markers may mediate 
the association between socioeconomic deprivation (a high-risk condition for 
depression/ other major mental illnesses) and cortical thickness and volumes 
pertaining to executive function, language and the limbic stress networks in the 
brain. In addition, I show for the first time in humans that circulating 
inflammatory markers mediate the relationship between socioeconomic 
deprivation and cortical thickness covariance network structural properties. I 
also present some of the first evidence to suggest that circulating TNF-α  levels 
correlate significantly with serotonin transporters availability in people suffering 
from psoriasis/ psoriatic arthritis. I also confirm the findings from an initial pilot 
show that treatment with TNF-α blockade is associated with  a reduction in SERT 
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availability. It should be noted that mechanistic pathways that link inflammation 
with major mental illnesses seem at best speculative in humans.  
Inflammation seems to be associated with MDD and may indeed play a role in the 
aetiology of MDD, at least in a “cohort” of vulnerable individuals - for example, 
those from high socioeconomic deprivation or those with a medical condition. 
Inflammation in these situations, may not only act as a precipitating factor that 
pushes a person into depression, but also a perpetuating factor that may pose an 
obstacle to recovery. In Figure 8-1 I have summarised potential pathways 
through which inflammation may play a role in the etiopathogenesis of major 
depression.   Inflammatory pathways are  activated in response to a stressor – 
endogenous (medical illness) or exogenous (psychological/ medication/ 
socioeconomic status) as shown in Figure 8-1 (1). This inflammatory load, acts as 
a precipitating factor in those who are vulnerable (predisposed). This 
relationship is perhaps bidirectional; for example, the inflammation may worsen 
a physical morbidity. It is known that psychological and physical stressors can 
worsen clinical outcomes in a number of physical conditions. There are a number 
of potential pathways through which high inflammation may precipitate a 
depressive episode (Figure 8-1- (2)). These have been detailed in the 
introductory chapter, and discussions throughout the thesis. However, the key 
mechanisms that link circulating inflammatory markers to central inflammation 
in the brain in humans, remain to be established.  It should be noted that there 
are perhaps other pathways that mediate the relationship between stressors and 
depressed mood. These need to be accounted for when modelling causal 
mechanistic associations between stressors and depression (Figure 8-1 -(3)). 
There are also pathways through which depression may worsen a pre-existing 
medical condition (or the ability to cope with other stressors) For example, the 
presence of depression itself may increase inflammation (Figure 8-1-(4)).  The 
raised inflammation may further perpetuate and maintain the major depressive 
phenotype by preventing recovery (Figure 8-1 (5)and (6)).  
 Inflammatory markers may be potential biomarkers, aiding diagnosis or even 
helping to predict prognosis in major depressive illness. Future work will focus 
on cementing the precise role of inflammation in depressive illness, through 
more sophisticated animal models and clinical and cognitive neuroscience, and 
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will hopefully result in beneficial treatments for what remains a significantly 
disabling psychiatric illness.  
 
Figure 8-1: Potential pathways through which inflammation may play a part in the 
pathogenesis of major depression.  
 
 
Reused with permission from(Krishnadas and Cavanagh, 2012) 
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9 Appendices 
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